Document:

Exhibit

EXHIBIT 10.5

EL PASO ELECTRIC COMPANY
AMENDED AND RESTATED 2007 LONG-TERM INCENTIVE PLAN

RESTRICTED STOCK AWARD AGREEMENT
(FOR NON-EMPLOYEE DIRECTORS)

El Paso Electric Company, a Texas corporation (the "Company"), has granted to the _____________ (the “Participant”), under the El Paso Electric Company Amended and Restated 2007 Long-Term Incentive Plan (the “Plan”), a restricted stock award of 3,500 Shares (the "Award") on ______________ (the “Award Date”), upon and subject to the restrictions, terms and conditions set forth below.  Capitalized terms not defined herein shall have the meanings specified in the Plan.  

1. Acceptance of Award Agreement.  The Award shall be null and void unless the Participant shall accept this Award Agreement by executing it in the space provided below and returning it to the Company.  As soon as practicable after the Participant has executed this Award Agreement, shares will be allocated to the Participant 's account in book‐entry form in a manner that effectively prevents transfers during the Restriction Period (as defined below).

2. Rights as a Shareholder.  The Participant shall have the right to vote the Shares subject to the Award and to receive dividends and other distributions thereon; provided, however, that a dividend or other distribution with respect to Shares (including, without limitation, a stock dividend or stock split), other than a regular cash dividend, shall be subject to the same restrictions as the Shares with respect to which such dividend or other distribution was made.

3. Removal of Restrictions.  At the termination of the Restriction Period, the Company shall cause any restriction of transfer to be removed from the Participant’s account in book‐entry form with respect to the Shares for which restrictions have lapsed pursuant to Section 4 hereof and subject to Section 5.2.

4. “Restriction Period” and Vesting.  The restrictions on the applicable portion of the Award shall lapse on _______________ the “Vest Date” if Participant continues service on the Board from the Award Date through such Vest Date.

5.    Additional Terms and Conditions of Award.

5.1. Non-transferability of Award.  During the Restriction Period, the Shares subject to the Award as to which restrictions remain in effect may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process.  Upon any attempt to so sell, transfer, assign, pledge, hypothecate or encumber, or otherwise dispose of such shares, the Award shall immediately become null and void.

1
#85822115v1    

5.2.    [Reserved.]

5.3. Award Agreement Subject to the Plan.  This Award Agreement is subject to the provisions of the Plan and shall be interpreted in accordance therewith.  The Participant hereby acknowledges receipt of a copy of the Plan. To the extent that any provision of this Award Agreement conflicts with the express terms of the Plan, it is hereby acknowledged and agreed that the terms of the Plan shall control and, if necessary, the applicable provisions of this Award Agreement shall be hereby deemed amended so as to carry out the purpose and intent of the Plan.

5.4 Severability. In the event any provision of this Award Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of this Award Agreement, and this Award Agreement shall be construed and enforced as if the illegal or invalid provision had not been included.
5.5 Compliance with Recoupment Policy.  Any amounts payable, paid, or distributed under this Award Agreement are subject to the recoupment policy of the Company as in effect from time to time.
6.    Miscellaneous Provisions.

6.1. Successors.  This Award Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall acquire any rights hereunder in accordance with this Award Agreement or the Plan.

6.2. Notices.  All notices, requests or other communications provided for in this Award Agreement shall be made, if to the Company, to El Paso Electric Company, Stanton Tower, 100 N. Stanton, El Paso, Texas 79901, Attention:  Corporate Secretary, and if to the Participant, to Participant’s Name at the last address provided to the Company.  All notices, requests or other communications provided for in this Award Agreement shall be made in writing either (a) by personal delivery to the party entitled thereto, (b) by facsimile with confirmation of receipt, (c) by mailing in the United States mails to the last known address of the party entitled thereto or (d) by express courier service.  The notice, request or other communication shall be deemed to be received upon personal delivery, upon confirmation of receipt of facsimile transmission, or upon receipt by the party entitled thereto if by United States mail or express courier service; provided, however, that if a notice, request or other communication is not received during regular business hours, it shall be deemed to be received on the next succeeding business day of the Company.

6.3. Counterparts. This Award Agreement may be executed in two counterparts, each of which shall be deemed an original and both of which shall constitute one and the same instrument together, shall constitute one and the same instrument.

2
#85822115v1    

	
			
	EL PASO ELECTRIC COMPANY

	 
	 
	 

	 
	 
	 

	By:
	 
	 

	Name:
	 
	 

	Title:
	 
	 

Accepted this ____ day of ______________, 20__.

	
	
	

3
#85822115v1January
30, 2018

 

Brands
International Corporation

Attn:
Mark Rubinoff, CEO

Via
email 

 

RE:
Amend the 12-26-17 Letter of Intent Termination Date to March 20, 2018

 

Dear
Mr. Rubinoff:

 

Novo
Integrated Sciences, Inc., a Nevada corporation (“NIS”) and Brands International Corporation are parties to the Letter
of Intent, dated 12-26-17, as attached hereto as Exhibit A (the “LOI”).

 

The
purpose of this letter is to amend the LOI to extend the termination date therein. As we have discussed, the “Termination
Date” for all purposes under the LOI is hereby amended to be March 20, 2018. The LOI, as amended herein, shall remain in
full force and effect.

 

We
continue to look forward to working with you to complete the transaction successfully and expeditiously. If the foregoing correctly
sets forth your understanding, please execute a copy of this Letter in the space set forth below and return to me.

 

	 	Sincerely,
    
	 	 	 
	 	Novo
    Integrated Sciences, Inc.
	 	 	 
	 	By:	/s/
    Christopher David 
	 	Name:	Christopher
    David
	 	Title:	President
	 	 	 
	 	Agreed
    and accepted:
	 	 	 
	 	Brands
    International Corporation
	 	 	 
	 	By:	/s/
    Mark Rubinoff 
	 	Name:	Mark
    Rubinoff
	 	Title:	Chief
    Executive Officer

 

11120
NE 2nd Street, Suite 200 Bellevue, WA 98004 USA

Phone:
(206) 617-9797

www.novointegrated.com

 

    	 	 	 

    	P a g e | 2

    

 

Exhibit
‘A’

 

Letter
of Intent

 

(Attached)

 

LOI
filed in 8-K (dated 1-2-18)Exhibit 10.1

 

 

Execution Version

 

 

 

 

 

 

 

 

AGREEMENT
AND PLAN OF MERGER

 

among

 

AMERICAN
BRIVISION (HOLDING) CORPORATION,

 

BIOLITE ACQUISITION CORP.,

 

BIOKEY
ACQUISITION CORP.,

 

BIOLITE
HOLDING, INC.

 

and

 

BIOKEY,
INC.

 

Dated as of January 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

Execution Version

 

AGREEMENT
AND PLAN OF MERGER

 

AGREEMENT
AND PLAN OF MERGER, dated as of January 31, 2018 (this “Agreement"), by and among American Brivision (Holding)
Corporation, a Nevada corporation (“Parent”), BioLite Acquisition Corp., a Nevada corporation and a direct
wholly-owned Subsidiary of Parent (“Merger Sub 1”), BioKey Acquisition Corp., a California corporation and
a direct wholly-owned Subsidiary of Parent (“Merger Sub 2”, and together with Merger Sub 1, the “Merger
Subs”)), BioLite Holding, Inc., a Nevada corporation (“BioLite”), and BioKey, Inc., a California
corporation (“BioKey”).

 

WHEREAS,
the Boards of Directors of Parent, Merger Sub 1, Merger Sub 2, BioLite, and BioKey have each approved (i) this Agreement, (ii)
the merger of Merger Sub 1 with and into BioLite (the “BioLite Merger”), and (iii) the merger of Merger Sub
2 with and into BioKey (the “BioKey Merger”, and together with the BioLite Merger, the “Mergers”),
in accordance with Chapter 92A of the Nevada Revised Statutes (the “NRS”), and the California General Corporation
Law, as applicable (the “CGCL”), and the terms and conditions set forth herein, which Mergers will result in,
among other things, (i) the respective surviving companies becoming wholly owned subsidiaries of Parent and (ii) BioLite and BioKey
stockholders becoming stockholders of Parent;

 

WHEREAS,
for federal income tax purposes, it is intended that the Mergers qualify as tax-free reorganizations within the meaning of Section
368(a)(1)(C) of the Code and the regulations promulgated thereunder; and

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants, agreements and representations herein contained, and intending
to be legally bound hereby, Parent, Merger Sub 1, Merger Sub 2, BioLite, and BioKey hereby agree as follows:

 

ARTICLE
1

THE MERGER

 

Section
1.1The Mergers. Upon the terms and subject to the conditions of this Agreement and in accordance with the NRS and the
CGCL, as applicable, at the Effective Time, (i) Merger Sub 1 shall be merged with and into BioLite, and (ii) Merger Sub 2 shall
be merged with and into BioKey. As a result of the BioLite Merger, the separate corporate existence of Merger Sub 1 shall cease
and BioLite shall continue as the surviving corporation of the BioLite Merger (the “BioLite Surviving Corporation”).
As a result of the BioKey Merger, the separate corporate existence of Merger Sub 2 shall cease and BioKey shall continue as the
surviving corporation of the BioKey Merger (the “BioKey Surviving Corporation”, and together with the BioLite
Surviving Corporation, the “Surviving Corporations”).

 

Section
1.2Closing; Effective Time. Subject to the provisions of ARTICLE 8, the closing of the Mergers (the “Closing”)
shall take place at the offices of Sichenzia Ross Ference Kesner LLP, 1185 Avenue of the Americas, 37th Floor, New
York 10036, as soon as practicable, but in no event later than the second Business Day after the satisfaction or waiver (to the
extent permitted by Law) of the conditions set forth in ARTICLE 8 (excluding conditions that, by their terms, cannot be satisfied
until the Closing, but subject to the satisfaction or waiver (to the extent permitted by Law) of such conditions at the Closing),
or at such other place or on such other date as Parent, BioLite and BioKey may mutually agree. The date on which the Closing actually
occurs is hereinafter referred to as the “Closing Date“. At the Closing, the parties hereto shall cause the
Mergers to be consummated by (i) filing Articles of Merger (the “BioLite Articles of Merger”) with the Secretary
of State of the State of Nevada, in such form as required by, and executed in accordance with, the relevant provisions of the
NRS and shall make all other filings or recordings required under the NRS in connection with the BioLite Merger, and (ii) filing
an agreement of merger (the “BioKey Certificate of Merger”) with the Secretary of State of the State of California,
in such form as required by, and executed in accordance with, the relevant provisions of the CGCL, and shall make all other filings
or recordings required under the CGCL in connection with the BioKey Merger (the later of the date and time of the acceptance of
the filing of the BioLite Articles of Merger by the Secretary of State of the State of Nevada, and the date and time of the acceptance
of the filing of the BioKey Certificate of Merger by the Secretary of State of the State of California, or such later time as
is specified in the BioLite Articles of Merger or the BioKey Certificate of Merger and as is agreed to by the parties hereto,
being hereinafter referred to as the “Effective Time”).

 

     

     

    

 

Section
1.3Effects of the Mergers. The Mergers shall have the effects set forth herein and in the applicable provisions of
the NRS and CGCL, as applicable. Without limiting the generality of the foregoing and subject thereto, at the Effective Time,
(i) all the property, rights, privileges, immunities, powers and franchises of BioLite and Merger Sub 1 shall vest in the BioLite
Surviving Corporation and all debts, liabilities and duties of BioLite and Merger Sub 1 shall become the debts, liabilities and
duties of the BioLite Surviving Corporation, and (ii) ) all the property, rights, privileges, immunities, powers and franchises
of BioKey and Merger Sub 2 shall vest in the BioKey Surviving Corporation and all debts, liabilities and duties of BioKey and
Merger Sub 2 shall become the debts, liabilities and duties of the BioKey Surviving Corporation.

 

Section
1.4Articles of Incorporation; Bylaws. (a) Pursuant to the BioLite Merger, the Articles of Incorporation of BioLite
shall be amended and restated immediately after the Effective Time to be in the form of the Articles of Incorporation of Merger
Sub 1 in effect immediately prior to the Effective Time and, as so amended, such Articles of Incorporation shall be the Articles
of Incorporation of the BioLite Surviving Corporation until thereafter amended in accordance with its terms and as provided by
Law.

 

(b)       Pursuant
to the BioLite Merger, the Bylaws of Merger Sub 1 in effect immediately prior to the Effective Time shall be the Bylaws of the
BioLite Surviving Corporation until thereafter amended in accordance with their terms and the Articles of Incorporation of the
BioLite Surviving Corporation and as provided by Law.

 

(c)       Pursuant
to the BioKey Merger, the Articles of Incorporation of BioKey shall be amended and restated immediately after the Effective Time
to be in the form of the Articles of Incorporation of Merger Sub 2 in effect immediately prior to the Effective Time and, as so
amended, such Articles of Incorporation shall be the Articles of Incorporation of the BioKey Surviving Corporation until thereafter
amended in accordance with its terms and as provided by Law.

 

    - 2 -

     

    

 

(d) Pursuant to the BioKey Merger, the Bylaws of Merger Sub 2 in effect
immediately prior to the Effective Time shall be the Bylaws of the BioKey Surviving Corporation until thereafter amended in accordance
with their terms and the Articles of Incorporation of the BioKey Surviving Corporation and as provided by Law.

 

Section
1.5Directors and Officers. The persons set forth on Schedule 1.5 shall be the initial directors and officers of each
of the Surviving Corporations immediately following the Effective Time, each to hold office in accordance with the respective
Articles of Incorporation and the Bylaws of the Surviving Corporations until their respective successors are duly elected (with
respect to such directors) or appointed and qualified or until their death, resignation or removal in accordance with the Surviving
Corporations’ Articles of Incorporation and Bylaws, as applicable.

 

Section
1.6BioLite and BioKey Stock Options and Warrants. At the Effective Time, there shall be no outstanding options or warrants
to purchase capital stock of BioLite and BioKey. Before the Effective Time, BioKey will notify the holders of BioKey options about
the BioKey Merger contemplated herein. Each holder of BioKey options has the right to decide whether he or she will exercise the
options on or before the BioKey Stockholders Meeting. BioKey shall on best effort basis cancel and terminate all the issued, outstanding
and unexercised options of BioKey immediately after the BioKey Stockholders Meeting. Notwithstanding the foregoing, any and all
outstanding and unexercised options of BioKey will be deemed automatically cancelled and terminated upon Closing of the BioKey
Merger. The Principal Shareholders of BioKey, as defined below, hereby, jointly and severally, indemnify and holds harmless all
the other Parties, each of the other Parties’ subsidiaries and affiliates, and other Parties’ shareholders, officers,
directors, agents and employees (hereinafter the “Injured Party,” as applicable), for any claim, loss, damage, cost
and expense, including reasonable attorney’s fees, that the Injured Party may suffer or incur, arising from, in connection
with, or relating to, such cancellation and termination of BioKey options stated herein. The Principal Shareholders of BioKey
mean each of the beneficial owners of BioKey as of the date hereof that owns the top five largest equity interests in BioKey.

 

Section
1.7Adjustments to Exchange Ratios and Share Amounts. Notwithstanding any other provision of this Agreement, the BioLite
Common Exchange Ratio and the BioKey Common Exchange Ratio shall not be adjusted, without the prior written consent of BioLite,
BioKey and Parent, provided, however, that such BioLite Common Exchange Ratio and BioKey Common Exchange Ratio, shall be equitably
adjusted to reflect appropriately the effect of any stock split, reverse stock split, stock dividend (including any dividend or
distribution of securities convertible into Parent Common Stock, BioLite Capital Stock or BioKey Capital Stock), extraordinary
cash dividends, reorganization, recapitalization, reclassification, combination, exchange of shares or other like change with
respect to Parent Common Stock, BioLite Capital Stock, or BioKey Capital Stock occurring on or after the date hereof and prior
to the Effective Time.

 

    - 3 -

     

    

 

ARTICLE
2

EFFECT OF THE MERGERS ON THE CAPITAL STOCK

OF THE CONSTITUENT CORPORATIONS

 

Section
2.1Conversion of Securities. At the Effective Time, by virtue of the Mergers and without any action on the part of
Parent, Merger Subs, BioLite, BioKey or the holders of any of the following securities, the following shall occur:

 

(a)  subject
to Section 2.2, each share of the common stock, par value $0.0001 per share, of BioLite (the “BioLite Common Stock”)
issued and outstanding immediately prior to the Effective Time (other than any BioLite Dissenting Shares), shall be converted
into the right to receive 1.82 (the “BioLite Common Exchange Ratio” or the “BioLite Merger Consideration”)
validly issued, fully paid and non-assessable shares, par value $0.001 per share, of Parent (the “Parent Common Stock”).

 

(b)  each
share of common stock of Merger Sub 1 issued and outstanding immediately prior to the Effective Time shall be converted into one
share of common stock of the BioLite Surviving Corporation.

 

(c)  At
the Effective Time, all shares of BioLite Common Stock shall cease to be outstanding, shall automatically be cancelled and shall
cease to exist and each holder of a certificate (a “BioLite Certificate”) that immediately prior to the Effective
Time represented any such shares of BioLite Common Stock shall cease to have any rights with respect thereto, except the right
to receive the BioLite Merger Consideration.

 

(d)  subject
to Section 2.2, each share of the common stock, having no par value of BioKey (the “BioKey Common Stock”) and
BioKey preferred stock, having no par value (the “BioKey Preferred Stock”; BioKey Common Stock and BioKey
Preferred Stock, together, the “BioKey Capital Stock”), issued and outstanding immediately prior to the Effective
Time (other than any BioKey Dissenting Shares), shall be converted (on an as-converted to common stock basis with respect to the
BioKey Preferred Stock) into the right to receive one (1) (the “BioKey Common Exchange Ratio” or the “BioKey
Merger Consideration”) validly issued, fully paid and non-assessable shares of the Parent Common Stock.

 

(e)  each
share of common stock of Merger Sub 2 issued and outstanding immediately prior to the Effective Time shall be converted into one
share of common stock of the BioKey Surviving Corporation.

 

(f)   At
the Effective Time, all shares of BioKey Common Stock and BioKey Preferred Stock shall cease to be outstanding, shall automatically
be cancelled and shall cease to exist and each holder of a certificate (a “BioKey Certificate”) that immediately
prior to the Effective Time represented any such shares of BioKey Common Stock or BioKey Preferred Stock shall cease to have any
rights with respect thereto, except the right to receive the BioKey Merger Consideration.

 

    - 4 -

     

    

 

Section
2.2Surrender of Shares. (a) Prior to the Effective Time, Merger Sub 1 shall enter into an agreement with Parent’s
transfer agent to act as agent for the stockholders of BioLite (the “BioLite Stockholders”) in connection with
the BioLite Merger (the “BioLite Exchange Agent”) and to receive the BioLite Merger Consideration to which
the BioLite Stockholders shall become entitled pursuant to this ARTICLE 2. At or prior to the Effective Time, Parent shall, or
shall cause the BioLite Surviving Corporation to, deposit with the BioLite Exchange Agent to be held in trust for the benefit
of holders of shares of BioLite Common Stock such number of certificates of Parent Common Stock representing the shares of Parent
Common Stock to be issued pursuant to Section 2.1(a) (the “BioLite Exchange Fund”). The BioLite Exchange Fund
shall not be used for any purpose other than to cause the exchange pursuant to this ARTICLE 2, except as provided in this Agreement.
The BioLite Surviving Corporation shall pay all charges and expenses, including those of the BioLite Exchange Agent, incurred
by it in connection with the exchange of shares of BioLite Common Stock for the BioLite Merger Consideration and other amounts
contemplated by this ARTICLE 2. Parent shall have the right to withdraw from the BioLite Exchange Fund any shares of Parent Common
Stock delivered by Parent or the BioLite Surviving Corporation with respect to any BioLite Dissenting Shares, the amount so withdrawn
not to exceed the number of shares of Parent Common Stock held in the BioLite Exchange Fund with respect to such Dissenting Shares.

 

(b)Prior
to the Effective Time, Merger Sub 2 shall enter into an agreement with Parent’s transfer agent to act as agent for the stockholders
of BioKey (the “BioKey Stockholders”) in connection with the BioKey Merger (the “BioKey Exchange Agent”)
and to receive the BioKey Merger Consideration to which the BioKey Stockholders shall become entitled pursuant to this ARTICLE
2. At or prior to the Effective Time, Parent shall, or shall cause the BioKey Surviving Corporation to, deposit with the BioKey
Exchange Agent to be held in trust for the benefit of holders of shares of BioKey Common Stock and BioKey Preferred Stock such
number of certificates of Parent Common Stock representing the shares of Parent Common Stock to be issued pursuant to Section
2.1(d) (the “BioKey Exchange Fund”). The BioKey Exchange Fund shall not be used for any purpose other than
to cause the exchange pursuant to this ARTICLE 2, except as provided in this Agreement. The BioKey Surviving Corporation shall
pay all charges and expenses, including those of the BioKey Exchange Agent, incurred by it in connection with the exchange of
shares of BioKey Common Stock and BioKey Preferred Stock for the BioKey Merger Consideration and other amounts contemplated by
this ARTICLE 2. Parent shall have the right to withdraw from the BioKey Exchange Fund any shares of Parent Common Stock delivered
by Parent or the BioKey Surviving Corporation with respect to any BioKey Dissenting Shares, the amount so withdrawn not to exceed
the number of shares of Parent Common Stock held in the BioKey Exchange Fund with respect to such BioKey Dissenting Shares. 

 

    - 5 -

     

    

 

(c) Promptly
after the Effective Time, but in any event no later than the fifth (5th) Business Day thereafter, Parent shall cause
to be mailed to each record holder as of the Effective Time of (x) a BioLite or BioKey Certificate or Certificates which immediately
prior to the Effective Time represented shares of BioLite Common Stock, BioKey Common Stock or BioKey Preferred Stock, as applicable,
(y) uncertificated shares of BioLite Common Stock, BioKey Common Stock, or BioKey Preferred Stock, as applicable, represented
by book-entry (“Book-Entry Shares“), which, in each case, were converted into the right to receive the BioLite
Merger Consideration or BioKey Merger Consideration, as applicable, with respect thereto, (i) a form of letter of transmittal
(which shall be in customary form and shall specify that delivery shall be effected, and risk of loss and title to the BioLite
or BioKey Certificates, as applicable, or Book-Entry Shares shall pass, only upon proper delivery of the BioLite or BioKey Certificates,
as applicable, to the BioLite or BioKey Exchange Agent, as applicable, or, in the case of Book-Entry Shares, upon adherence to
the procedures set forth in the letter of transmittal, together with such letter(s) of transmittal properly completed and duly
executed to the BioLite or BioKey Exchange Agent, as applicable) and (ii) instructions for use in effecting the surrender of the
BioLite or BioKey Certificates or Book-Entry Shares in exchange for the BioLite Merger Consideration or BioKey Merger Consideration,
as applicable. Upon surrender to the BioLite or BioKey Exchange Agent, as applicable of a BioLite or BioKey Certificate, as applicable,
or Book-Entry Share, together with such letter of transmittal, duly completed and validly executed in accordance with the instructions
thereto, and such other documents as may be required pursuant to such instructions (a “Proper Delivery”), the
holder of such BioLite or BioKey Certificate, as applicable, or Book-Entry Share shall be entitled to receive upon such surrender
of such BioLite or BioKey Certificate, as applicable, or Book-Entry Share the BioLite Merger Consideration or BioKey Merger Consideration,
as applicable, pursuant to Section 2.1(a) or 2.1(d), as applicable, and such BioLite or BioKey Certificate, as applicable, or
Book-Entry Share shall then be canceled. Payment of the BioLite Merger Consideration and BioKey Merger Consideration shall be
made as promptly as practicable after the date of Proper Delivery. If delivery of the BioLite Merger Consideration or BioKey Merger
Consideration is to be made to a Person other than the Person in whose name the BioLite Certificate or BioKey Certificate, as
applicable, is registered, it shall be a condition of payment that the BioLite or BioKey Certificate, as applicable, or Book-Entry
Share so surrendered shall be properly endorsed or shall be otherwise in proper form for transfer and that the Person requesting
such payment shall have paid any transfer and other Taxes required by reason of the payment of the BioLite Merger Consideration
or BioKey Consideration, as applicable, to a Person other than the registered holder of the BioLite or BioKey Certificate, as
applicable, or Book-Entry Share surrendered or shall have established to the satisfaction of the applicable Surviving Corporation
that such Tax either has been paid or is not applicable. Until surrendered as contemplated by this Section 2.2(c), each BioLite
or BioKey Certificate, as applicable, or Book-Entry Share shall be deemed at any time after the Effective Time to represent only
the right to receive upon such surrender of such BioLite or BioKey Certificate, as applicable, or Book-Entry Share the BioLite
Merger Consideration or BioKey Merger Consideration, as applicable, pursuant to Section 2.1(a) or 2.1(d), as applicable.

 

    - 6 -

     

    

 

(d)  At
a time that is the earlier of the date that is approximately six(6) months after the Effective Time or as soon as practicable,
each Surviving Corporation shall be entitled to require the BioLite Exchange Agent or BioKey Exchange Agent, as applicable, to
deliver to it any portion of the BioLite Exchange Fund or BioKey Exchange Fund, as applicable, which has been made available to
the BioLite Exchange Agent or BioKey Exchange Agent, as applicable, and which has not been disbursed to holders of BioLite or
BioKey Certificates, as applicable, or Book-Entry Shares and thereafter such holders shall be entitled to look to Parent and the
applicable Surviving Corporation (subject to abandoned property, escheat or other similar Laws) only as general creditors thereof
with respect to the BioLite Merger Consideration or BioKey Merger Consideration, as applicable, exchangeable upon due surrender
of their BioLite or BioKey Certificates, as applicable, or Book-Entry Shares. Each Surviving Corporation shall pay all charges
and expenses, including those of the BioLite Exchange Agent or BioKey Exchange Act, as applicable, incurred by it in connection
with the exchange of shares of BioLite Common Stock, BioKey Common Stock or BioKey Preferred Stock, as applicable, for the BioLite
Merger Consideration or BioKey Merger Consideration, as applicable, and other amounts contemplated by this ARTICLE 2. None of
Parent, Merger Sub 1, Merger Sub 2, BioLite, BioKey, the BioLite Exchange Agent, or the BioKey Exchange Agent, shall be liable
to any person in respect of any property delivered to a public official pursuant to any applicable abandoned property, escheat
or similar Law. The BioLite Merger Consideration and BioKey Merger Consideration paid in accordance with the terms of this ARTICLE
2 in respect of BioLite or BioKey Certificates, as applicable, or Book-Entry Shares that have been surrendered in accordance with
the terms of this Agreement shall be deemed to have been paid in full satisfaction of all rights pertaining to the shares of BioLite
Common Stock, BioKey Common Stock, or BioKey Preferred Stock, as applicable, represented thereby.

 

(e) After
the Effective Time, the stock transfer books of BioLite and BioKey shall be closed and thereafter there shall be no further registration
of transfers of shares of BioLite Common Stock, BioKey Common Stock, or BioKey Preferred Stock, that were outstanding prior to
the Effective Time. If, after the Effective Time, BioLite Certificates or BioKey Certificates are presented to the BioLite Surviving
Corporation or BioKey Surviving Corporation, as applicable, for transfer or transfer is sought for Book-Entry Shares, such BioLite
or BioKey Certificates, as applicable, or Book-Entry Shares shall be canceled and exchanged for the consideration provided for,
and in accordance with the procedures set forth in, this ARTICLE 2, subject to applicable Law in the case of BioLite Dissenting
Shares or BioKey Dissenting Shares, as applicable. Such stock transfer books shall be delivered to the applicable Surviving Corporation
as soon as reasonably possible after the Effective Time.

 

(f) In
the event that any BioLite Certificate or BioKey Certificate shall have been lost, stolen or destroyed, upon the making of an
affidavit of that fact by the holder thereof claiming such BioLite Certificate or BioKey Certificate, as applicable, to be lost,
stolen or destroyed, and, if reasonably requested, the posting by the holder of a bond in customary amount as indemnity against
any claim that may be made against it with respect to the BioLite Certificate or BioKey Certificate, as applicable, the BioLite
Exchange Agent or BioKey Certificate, as applicable, will deliver in exchange for the lost, stolen or destroyed BioLite Certificate
or BioKey Certificate, as applicable, the BioLite Merger Consideration or BioKey Merger Consideration, as applicable, payable
in respect of the shares of BioLite Common Stock, BioKey Common Stock, or BioKey Preferred Stock, as applicable, represented by
such BioLite Certificate or BioKey Certificate pursuant to this ARTICLE 2.

 

    - 7 -

     

    

 

Section
2.3Dissenting Shares. (a) Notwithstanding anything in this Agreement to the contrary, shares of BioLite Common Stock
issued and outstanding immediately prior to the Effective Time that are held by any holder who is entitled to dissent from the
BioLite Merger under NRS 92A.380 and who exercises that right when and in the manner required by NRS 92A.400 to 92A.480, inclusive
(“BioLite Dissenting Shares”), shall be entitled to receive payment of the “fair value” of such
BioLite Dissenting Shares held by them in accordance with the provisions of the NRS. BioLite shall serve prompt notice to Parent
of any demands for appraisal of any shares of BioLite Common Stock, attempted withdrawals of such notices or demands and any other
negotiations, petitions and proceedings with respect to such demands. BioLite shall give Parent the opportunity to direct all
negotiations and proceedings with respect to demands for appraisal or dissenters’ rights and BioLite shall not, without
the prior written consent of Parent, make any payment with respect to, or settle or offer to settle, any such demands. All fees,
payments, and expenses of BioLite relating to all negotiations, petitions and proceedings with respect to demands for appraisal
or dissenters’ rights shall be paid by Parent.

 

(b)
Notwithstanding anything in this Agreement to the contrary, shares of BioKey Common Stock and BioKey Preferred Stock issued and
outstanding immediately prior to the Effective Time that are held by any holder who is entitled to dissent from the BioKey Merger
under Chapter 13 of the CGCL and who exercises that right when and in the manner required by Chapter 13 of the CGCL (“BioKey
Dissenting Shares”), shall be entitled to receive payment of the “fair market value” of such BioKey Dissenting
Shares held by them in accordance with the provisions of Chapter 13 of the CGCL. BioKey shall serve prompt notice to Parent of
any demands for appraisal of any shares of BioKey Common Stock or BioKey Preferred Stock, attempted withdrawals of such notices
or demands and any other negotiations, petitions and proceedings with respect to such demands. BioKey shall give Parent the opportunity
to direct all negotiations and proceedings with respect to demands for appraisal or dissenters’ rights and BioKey shall
not, without the prior written consent of Parent, make any payment with respect to, or settle or offer to settle, any such demands.
All fees, payments, and expenses of BioKey relating to all negotiations, petitions and proceedings with respect to demands for
appraisal or dissenters’ rights shall be paid by Parent.

 

Section
2.4Fractional Shares. No fractional shares of Parent Common Stock will be issued by virtue of the Mergers and any BioLite
Stockholder or BioKey Stockholder entitled hereunder to receive a fractional share of Parent Common Stock (after aggregating all
fractional shares of Parent Common Stock that would otherwise be received by such holder) but for this Section 2.4 will be rounded
up to the next whole share.

 

Section
2.5Performance of Merger Subs. Parent hereby unconditionally and irrevocably guarantees, and covenants and agrees with
BioLite and BioKey, to be jointly and severally liable with each Merger Sub for the due and punctual performance of each and every
obligation of each Merger Sub arising under this Agreement.

 

    - 8 -

     

    

 

ARTICLE
3

REPRESENTATIONS AND WARRANTIES OF BIOLITE

 

BioLite
hereby represents and warrants to Parent, BioKey, and each Merger Sub that, except as set forth on the BioLite Schedule of Exceptions
delivered by BioLite to the Parent, BioKey, and each Merger Sub prior to the execution of this Agreement and thereafter prior
to Closing (the “BioLite Schedule of Exceptions”), it being understood that a disclosure in any section of
the BioLite Schedule of Exceptions shall be deemed to have been set forth in all other applicable sections of the BioLite Schedule
of Exceptions where it is readily apparent on the face of the disclosure that such disclosure is applicable to such other sections,
notwithstanding the omission of any cross reference to such other section; and it being further understood that the BioLite Schedule
of Exceptions will be updated from time to time for events that occur between execution of this Agreement and Closing and a final
copy of the BioLite Schedule of Exceptions will be delivered to Parent, BioKey, and each Merger Sub prior to the Closing:

 

Section
3.1Organization and Qualification. BioKey and each Subsidiary thereof is a corporation duly organized, validly existing
and in good standing or active status under the Laws of the jurisdiction in which it is incorporated and has all requisite corporate
power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted, except
where any failure to be so organized, existing or in good standing or active status or to have such power or authority would not,
or would not reasonably be expected to, individually or in the aggregate, have a BioLite Material Adverse Effect. BioLite and
each Subsidiary thereof is duly qualified or licensed to do business, and is in good standing, in each jurisdiction where the
character of the properties owned, leased or operated by it or the nature of its activities makes such qualification or licensing
necessary, except for any failure to be so qualified or licensed or in good standing which would not, or would not reasonably
be expected to, individually or in the aggregate, have a BioLite Material Adverse Effect. “BioLite Material Adverse Effect”
means any change, effect, event or occurrence that has a material adverse effect on the assets, business, financial condition
or results of operations of BioLite and its Subsidiaries taken as a whole or that would reasonably be expected to prevent or materially
delay BioLite from performing its obligations under this agreement in any material respect or materially delay consummating the
transactions contemplated hereby;

 

Section
3.2Articles of Incorporation and Bylaws. BioLite has heretofore furnished or otherwise made available to Parent and
BioKey a complete and correct copy of the articles of incorporation (the “Articles of Incorporation”) and bylaws
(the “Bylaws”) of BioLite and each of its Subsidiaries as in effect on the date hereof and all minutes of their
Board of Directors since January 1, 2015, other than those with respect to consideration and approval of the Mergers and related
transactions. The Articles of Incorporation and Bylaws of BioLite and its Subsidiaries are in full force and effect and no other
organizational documents are applicable to or binding upon BioLite or its Subsidiaries. Neither BioLite nor its Subsidiaries is
in violation of any provisions of its Articles of Incorporation or Bylaws in any material respect.

 

Section
3.3Capitalization. (a) The authorized capital stock of BioLite consists of five hundred million (500,000,000) shares
of common stock, par value $0.0001 per share.

 

(b)  As
of the date of this Agreement: (i) forty-one million two hundred and seven thousand four hundred forty-four (41,207,444) shares
of BioLite Common Stock were issued and outstanding, all of which were validly issued, fully paid and non-assessable and were
issued free of preemptive rights, (ii) none of BioLite Common Stock were reserved for issuance upon or otherwise deliverable in
connection with the grant of equity-based awards or the exercise of outstanding options to purchase BioLite Common Stock. BioLite
does not have any stock, equity compensation or similar plan pursuant to which BioLite may issue or grant equity-based awards
to its employees, directors and consultants.

 

    - 9 -

     

    

 

(c)  As
of the date of this Agreement, except as set forth in clauses (a) and (b) of this Section 3.3, and except as set forth on Section
3.3 of the BioLite Schedule of Exceptions: (i) there are not outstanding or authorized any (A) shares of capital stock or other
voting securities of BioLite, (B) securities of BioLite convertible into or exercisable or exchangeable for shares of capital
stock or voting securities of BioLite or (C) options or other rights to acquire from BioLite, or any obligation of BioLite to
issue, any capital stock, voting securities or securities convertible into or exercisable or exchangeable for capital stock or
voting securities of BioLite (collectively, “BioLite Securities“); (ii) there are no outstanding obligations
of BioLite to repurchase, redeem or otherwise acquire any BioLite Securities; and (iii) there are no other options, calls, warrants
or other rights, agreements, arrangements or commitments of any character relating to the issued or unissued capital stock or
other voting securities of BioLite to which BioLite is a party.

 

(d)  Neither
BioLite nor any of its Subsidiaries has outstanding bonds, debentures, notes or other obligations, the holders of which have the
right to vote (or that are convertible into or exercisable for securities having the right to vote) with the stockholders of BioLite
on any matter.

 

(e)  Section
3.3(e) of the BioLite Schedule of Exceptions sets forth (x) each of BioLite’s Subsidiaries and the ownership interest of
BioLite in each such Subsidiary, as well as the ownership interest of any other Person or Persons in each such Subsidiary (including
any options or other rights to acquire an equity interest) and (y) BioLite’s or its Subsidiaries’ capital stock, equity
interest or other direct or indirect ownership interest in any other Person other than securities in a publicly traded company
held for investment by BioLite or any of its Subsidiaries and consisting of less than 1% of the outstanding capital stock of such
company. BioLite has good title to all of its ownership interests in each of its Subsidiaries, free and clear of all Liens.

 

(f) Except
as set forth in Section 3.3(f) of the BioLite Schedule of Exceptions, BioLite and its Subsidiaries have good title to all of their
respective assets and properties, free and clear of all Liens.

 

(g) Except
as set forth in Section 3.3(g) of the BioLite Schedule of Exceptions, there are no voting trusts, proxies or other agreements,
arrangements, commitments or understandings of any character to which BioLite or its Subsidiaries or, to the Knowledge of BioLite,
is a party or by which BioLite is bound with respect to the issuance, holding, acquisition, voting or disposition of any shares
of capital stock or other security or equity interest of BioLite or its Subsidiaries.

 

Section
3.4Authority. (a) BioLite has all necessary corporate power and authority to execute and deliver this Agreement, to
perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance
of this Agreement by BioLite and the consummation by BioLite of the transactions contemplated hereby have been duly and validly
authorized by all necessary corporate action on the part of BioLite, subject, in the case of the BioLite Merger, to the approval
of this Agreement by the holders of at least a majority in combined voting power of the outstanding shares of BioLite Common Stock
(the “BioLite Requisite Vote”), and the filing with the Secretary of State of the State of Nevada of the BioLite
Articles of Merger as required by the NRS. The affirmative vote of a majority of the outstanding BioLite Common Stock is the only
vote required, if any such vote is required by applicable Law, of BioLite’s capital stock necessary in connection with the
approval and consummation of the BioLite Merger. No other vote of BioLite’s Stockholders is necessary in connection with
this Agreement or the consummation of any of the transactions contemplated hereby. This Agreement has been duly and validly executed
and delivered by BioLite and, assuming the due authorization, execution and delivery hereof by Parent, BioKey and each Merger
Sub, constitutes a legal, valid and binding obligation of BioLite enforceable against BioLite in accordance with its terms, subject
to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to
or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or
at law) and any implied covenant of good faith and fair dealing.

 

    - 10 -

     

    

 

(b) The
Board of Directors of BioLite has, by resolutions duly adopted at a meeting duly called and held (the "BioLite Board Approval")
(i) authorized the execution, delivery and performance of this Agreement, (ii) approved, and declared advisable, this Agreement,
and the BioLite Merger, (iii) determined that the terms of the BioLite Merger are fair to and in the best interests of the BioLite
Stockholders, and (iv) authorized the submission of this Agreement to the BioLite Stockholders for their approval and recommended
that the BioLite Stockholders approve this Agreement (the “BioLite Merger Recommendation”).

 

Section
3.5No Conflict; Required Filings and Consents. Except as set forth on Schedule 3.5(a) of the BioLite Schedule of Exceptions
and those contemplated by clauses (i) through (v) of subsection (b) below: (a) the execution, delivery and performance of this
Agreement by BioLite do not and will not (i) conflict with or violate the respective Articles of Incorporation or Bylaws of BioLite
or any Subsidiary, (ii) assuming that all consents, approvals and authorizations contemplated by clauses (i) through (v) of subsection
(b) below have been obtained and all filings described in such clauses have been made, conflict with or violate any foreign or
domestic federal, state or local law, statute, code, ordinance, regulation, rule, consent agreement, constitution or treaty of
any Governmental Body, including common law; and, in each case, any comparable state law (“Law”) applicable
to BioLite or any Subsidiary or by which any of their respective properties are bound or (iii) (A) result in any breach or violation
of or constitute a default (or an event which with notice or lapse of time or both would become a default), (B) result in the
loss of a benefit under, or give rise to any right of termination, cancellation, amendment or acceleration of, or (C) result in
the creation of any Lien on any of the properties or assets of BioLite or any of its Subsidiaries under, any note, bond, mortgage,
indenture, contract, agreement, lease, license, permit or other instrument or obligation (each, a “BioLite Contract“)
to which BioLite or any of its Subsidiaries is a party or by which BioLite or any of its Subsidiaries or any of their respective
properties are bound, except, in the case of clauses (ii) and (iii), for any such conflict, violation, breach, default, acceleration,
loss, right or other occurrence which would not, or would not reasonably be expected to, individually or in the aggregate, have
or reasonably be expected to have, a BioLite Material Adverse Effect.

 

(b)       The
execution, delivery and performance of this Agreement by BioLite and the consummation of the BioLite Merger do not and will not
require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Body, except
for (i) the filing with the SEC and declaration of effectiveness of the registration statement on Form S-4 (the “S-4”)
in which BioLite Exchange Fund and BioKey Exchange Fund are registered and any filings or approvals under applicable state securities
laws with respect to the issuance of Parent Common Stock in connection with the Mergers, (ii) the BioLite Requisite Vote, (iii)
the filing with the Secretary of State of the State of Nevada of the BioLite Articles of Merger as required by the NRS, and (iv)
any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain would
not individually or in the aggregate, have or reasonably be expected to have, a BioLite Material Adverse Effect (and together
with the consents, approvals and authorizations set forth on Schedule 3.5(a) of the BioLite Schedule of Exceptions, collectively,
the “BioLite Required Consents”).

 

    - 11 -

     

    

 

Section
3.6Compliance.

 

(a) To
the Knowledge of BioLite, BioLite and its Subsidiaries are not in violation of any Law applicable to BioLite or any of its Subsidiaries
or by which any of their properties are bound, and has not been notified in writing by any Governmental Body of any violation,
or any investigation with respect to any such Law, except for any such violation which would not, or would not reasonably be expected
to, individually or in the aggregate, have a BioLite Material Adverse Effect.

 

(b) BioLite
and its Subsidiaries, and their respective predecessors, have complied and are in compliance in all material respects with all
applicable Laws and orders and no BioLite Proceeding has been filed or commenced, or to the Knowledge of BioLite, threatened alleging
any failure so to comply, including, any claims arising under the Anti-Kickback Statute, False Claims Act, or any other federal
or state Law, whether or not corrected. BioLite and its Subsidiaries have not received any notice or communication from any Governmental
Body alleging any non-compliance of the foregoing.

 

(c) Neither
BioLite, nor any of its Subsidiaries, nor, to BioLite’s Knowledge, any of their officers, managers, members, directors,
agents, employees or any other Persons acting on their behalf has (i) made any illegal payment to any officer or employee of any
Governmental Body, or any customer or supplier of BioLite or its Subsidiaries, or (ii) accepted or received any unlawful contributions,
payments, expenditures or gifts; and no Proceeding has been filed or commenced alleging any such illegal payments.

 

Section
3.7Financial Statements

 

(a) BioLite
has provided to the Parent and BioKey audited consolidated financial statements of BioLite (including any related notes thereto)
for the fiscal years ended December 31, 2016 and 2015 (the “BioLite Audited Financial Statements”) which have
been prepared in accordance with GAAP and Regulation S-X for interim financial statements in all material respects applied on
a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and fairly present in all
material respects the consolidated financial position of BioLite at the respective dates thereof and the consolidated statements
of operations, cash flows and changes in stockholders’ equity for the periods indicated therein. The BioLite Interim Financial
Statements, provided to the Parent, will have been prepared in accordance with GAAP and Regulation S-X for interim financial statements
in all material respects applied on a consistent basis throughout the periods involved (except as may be indicated in the notes
thereto) and will fairly present in all material respects the consolidated financial position of BioLite as of the respective
dates thereof and the consolidated statements of operations and cash flows for the periods indicated therein (subject to normal
period-end adjustments).

 

    - 12 -

     

    

 

(b) BioLite
does not have any liabilities of any nature, except liabilities that (i) will be accrued or reserved against in the BioLite Interim
Financial Statements, when provided to Parent and BioKey, or will be reflected in the notes thereto, (ii) were incurred in the
ordinary course of business since the date of such financial statements, (iii) are incurred in connection with the transactions
contemplated by this Agreement, (iv) have been discharged or paid in full prior to the date of this Agreement in the ordinary
course of business, or (v) would not, or would not reasonably be expected to, individually or in the aggregate, have a BioLite
Material Adverse Effect. Section 3.7(b) of the BioLite Schedule of Exceptions sets forth a list of all outstanding debt for money
borrowed, the applicable lender, interest rate and the applicable payment dates except for obligations issued, undertaken or assumed
as the deferred purchase price of property or services, including without limitation any operating lease or capital lease, that
do not exceed $25,000 in the aggregate.

 

Section
3.8Absence of Certain Changes or Events. Except as set forth on Section 3.8 of the BioLite Schedule of Exceptions,
since September 30, 2017, until the date of this Agreement, and except as contemplated by this Agreement, BioLite and each Subsidiary
has conducted its business in the ordinary course consistent with past practice and there has not been (a) any change, event or
occurrence which has had or would reasonably be expected to have BioLite Material Adverse Effect; (b) any declaration, setting
aside or payment of any dividend or other distribution in cash, stock, property or otherwise in respect of BioLite’s capital
stock; (c) any redemption, repurchase or other acquisition of any shares of capital stock of BioLite (other than in connection
with the forfeiture or exercise of equity based awards, options in accordance with existing agreements or terms); (d) any granting
by BioLite to any of its directors, officers or employees of any material increase in compensation or benefits, except for increases
in the ordinary course of business consistent with past practice or that are required under any BioLite Plan; (e) any granting
to any director, officer or employee of the right to receive any severance or termination pay, except as provided for under any
plan or agreement in effect prior to September 30, 2017; (f) any entry by BioLite or any of its Subsidiaries into any employment,
consulting, indemnification, termination, change of control or severance agreement or arrangement with any present or former
director, officer or employee of BioLite, or any amendment to or adoption of any BioLite Plan or collective bargaining agreement;
(g) any material change by BioLite or any of its Subsidiaries in its accounting principles, except as may be required to conform
to changes in statutory or regulatory accounting rules or GAAP or regulatory requirements with respect thereto; or (h) any material
change in the tax accounting period or method or settlement of a material Tax claim or assessment, in each case, relating to BioLite
or a Subsidiary of BioLite, unless required by GAAP or applicable Law.

 

Section
3.9Absence of Litigation. Except as set forth on Section 3.9 of the BioLite Schedule of Exceptions, there are no suits,
claims, actions, proceedings, arbitrations, mediations or, to the Knowledge of BioLite, governmental investigations (“BioLite
Proceedings”) pending or, to the Knowledge of BioLite, threatened against BioLite or any of its Subsidiaries, other
than any BioLite Proceeding that would not, or would not reasonably be expected to, individually or in the aggregate, have a BioLite
Material Adverse Effect. Neither BioLite or any of its Subsidiaries nor any of their properties is or are subject to any order,
writ, judgment, injunction, decree or award except for those that would not, or would not reasonably be expected to, individually
or in the aggregate, have a BioLite Material Adverse Effect.

 

    - 13 -

     

    

 

Section
3.10Employee Benefit Plans. (a) Section 3.10 of the BioLite Schedule of Exceptions contains a true and complete list
of each BioLite Plan (as defined below). As used herein, the term “BioLite Plan” means each material employee
benefit plan (within the meaning of Section 3(3) of the Employment Retirement Income Security Act of 1974 (“ERISA”)),
including each “employee pension benefit plan” (as defined in Section 3(2) of ERISA), and each “employee welfare
benefit plan” (as defined in Section 3(1) of ERISA), each material employee benefit plan maintained outside the United States,
and each other material plan, arrangement or policy (written or oral) to provide benefits, other than salary or commissions, as
compensation for services rendered, including, without limitation, employment agreements, executive compensation agreements, incentive
arrangements, salary continuation, stock option, stock grant or stock purchase rights, phantom rights, deferred compensation,
bonus, severance policies or agreements, retention policies or agreements, change in control policies or agreements, fringe benefits
or other employee benefits, in each case maintained or sponsored by BioLite or any of its Subsidiaries or to which BioLite or
any of its Subsidiaries contributes to or for which BioLite or any of its Subsidiaries has or may have any liability, contingent
or otherwise, either directly or as a result of a BioLite ERISA Affiliate, or any other plan, arrangement or policy mandated by
applicable Law, for the benefit of any current, former or retired employee, officer, consultant, independent contractor or director
of BioLite, its Subsidiaries or any BioLite ERISA Affiliate (collectively, the “BioLite Employees”). BioLite
has made available to Parent and BioKey copies of all material documents constituting the BioLite Plans, the three most recently
filed Forms 5500 for such BioLite Plans and financial statements attached thereto, all Internal Revenue Service (the “IRS”)
determination letters for the BioLite Plans, all notices that were issued within the preceding three years by the IRS, Department
of Labor, or any other Governmental Body with respect to the BioLite Plans, all employee manuals or handbooks containing personnel
or employee relations policies, and all other material documents relating to the BioLite Plans. For purposes of this Section 3.10,
the term BioLite includes any BioLite ERISA Affiliate. The term “BioLite ERISA Affiliate” means any person, that together
with BioLite, is or was at any time treated as a single employer under section 414 of the Code or section 4001 of ERISA and any
general partnership of which BioLite is or has been a general partner.

 

(b) Each
BioLite Plan has been operated and administered in all respects in accordance with its terms and applicable Law, including, but
not limited to, ERISA and the Code, except for instances of noncompliance that would not have, individually or in the aggregate,
a BioLite Material Adverse Effect. All reporting, disclosure and notice requirements under ERISA, the Code and other applicable
Laws have been fully and completely satisfied with respect to each BioLite Plan, except for instances of noncompliance that would
not have, individually or in the aggregate, a BioLite Material Adverse Effect. With respect to each BioLite Plan, there has occurred
no non-exempt “prohibited transaction” (within the meaning of section 4975 of the Code or section 406 of ERISA) or
breach of any fiduciary duty described in section 404 of ERISA that could, if successful, result in any liability, direct or indirect,
for BioLite or any of its Subsidiaries or, to the Knowledge of BioLite, any stockholder, officer, director or employee of BioLite
or any of its Subsidiaries, except for instances of noncompliance that would not have, individually or in the aggregate, a BioLite
Material Adverse Effect. There are no pending or threatened claims by or on behalf of any BioLite Plan, or by or on behalf of
any participants or beneficiaries of any BioLite Plans under ERISA or applicable Law, or claiming benefit payments other than
those made in the ordinary operation of such plans. To the Knowledge of BioLite, no BioLite Plan is presently under investigation,
audit or examination by any Governmental Body, and no matters are pending with respect to any BioLite Plan under any IRS program.

 

    - 14 -

     

    

 

(c) Each
BioLite Plan intended to be qualified under section 401(a) of the Code, and the trust forming a part thereof, has received a favorable
determination letter from the IRS as to its qualification under the Code and to the effect that each such trust is exempt from
taxation under section 501(a) of the Code, or has an opinion letter from the IRS to the same effect, and each such determination
or opinion letter remains in effect and has not been revoked. Except as disclosed on Section 3.10(a) of the BioLite Schedule of
Exceptions, BioLite and its Subsidiaries have never maintained, sponsored or had any liability with respect to any other plan
subject to the requirements of section 401(a) of the Code. To the Knowledge of BioLite, nothing has occurred since the date of
such determination letter that could cause the loss of such qualification or tax-exempt status or the imposition of any liability,
lien, penalty or tax under ERISA or the Code. Each BioLite Plan has been timely amended to comply with applicable Law.

 

(d) BioLite
and its Subsidiaries do not sponsor, maintain or contribute to, and have never sponsored, maintained or contributed to, or had
any liability with respect to, any employee benefit plan subject to section 302 of ERISA, section 412 of the Code or Title IV
of ERISA. None of the BioLite Plans is a multiemployer plan (as defined in section 3(37) of ERISA). BioLite and its Subsidiaries
do not contribute to, and have never contributed to or had any other liability with respect to, a multiemployer plan or with respect
to any plan that has two or more contributing sponsors at least two of whom are not under common Control. There is not
now, and to the Knowledge of BioLite there are no existing circumstances that would reasonably be expected to give rise to, any
requirement for the posting of security with respect to BioLite Plan or the imposition of any pledge, lien, security interest
or encumbrance on assets of BioLite or any of its Subsidiaries under ERISA or the Code, or similar Laws of foreign jurisdictions.

 

(e) The
execution, delivery and performance by BioLite of this Agreement and the consummation of the transactions contemplated hereby
will not (either alone or upon occurrence of any additional or subsequent events) (i) constitute an event under any BioLite Plan
or any trust or loan related to any of those plans or agreements that will or may result in a prohibition of the transactions
contemplated by this Agreement or any payment, acceleration, forgiveness of indebtedness, vesting, distribution, increase in benefits
or obligation to fund benefits with respect to any BioLite Employee, or (ii) result in the triggering or imposition of any restrictions
or limitations on the right of BioLite to amend or terminate any BioLite Plan. No BioLite Plan, program, agreement or other arrangement,
either individually or collectively, provides for any payment or benefits becoming due to any director or employee of BioLite
that will be considered an “excess parachute payment” under section 280G of the Code. BioLite and its Subsidiaries
have not declared any bonus compensation in contemplation of the transactions contemplated by this Agreement. No payments or benefits
under any BioLite Plan or other agreement of BioLite or any of its Subsidiaries are, or are expected to be, subject to the disallowance
of a deduction under section 162(m) of the Code. BioLite and its Subsidiaries do not have any obligation to indemnify, hold harmless
or gross-up any individual with respect to any excise tax, penalty tax or interest under section 280G or 409A of the Code. Each
BioLite Plan that is a “nonqualified deferred compensation plan” (as defined in section 409A(d)(1) of the Code) is
in documentary compliance with the requirements of section 409A of the Code. Each nonqualified deferred compensation plan has
been operated since January 1, 2005 in good faith compliance with section 409A of the Code. No option (other than an option the
terms of which comply with the requirements of section 409A of the Code) has an exercise price that has been or may be less than
the fair market value of the underlying stock as of the date such option was granted or has any feature for the deferral of compensation
that could render the grant subject to section 409A of the Code.

 

    - 15 -

     

    

 

(f) With
respect to any BioLite Plan that is a group health plan (within the meaning of section 4980B(g)(2) of the Code), such BioLite
Plan complies, and in each and every case has complied, with all requirements of section 4980B of the Code, ERISA, Title XXII
of the Public Health Service Act, the applicable provisions of the Social Security Act, the Health Insurance Portability and Accountability
Act of 1996, and other applicable Laws, except for instances of noncompliance that would not have, individually or in the aggregate,
a BioLite Material Adverse Effect. No BioLite Plan provides health or other benefits after an employee’s or former employee’s
retirement or other termination of employment except as required under section 4980B of the Code.

 

(g) BioLite
and each of its Subsidiaries have paid all amounts that BioLite and each of its Subsidiaries are required to pay as contributions
to the BioLite Plans as of the last day of the most recent fiscal year of each of the BioLite Plans; all benefits accrued under
any funded or unfunded BioLite Plan have been paid, accrued or otherwise adequately reserved in accordance with GAAP; and all
monies withheld from employee paychecks with respect to the BioLite Plans have been transferred to the appropriate BioLite Plan
in a timely manner as required by applicable Law.

 

(h) BioLite
and its Subsidiaries have made no plan or commitment to create any additional BioLite Plan or to modify or change any existing
BioLite Plan.

 

(i) BioLite
does not maintain any benefit or compensation arrangement outside the jurisdiction of the United States, or one that covers any
employee residing or working outside the United States.

 

Section
3.11Labor and Employment Matters. BioLite and its Subsidiaries do not have any labor contracts or collective bargaining
agreements with any persons employed by BioLite or any of its Subsidiaries or any persons otherwise performing services primarily
for BioLite and its Subsidiaries. To the Knowledge of BioLite, there are no unfair labor practice complaints pending against BioLite
or any of its Subsidiaries before the National Labor Relations Board (the “NLRB”) or any other labor relations
tribunal or authority. There are no strikes, work stoppages, slowdowns, lockouts, arbitrations or grievances, or other labor disputes
pending or, to the Knowledge of BioLite, threatened against or involving BioLite or any of its Subsidiaries. No labor organization
or group of employees of BioLite or any of its Subsidiaries has made a pending demand for recognition or certification. BioLite
and its Subsidiaries have not experienced any labor strike, dispute or stoppage or other labor difficulty involving its employees,
and there are no representation or certification proceedings or petitions seeking a representation proceeding presently pending
or threatened to be brought or filed, with the NLRB or any other labor relations tribunal or authority. BioLite and its Subsidiaries
are in compliance with all applicable Laws respecting employment and employment practices, classification of employees, terms
and conditions of employment, wages and hours, occupational safety and health, immigration and immigration practices, including,
but not limited to, any such Laws respecting employment discrimination, termination of employment, workers’ compensation,
family and medical leave, the Immigration Reform and Control Act, except for instances of noncompliance that would not have, individually
or in the aggregate, a BioLite Material Adverse Effect.

 

    - 16 -

     

    

 

Section
3.12Insurance. All material insurance policies of BioLite and its Subsidiaries are listed in Section 3.12 of the BioLite
Schedule of Exceptions. Except as would not, or would not reasonably be expected to, individually or in the aggregate, have a
BioLite Material Adverse Effect: (a) all insurance policies of BioLite and its Subsidiaries are in full force and effect and provide
insurance in such amounts and against such risks as is sufficient to comply with applicable Law; (b) BioLite and its Subsidiaries
are not in breach or default, and BioLite and its Subsidiaries have not taken any action or failed to take any action which, with
notice or the lapse of time, would constitute such a breach or default, or permit termination or modification of, any of such
insurance policies; and (c) to the Knowledge of BioLite, no notice in writing of cancellation or termination has been received
with respect to any such policy except customary notices of cancellation in advance of scheduled expiration.

 

Section
3.13Properties. BioLite and its Subsidiaries own no real property. Section 3.13 of the BioLite Schedule of Exceptions
contains a complete and correct list of all real property leased by BioLite and its Subsidiaries (the “BioLite Leased
Property”). BioLite and its Subsidiaries have good and valid leasehold interests in all BioLite Leased Property. With
respect to all BioLite Leased Property, there is not, under any of such leases, any existing default by BioLite or any of its
Subsidiaries or, to the Knowledge of BioLite, the counterparties thereto, or event which, with notice or lapse of time or both,
would become a material default by BioLite or any of its Subsidiaries or, to the Knowledge of BioLite, the counterparties thereto.
The BioLite Leased Property is maintained in a state of repair and condition that is consistent with the normal conduct of BioLite’s
business.

 

Section
3.14Tax Matters. Subject to such exceptions that would not have a BioLite Material Adverse Effect:

 

(a) Each
of BioLite and its Subsidiaries has timely filed all Tax Returns required to be filed by it or has timely filed appropriate extensions
and each such Tax Return was complete and correct in all material respects at the time of filing. Each of BioLite and its Subsidiaries
has timely paid or caused to be timely paid all Taxes shown on such Tax Returns to be due with respect to the taxable periods
covered by such Tax Returns and all other Taxes as are due (including Taxes for which no Tax Returns are required to be filed),
and the BioLite Interim Financial Statements, when provided to the Parent, will reflect an adequate reserve (in addition to any
reserve for deferred Taxes established to reflect timing differences between book and Tax income) for all Taxes payable by BioLite
and its Subsidiaries for all taxable periods and portions thereof through the date of such financial statements.

 

    - 17 -

     

    

 

(b) To
the Knowledge of BioLite, no Tax Return of BioLite or any of its Subsidiaries is under audit or examination by any taxing authority.
Neither BioLite nor any of its Subsidiaries has received written or, to the Knowledge of BioLite, verbal notice of such an audit
or examination. There is no deficiency, refund litigation, proposed adjustment or matter in controversy with respect to any Taxes
due and owing by BioLite or any of its Subsidiaries. Each deficiency resulting from any completed audit or examination of BioLite
relating to Taxes by any taxing authority has been timely paid. Neither BioLite nor any of its Subsidiaries has received written
notice from a taxing authority in any jurisdiction in which BioLite or any Subsidiary has not filed a Tax Return for any period
that BioLite or such Subsidiary is required to file a Tax Return in such jurisdiction.

 

(c) There
is no currently effective written agreement or other written document extending or waiving, or having the effect of extending
or waiving, the period of assessment (or reassessment) or collection of any Taxes of BioLite or any of its Subsidiaries, and no
such request for an extension or waiver is currently pending. No power of attorney (other than powers of attorney authorizing
employees of BioLite to act on behalf of BioLite) with respect to any Taxes has been executed or filed with any taxing authority.
Neither BioLite nor any of its Subsidiaries is party to or bound by any written Tax sharing agreement, Tax indemnity obligation
or similar arrangement with respect to Taxes (including any advance pricing agreement, closing agreement or other similar agreement
related to Taxes) (other than any such agreement, obligation or arrangement between or among BioLite and its Subsidiaries).

 

(d) Neither
BioLite nor any of its Subsidiaries (i) has been a member of an affiliated group of corporations with the meaning of Section 1504
of the Code or any group that has filed a combined, consolidated or unitary Tax Return (other than a group of which BioLite or
any of its Subsidiaries is or was the common parent) or (ii) has any liability for Taxes of another Person (other than BioLite
or its Subsidiaries) under Treasury Regulation sections 1.1502-6, 1.1502-78 (or similar provisions of state, local or foreign
Law), as a transferee or successor, by contract or otherwise.

 

(e) No
Liens for Taxes exist with respect to any assets or properties of BioLite or any of its Subsidiaries, except for statutory Liens
for Taxes not yet due and Liens either not in excess of $50,000, in the aggregate, except as set forth on Section 3.14(f) of the
BioLite Schedule of Exceptions.

 

(f) BioLite
and its Subsidiaries have complied in all respects with all applicable Laws relating to the payment and withholding of Taxes (including
withholding of Taxes pursuant to Sections 1441, 1442, 3121 and 3402 of the Code and similar provisions under any other domestic
or foreign Tax Laws) and have, within the time and the manner prescribed by Law, withheld from and paid over to the proper Governmental
Bodies all amounts required to be so withheld and paid over under applicable Laws.

 

(g) BioLite
and each of its Subsidiaries has disclosed on their United States federal income Tax Returns all positions taken therein that
could give rise to a substantial understatement of United States federal income tax within the meaning of Section 6662 of the
Code, and neither BioLite nor any of its Subsidiaries has ever participated in any listed transaction, as defined in Treasury
Regulation Section 1.6011-4(b)(2), required to be reported in a disclosure statement pursuant to Treasury Regulation Section 1.6011-4.

 

    - 18 -

     

    

 

(h) During
the two (2) year period ending on the date hereof, neither BioLite nor any of its Subsidiaries was a “distributing corporation”
or a “controlled corporation” in a transaction intended to be governed by Section 355 of the Code.

 

Section
3.15Information Supplied. None of the information supplied or to be supplied by BioLite expressly for inclusion or
incorporation by reference in (i) the S-4 Prospectus, will, at the time such document is filed with the SEC, at any time it is
amended or supplemented or at the time it is first published, sent or given to BioLite Stockholders, contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or (ii) if required to be delivered to
BioLite’s stockholders pursuant to applicable Law, a Proxy Statement as defined below will, at the date it is first mailed
to BioLite Stockholders and at the time of the BioLite Stockholders Meeting or at the date of any amendment thereof or supplement
thereto, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they are made, not misleading. The Proxy
Statement, at the date such Proxy Statement is first mailed to BioLite Stockholders and at the time of the BioLite Stockholders
Meeting, will comply as to form in all material respects with the requirements of the Exchange Act and the rules and regulations
promulgated thereunder. Notwithstanding the foregoing, BioLite makes no representation or warranty with respect to any information
supplied by Parent or Merger Sub 1 or any of their respective representatives which is contained or incorporated by reference
in the Prospectus. A Proxy Statement means a statement prepared by a company when soliciting stockholder votes on certain matters
and distributed to the company’s stockholders before its stockholder meeting to vote on such matters stated therein.

 

Section
3.16Reserved.

 

Section
3.17Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by and on behalf of BioLite or
any of its Subsidiaries or for which BioLite or any of its Subsidiaries may be financially liable.

 

Section
3.18Takeover Statutes. BioLite has no “rights plan,” “rights agreement,” or “poison pill”
in effect. Assuming the accuracy of the representations and warranties of Parent the Merger Subs, and BioKey, to the Knowledge
of BioLite as of the date hereof, no “fair price”, “moratorium”, “control share acquisition”,
“business combination” or other similar antitakeover statute or regulation enacted under U.S. state or federal Laws
applicable to BioLite, including those under the NRS, will be applicable to the BioLite Merger or the other transactions contemplated
hereby. No takeover, business combination, control share acquisition, fair price, moratorium or similar statutes apply or purport
to apply to this Agreement, the BioLite Merger or any of the other transactions contemplated by this Agreement.

 

    - 19 -

     

    

 

Section
3.19Intellectual Property. Except as set forth in Section 3.19 of the BioLite Schedule of Exceptions, to the Knowledge
of BioLite, BioLite or one of its Subsidiaries (as specifically identified on Schedule 3.19(a)) is the sole and exclusive (as
to any third party) owner or assignee of the entire right, title and interest in and to the Intellectual Property set forth on
Schedule 3.19(a) and all other Intellectual Property material to and used in its business, and is licensed perpetually and without
royalty or other payment obligations to third parties to the Intellectual Property set forth on Schedule 3.19(b), except as noted
on Schedule 3.19(b). BioLite or such Subsidiary owns or has the rights to use, free and clear of any security interests, liens,
claims, pledges, agreements, limitations in voting rights, charges or other encumbrances of any nature whatsoever (“Liens”),
but subject to any existing licenses or other grants of rights to third parties (to the extent set forth in Section 3.19(a) or
Section 3.19(b) of the BioLite Schedule of Exceptions), all material Intellectual Property as is necessary and sufficient (i)
for its businesses as currently conducted and (ii) for the services provided by BioLite and its Subsidiaries (collectively, the
“BioLite Intellectual Property Rights”). Except as would not reasonably be expected to, individually or in
the aggregate, have a BioLite Material Adverse Effect, (a) there is no Proceeding pending, or to the Knowledge of BioLite threatened,
(i) alleging infringement, misappropriation, violation or dilution by BioLite or any of its Subsidiaries of any Intellectual Property
of a third party or challenging the validity, enforceability, ownership or use of any of the Intellectual Property set forth in
Section 3.19(a) or Section 3.19(b) of the BioLite Schedule of Exceptions or the BioLite Intellectual Property Rights therein and
(ii) by BioLite or any of its Subsidiaries alleging infringement or misappropriation of any Intellectual Property against a third
party; (b) the provision of products or services by BioLite and its Subsidiaries do not infringe the valid Intellectual Property
rights of any third party, and, to the Knowledge of BioLite, the BioLite Intellectual Property Rights are not being infringed
by any third party; (c) no BioLite Intellectual Property Right will terminate or cease to be a valid right of BioLite or any of
its Subsidiaries by reason of the execution and delivery of this Agreement by BioLite, the performance of BioLite of its obligations
hereunder, or the consummation by BioLite of the BioLite Merger; and (d) except as set forth in Section 3.19 of the BioLite Schedule
of Exceptions, BioLite and its Subsidiaries have not granted any license, sublicenses or any other rights in, to or under the
Intellectual Property. As used in this Agreement, “Intellectual Property” means all patents, inventions, copyrights,
software, trademarks, service marks, domain names, trade dress, trade secrets and all other intellectual property and intellectual
property rights of any kind or nature. For purposes of this Agreement, the term “patents” means United States and
non-U.S. patents (utility or design, as applicable), provisional patent applications, non-provisional patent applications, continuations,
continuations-in-part, divisions, any such patents resulting from reissue, reexamination, renewal or extension (including any
supplementary protection certificate) of any patent, patent disclosures, substitute applications, and any confirmation patent
or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.

 

Section
3.20Contracts. (a) Except for this Agreement and except for Contracts set forth in Section 3.20 of the BioLite Schedule
of Exceptions, as of the date of this Agreement, BioLite or any of its Subsidiaries thereof is not a party to or bound by any
Contract: (i) that would be required to be filed by BioLite as a “material contract” pursuant to Item 601(b)(10) of
Regulation S-K under the Securities Act; (ii) contains covenants binding upon BioLite or any of its Subsidiaries that restrict
the ability of BioLite or any of its Subsidiaries (or which, following the consummation of the BioLite Merger, would materially
restrict the ability of the BioLite Surviving Corporation or any BioLite Affiliate) to compete in any business or geographic area;
or (iii) involving the payment or receipt of royalties or other amounts of more than $10,000 related to any product of BioLite
or any BioLite Affiliate , or (iv) that would prevent, materially delay or materially impede BioLite’s ability to consummate
the BioLite Merger or the other transactions contemplated by this Agreement. Each such Contract described in clauses (i) through
(iii) as well as each Contract listed in Section 3.20)a) or Section 3.20(b) of the BioLite Schedule of Exceptions is referred
to herein as a “BioLite Material Contract“.

 

    - 20 -

     

    

 

(b) Each
of the BioLite Material Contracts is valid and binding on BioLite or the applicable Subsidiary of BioLite, as the case may be,
and, to the Knowledge of BioLite, each other party thereto and is in full force and effect, except for such failures to be valid
and binding or to be in full force and effect as would not, or would not reasonably be expected to, individually or in the aggregate,
have a BioLite Material Adverse Effect. There is no default under any BioLite Material Contract by BioLite or any of its Subsidiaries
and no event has occurred that with the lapse of time or the giving of notice or both would constitute a default thereunder by
BioLite or any of its Subsidiaries, in each case except as would not, or would not reasonably be expected to, individually or
in the aggregate, have a BioLite Material Adverse Effect.

 

Section
3.21Affiliate Transactions. Except as otherwise disclosed in Section 3.21 of the BioLite Schedule of Exceptions, no
executive officer or director of BioLite or any Subsidiary thereof or any Person owning 4.99% or more of the shares of BioLite
Common Stock or any other “affiliate” as defined in Rule 12b-2 under the Exchange Act (each a “BioLite Affiliate“)
is a party to any Contract with or binding upon BioLite or any Subsidiary thereof or any of its properties or assets or has any
material interest in any material property owned by BioLite or has engaged in any material transaction with any of the foregoing
within the last twelve (12) months preceding the date of this Agreement, in each case, that is of a type that would be required
to be disclosed under Item 404 of Regulation S-K under the Securities Act.

 

Section
3.22Potential Products; FDA; EMEA. (a) BioLite possesses all certificates, authorizations and permits issued by the
appropriate federal, state or foreign regulatory authorities necessary to conduct its business as currently conducted, including
without limitation all such certificates, authorizations and permits required by the United States Food and Drug Administration
(the “FDA”) or any other federal, state or foreign agencies or bodies engaged in the regulation of pharmaceuticals
or biohazardous materials, except where the failure to so possess such certificates, authorizations and permits, individually
or in the aggregate, would not reasonably be expected to result in a BioLite Material Adverse Effect. BioLite has not received
any written notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit
which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected
to have a BioLite Material Adverse Effect.

 

    - 21 -

     

    

 

(b)
BioLite has not received any written notices or statements from the FDA, the European Medicines Agency (the “EMEA”)
or any other governmental agency that (i) any drug candidate of BioLite (each a “Potential Product”) may or will be
rejected or determined to be non-approvable; (ii) a delay in time for review and/or approval of a marketing authorization application
or marketing approval application in any jurisdiction for any Potential Product is or may be required, requested or being implemented;
(iii) one or more clinical studies for any Potential Product shall or may be requested or required in addition to the clinical
studies submitted to the FDA prior to the date hereof as a precondition to or condition of issuance or maintenance of a marketing
approval for any Potential Product; (iv) any license, approval, permit or authorization to conduct any clinical trial of or market
any product or Potential Product of BioLite has been, will be or may be suspended, revoked, modified or limited, except in the
cases of clauses (i), (ii), (iii) and (iv) where such rejections, determinations, delays, requests, suspensions, revocations,
modifications or limitations would not reasonably be expected to have, individually or in the aggregate, a BioLite Material Adverse
Effect.

 

(c)
To BioLite’s knowledge, the preclinical and clinical testing, application for marketing approval of, manufacture, distribution,
promotion and sale of the products and Potential Products of BioLite is in compliance, in all material respects, with all laws,
rules and regulations applicable to such activities, including without limitation applicable good laboratory practices, good clinical
practices and good manufacturing practices, except for such non-compliance as would not reasonably be expected to have, individually
or in the aggregate, have a BioLite Material Adverse Effect. BioLite is not aware of any studies, tests or trial the results of
which reasonably call into question the results of the tests and trials conducted by or on behalf of BioLite. BioLite has not
received written notice of adverse finding, warning letter or clinical hold notice from the FDA or any non-U.S. counterpart of
any of the foregoing, or any untitled letter or other correspondence or notice from the FDA or any other governmental authority
or agency or any institutional or ethical review board alleging or asserting noncompliance with any law, rule or regulation applicable
in any jurisdiction, except notices, letters, and correspondences and non-U.S. counterparts thereof alleging or asserting such
noncompliance as would not reasonably be expected to have, individually or in the aggregate, have a BioLite Material Adverse Effect.
BioLite has not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or
issued, any recall, field correction, market withdrawal or replacement, safety alert, warning, “dear doctor” letter,
investigator notice, or other notice or action relating to an alleged or potential lack of safety or efficacy of any product or
Potential Product of BioLite, any alleged product defect of any product or Potential Product of BioLite, or any violation of any
material applicable law, rule, regulation or any clinical trial or marketing license, approval, permit or authorization for any
product or potential product of BioLite, and BioLite is not aware of any facts or information that would cause it to initiate
any such notice or action and has no knowledge or reason to believe that the FDA, the EMEA or any other governmental agency or
authority or any institutional or ethical review board or other non-governmental authority intends to impose, require, request
or suggest such notice or action.

 

    - 22 -

     

    

 

ARTICLE
4

REPRESENTATIONS AND WARRANTIES OF BIOKEY

 

BioKey
hereby represents and warrants to Parent, BioLite, and each Merger Sub that, except as set forth on the BioKey Schedule of Exceptions
delivered by BioKey to the Parent, BioLite, and each Merger Sub prior to the execution of this Agreement and thereafter prior
to Closing (the “BioKey Schedule of Exceptions”), it being understood that a disclosure in any section of the
BioKey Schedule of Exceptions shall be deemed to have been set forth in all other applicable sections of the BioKey Schedule of
Exceptions where it is readily apparent on the face of the disclosure that such disclosure is applicable to such other sections,
notwithstanding the omission of any cross reference to such other section; and it being further understood that the BioKey Schedule
of Exceptions will be updated from time to time for events that occur between execution of this Agreement and Closing and a final
copy of the BioKey Schedule of Exceptions will be delivered to Parent, BioLite, and each Merger Sub prior to the Closing:

 

Section
4.1Organization and Qualification. BioKey and each Subsidiary thereof is a corporation duly organized, validly existing
and in good standing or active status under the Laws of the jurisdiction in which it is incorporated and has all requisite corporate
power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted, except
where any failure to be so organized, existing or in good standing or active status or to have such power or authority would not,
or would not reasonably be expected to, individually or in the aggregate, have a BioKey Material Adverse Effect. BioKey and each
Subsidiary thereof is duly qualified or licensed to do business, and is in good standing, in each jurisdiction where the character
of the properties owned, leased or operated by it or the nature of its activities makes such qualification or licensing necessary,
except for any failure to be so qualified or licensed or in good standing which would not, or would not reasonably be expected
to, individually or in the aggregate, have a BioKey Material Adverse Effect. “BioKey Material Adverse Effect”
means any change, effect, event or occurrence that has a material adverse effect on the assets, business, financial condition
or results of operations of BioKey and its Subsidiaries taken as a whole or that would reasonably be expected to prevent or materially
delay BioKey from performing its obligations under this agreement in any material respect or materially delay consummating the
transactions contemplated hereby;

 

Section
4.2Articles of Incorporation and Bylaws. BioKey has heretofore furnished or otherwise made available to Parent and
BioKey a complete and correct copy of Articles of Incorporation and Bylaws of BioKey and each of its Subsidiaries as in effect
on the date hereof and all minutes of their Board of Directors since January 1, 2015, other than those with respect to consideration
and approval of the Mergers and related transactions. The Articles of Incorporation and Bylaws of BioKey and its Subsidiaries
are in full force and effect and no other organizational documents are applicable to or binding upon BioKey or its Subsidiaries.
Neither BioKey nor its Subsidiaries is in violation of any provisions of its Articles of Incorporation or Bylaws in any material
respect.

 

Section
4.3Capitalization. (a) The authorized capital stock of BioKey consists of (i) thirty million (30,000,000) shares of
common stock, having no par value, and (ii) twenty-three million five hundred sixty-two thousand (23,562,000) shares of preferred
stock, having no par value (the “BioKey Preferred Stock”), of which seven million (7,000,000) shares are designated
as Series A Preferred Stock (the “BioKey Series A Preferred”), one million one hundred sixty thousand (1,160,000)
shares are designated as Series B Preferred Stock (the “BioKey Series B Preferred”), fifteen million (15,000,000)
shares are designated as Series C Preferred Stock (the “BioKey Series C Preferred”), and four hundred two thousand
(402,000) shares are designated as Series C Nonvoting Preferred Stock (the “BioKey Nonvoting Series C Preferred”).

 

    - 23 -

     

    

 

(b) As
of the date of this Agreement: (i) seven million four hundred thirty-eight thousand thirty-four (7,438,034) shares of BioKey Common
Stock were issued and outstanding, all of which were validly issued, fully paid and non-assessable and were issued free of preemptive
rights, (ii) an aggregate of four million two-hundred fifty thousand (4,250,000) shares of BioKey Common Stock were reserved for
issuance upon or otherwise deliverable in connection with the grant of equity-based awards or the exercise of outstanding options
to purchase BioKey Common Stock issued pursuant to the BioKey 2015 Stock Plan (the “BioKey Stock Plan”), of
which three million nine hundred forty-eight thousand thirty-four (3,948,034) shares of BioKey Common Stock have been issued under
such BioKey Stock Plan and two hundred sixty-one thousand nine hundred forty (261,940) underlying the issued options exercisable
to purchase BioKey Common Stock and (iii) twenty-two million one hundred thirty-three thousand ninety-seven (22,133,097) shares
of BioKey Preferred Stock are outstanding, of which seven million (7,000,000) shares are Series A Preferred Stock, one million
one hundred sixty thousand (1,160,000) shares are Series B Preferred Stock, and thirteen million nine hundred seventy-three and
ninety-seven (13,973,097) shares are Series C Preferred Stock. Section 4.3 of the BioKey Schedule of Exceptions sets forth, as
of the date of this Agreement, each equity-based award, phantom right, and option outstanding under the BioKey Stock Plan or otherwise,
the number of shares of BioKey Common Stock issuable thereunder and the expiration date and exercise or conversion price relating
thereto. The outstanding but unexercised BioKey options existing at Closing shall be deemed automatically cancelled and terminated
without further consideration and such cancellation will be consistent with the BioKey Stock Plan. Unless disclosed on Section
4.3 of the BioKey Schedule of Exceptions, no other equity-based award, phantom right or option is outstanding under a BioKey Stock
Plan or otherwise.

 

(c) As
of the date of this Agreement, except as set forth in clauses (a) and (b) of this Section 4.3, and except as set forth on Section
4.3 of the BioKey Schedule of Exceptions: (i) there are not outstanding or authorized any (A) shares of capital stock or other
voting securities of BioKey, (B) securities of BioKey convertible into or exercisable or exchangeable for shares of capital stock
or voting securities of BioKey or (C) options or other rights to acquire from BioKey, or any obligation of BioKey to issue, any
capital stock, voting securities or securities convertible into or exercisable or exchangeable for capital stock or voting securities
of BioKey (collectively, “BioKey Securities“); (ii) there are no outstanding obligations of BioKey to repurchase,
redeem or otherwise acquire any BioKey Securities; and (iii) there are no other options, calls, warrants or other rights, agreements,
arrangements or commitments of any character relating to the issued or unissued capital stock or other voting securities of BioKey
to which BioKey is a party.

 

(d) Neither
BioKey nor any of its Subsidiaries has outstanding bonds, debentures, notes or other obligations, the holders of which have the
right to vote (or that are convertible into or exercisable for securities having the right to vote) with the stockholders of BioKey
on any matter.

 

    - 24 -

     

    

 

(e) Section
4.3(e) of the BioKey Schedule of Exceptions sets forth (x) each of BioKey’s Subsidiaries and the ownership interest of BioKey
in each such Subsidiary, as well as the ownership interest of any other Person or Persons in each such Subsidiary (including any
options or other rights to acquire an equity interest) and (y) BioKey’s or its Subsidiaries’ capital stock, equity
interest or other direct or indirect ownership interest in any other Person other than securities in a publicly traded company
held for investment by BioKey or any of its Subsidiaries and consisting of less than 1% of the outstanding capital stock of such
company. BioKey has good title to all of its ownership interests in each of its Subsidiaries, free and clear of all Liens.

 

(f) Except
as set forth in Section 4.3(f) of the BioKey Schedule of Exceptions, BioKey and its Subsidiaries have good title to all of their
respective assets and properties, free and clear of all Liens.

 

(g) Except
as set forth in Section 4.3(g) of the BioKey Schedule of Exceptions, there are no voting trusts, proxies or other agreements,
arrangements, commitments or understandings of any character to which BioKey or its Subsidiaries or, to the Knowledge of BioKey,
is a party or by which BioKey is bound with respect to the issuance, holding, acquisition, voting or disposition of any shares
of capital stock or other security or equity interest of BioKey or its Subsidiaries.

 

Section
4.4Authority. (a) BioKey has all necessary corporate power and authority to execute and deliver this Agreement, to
perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance
of this Agreement by BioKey and the consummation by BioKey of the transactions contemplated hereby have been duly and validly
authorized by all necessary corporate action on the part of BioKey, subject, in the case of the BioKey Merger, to the approval
of this Agreement by the holders of at least a majority in combined voting power of the outstanding shares of BioKey Common Stock
and a majority in combined voting power of the outstanding shares of BioKey Preferred Stock (together, the “BioKey Requisite
Vote”), and the filing with the Secretary of State of the State of California of the BioKey Certificate of Merger as required
by the CGCL. The affirmative vote of a majority of the outstanding BioKey Common Stock and a majority of the outstanding BioKey
Preferred Stock is the only vote required, if any such vote is required by applicable Law, of BioKey’s capital stock necessary
in connection with the approval and consummation of the BioKey Merger. No other vote of BioKey’s Stockholders is necessary
in connection with this Agreement or the consummation of any of the transactions contemplated hereby. This Agreement has been
duly and validly executed and delivered by BioKey and, assuming the due authorization, execution and delivery hereof by Parent,
BioLite and each Merger Sub, constitutes a legal, valid and binding obligation of BioKey enforceable against BioKey in accordance
with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other
similar Laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a
proceeding in equity or at law) and any implied covenant of good faith and fair dealing.

 

    - 25 -

     

    

 

(b) The
Board of Directors of BioKey has, by resolutions duly adopted at a meeting duly called and held (the "BioKey Board Approval")
(i) authorized the execution, delivery and performance of this Agreement, (ii) approved, and declared advisable, this Agreement,
and the BioKey Merger, (iii) determined that the terms of the BioKey Merger are fair to and in the best interests of the BioKey
Stockholders, and (iv) authorized the submission of this Agreement to the BioKey Stockholders for their approval and recommended
that the BioKey Stockholders approve this Agreement (the “BioKey Merger Recommendation”).

 

Section
4.5No Conflict; Required Filings and Consents. Except as set forth on Schedule 4.5(a) of the BioKey Schedule of Exceptions
and those contemplated by clauses (i) through (v) of subsection (b) below: (a) the execution, delivery and performance of this
Agreement by BioKey do not and will not (i) conflict with or violate the respective Articles of Incorporation or Bylaws of BioKey
or any Subsidiary, (ii) assuming that all consents, approvals and authorizations contemplated by clauses (i) through (v) of subsection
(b) below have been obtained and all filings described in such clauses have been made, conflict with or violate any foreign or
domestic federal, state or local law, statute, code, ordinance, regulation, rule, consent agreement, constitution or treaty of
any Governmental Body, including common law; and, in each case, any comparable state Law applicable to BioKey or any Subsidiary
or by which any of their respective properties are bound or (iii) (A) result in any breach or violation of or constitute a default
(or an event which with notice or lapse of time or both would become a default), (B) result in the loss of a benefit under, or
give rise to any right of termination, cancellation, amendment or acceleration of, or (C) result in the creation of any Lien on
any of the properties or assets of BioKey or any of its Subsidiaries under, any note, bond, mortgage, indenture, contract, agreement,
lease, license, permit or other instrument or obligation (each, a “BioKey Contract“) to which BioKey or any
of its Subsidiaries is a party or by which BioKey or any of its Subsidiaries or any of their respective properties are bound,
except, in the case of clauses (ii) and (iii), for any such conflict, violation, breach, default, acceleration, loss, right or
other occurrence which would not, or would not reasonably be expected to, individually or in the aggregate, have or reasonably
be expected to have, a BioKey Material Adverse Effect.

 

(b) The
execution, delivery and performance of this Agreement by BioKey and the consummation of the BioKey Merger do not and will not
require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Body, except
for (i) the filing with the SEC and declaration of effectiveness of the registration statement on Form S-4 (the “S-4”)
in which BioLite Exchange Fund and BioKey Exchange Fund are registered , (ii) the BioKey Requisite Vote, (iii) the filing with
the Secretary of State of the State of California of the BioKey Certificate of Merger as required by the CGCL, and (iv) any such
consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain would not individually
or in the aggregate, have or reasonably be expected to have, a BioKey Material Adverse Effect (and together with the consents,
approvals and authorizations set forth on Schedule 4.5(a) of the BioKey Schedule of Exceptions, collectively, the “BioKey
Required Consents”).

 

    - 26 -

     

    

 

Section
4.6Compliance.

 

(a) To
the Knowledge of BioKey, BioKey and its Subsidiaries are not in violation of any Law applicable to BioKey or any of its Subsidiaries
or by which any of their properties are bound, and has not been notified in writing by any Governmental Body of any violation,
or any investigation with respect to any such Law, except for any such violation which would not, or would not reasonably be expected
to, individually or in the aggregate, have a BioKey Material Adverse Effect.

 

(b) BioKey
and its Subsidiaries, and their respective predecessors, have complied and are in compliance in all material respects with all
applicable Laws and orders and no BioKey Proceeding has been filed or commenced, or to the Knowledge of BioKey, threatened alleging
any failure so to comply, including, any claims arising under the Anti-Kickback Statute, False Claims Act, or any other federal
or state Law, whether or not corrected. BioKey and its Subsidiaries have not received any notice or communication from any Governmental
Body alleging any non-compliance of the foregoing.

 

(c) Neither
BioKey, nor any of its Subsidiaries, nor, to BioKey’s Knowledge, any of their officers, managers, members, directors, agents,
employees or any other Persons acting on their behalf has (i) made any illegal payment to any officer or employee of any Governmental
Body, or any customer or supplier of BioKey or its Subsidiaries, or (ii) accepted or received any unlawful contributions, payments,
expenditures or gifts; and no Proceeding has been filed or commenced alleging any such illegal payments.

 

Section
4.7Financial Statements

 

(a) The
BioKey Audited Financial Statements, when provided to Parent and BioLite, will have been prepared in accordance with GAAP and
Regulation S-X for audited financial statements in all material respects applied on a consistent basis throughout the periods
involved (except as may be indicated in the notes thereto) and fairly present in all material respects the consolidated financial
position of BioKey at the respective dates thereof and the consolidated statements of operations, cash flows and changes in stockholders’
equity for the periods indicated therein. The BioKey Interim Financial Statements, when provided to Parent, will have been prepared
in accordance with GAAP and Regulation S-X for interim financial statements in all material respects applied on a consistent basis
throughout the periods involved (except as may be indicated in the notes thereto) and will fairly present in all material respects
the consolidated financial position of BioKey as of the respective dates thereof and the consolidated statements of operations
and cash flows for the periods indicated therein (subject to normal period-end adjustments).

 

(b) As
of such time when BioKey will have provided to the Parent the BioKey Interim Financial Statements, BioKey will not have any liabilities
of any nature, except liabilities that (i) are accrued or reserved against in the BioKey Interim Financial Statements or are reflected
in the notes thereto, (ii) were incurred in the ordinary course of business since the date of such financial statements, (iii)
are incurred in connection with the transactions contemplated by this Agreement, (iv) have been discharged or paid in full prior
to the date of this Agreement in the ordinary course of business, or (v) would not, or would not reasonably be expected to, individually
or in the aggregate, have a BioKey Material Adverse Effect. Section 4.7(b) of the BioKey Schedule of Exceptions sets forth a list
of all outstanding debt for money borrowed, the applicable lender, interest rate and the applicable payment dates except for obligations
issued, undertaken or assumed as the deferred purchase price of property or services, including without limitation any operating
lease or capital lease, that do not exceed $25,000 in the aggregate.

 

    - 27 -

     

    

 

Section
4.8Absence of Certain Changes or Events. Except as set forth on Section 4.8 of the BioKey Schedule of Exceptions, since
September 30, 2017, until the date of this Agreement, and except as contemplated by this Agreement, BioKey and each Subsidiary
has conducted its business in the ordinary course consistent with past practice and there has not been (a) any change, event or
occurrence which has had or would reasonably be expected to have BioKey Material Adverse Effect; (b) any declaration, setting
aside or payment of any dividend or other distribution in cash, stock, property or otherwise in respect of BioKey’s capital
stock; (c) any redemption, repurchase or other acquisition of any shares of capital stock of BioKey (other than in connection
with the forfeiture or exercise of equity based awards, options in accordance with existing agreements or terms); (d) any granting
by BioKey to any of its directors, officers or employees of any material increase in compensation or benefits, except for increases
in the ordinary course of business consistent with past practice or that are required under any BioKey Plan; (e) any granting
to any director, officer or employee of the right to receive any severance or termination pay, except as provided for under any
plan or agreement in effect prior to September 30, 2017; (f) any entry by BioKey or any of its Subsidiaries into any employment,
consulting, indemnification, termination, change of control or severance agreement or arrangement with any present or former
director, officer or employee of BioKey, or any amendment to or adoption of any BioKey Plan or collective bargaining agreement;
(g) any material change by BioKey or any of its Subsidiaries in its accounting principles, except as may be required to conform
to changes in statutory or regulatory accounting rules or GAAP or regulatory requirements with respect thereto; or (h) any material
change in a tax accounting period or method or settlement of a material Tax claim or assessment, in each case, relating to BioKey
or a Subsidiary of BioKey, unless required by GAAP or applicable Law.

 

Section
4.9Absence of Litigation. Except as set forth on Section 4.9 of the BioKey Schedule of Exceptions, there are no suits,
claims, actions, proceedings, arbitrations, mediations or, to the Knowledge of BioKey, governmental investigations (“BioKey
Proceedings”) pending or, to the Knowledge of BioKey, threatened against BioKey or any of its Subsidiaries, other than
any BioKey Proceeding that would not, or would not reasonably be expected to, individually or in the aggregate, have a BioKey
Material Adverse Effect. Neither BioKey or any of its Subsidiaries nor any of their properties is or are subject to any order,
writ, judgment, injunction, decree or award except for those that would not, or would not reasonably be expected to, individually
or in the aggregate, have a BioKey Material Adverse Effect.

 

Section
4.10Employee Benefit Plans. (a) Section 4.10 of the BioKey Schedule of Exceptions contains a true and complete list
of each BioKey Plan (as defined below). As used herein, the term “BioKey Plan” means each material employee
benefit plan (within the meaning of Section 3(3) of ERISA, including each “employee pension benefit plan” (as defined
in Section 3(2) of ERISA), and each “employee welfare benefit plan” (as defined in Section 3(1) of ERISA), each material
employee benefit plan maintained outside the United States, and each other material plan, arrangement or policy (written or oral)
to provide benefits, other than salary or commissions, as compensation for services rendered, including, without limitation, employment
agreements, executive compensation agreements, incentive arrangements, salary continuation, stock option, stock grant or stock
purchase rights, phantom rights, deferred compensation, bonus, severance policies or agreements, retention policies or agreements,
change in control policies or agreements, fringe benefits or other employee benefits, in each case maintained or sponsored by
BioKey or any of its Subsidiaries or to which BioKey or any of its Subsidiaries contributes to or for which BioKey or any of its
Subsidiaries has or may have any liability, contingent or otherwise, either directly or as a result of a BioKey ERISA Affiliate,
or any other plan, arrangement or policy mandated by applicable Law, for the benefit of any current, former or retired employee,
officer, consultant, independent contractor or director of BioKey, its Subsidiaries or any BioKey ERISA Affiliate (collectively,
the “BioKey Employees”). BioKey has made available to Parent and BioLite copies of all material documents constituting
the BioKey Plans, the three most recently filed Forms 5500 for such BioKey Plans and financial statements attached thereto, all
IRS determination letters for the BioKey Plans, all notices that were issued within the preceding three years by the IRS, Department
of Labor, or any other Governmental Body with respect to the BioKey Plans, all employee manuals or handbooks containing personnel
or employee relations policies, and all other material documents relating to the BioKey Plans. For purposes of this Section 4.10,
the term BioKey includes any BioKey ERISA Affiliate. The term “BioKey ERISA Affiliate” means any person, that together
with BioKey, is or was at any time treated as a single employer under section 414 of the Code or section 4001 of ERISA and any
general partnership of which BioKey is or has been a general partner.

 

    - 28 -

     

    

 

(b) Each
BioKey Plan has been operated and administered in all respects in accordance with its terms and applicable Law, including, but
not limited to, ERISA and the Code, except for instances of noncompliance that would not have, individually or in the aggregate,
a BioKey Material Adverse Effect. All reporting, disclosure and notice requirements under ERISA, the Code and other applicable
Laws have been fully and completely satisfied with respect to each BioKey Plan, except for instances of noncompliance that would
not have, individually or in the aggregate, a BioKey Material Adverse Effect. With respect to each BioKey Plan, there has occurred
no non-exempt “prohibited transaction” (within the meaning of section 4975 of the Code or section 406 of ERISA) or
breach of any fiduciary duty described in section 404 of ERISA that could, if successful, result in any liability, direct or indirect,
for BioKey or any of its Subsidiaries or, to the Knowledge of BioKey, any stockholder, officer, director or employee of BioKey
or any of its Subsidiaries, except for instances of noncompliance that would not have, individually or in the aggregate, a BioKey
Material Adverse Effect. There are no pending or threatened claims by or on behalf of any BioKey Plan, or by or on behalf of any
participants or beneficiaries of any BioKey Plans under ERISA or applicable Law, or claiming benefit payments other than those
made in the ordinary operation of such plans. To the Knowledge of BioKey, no BioKey Plan is presently under investigation, audit
or examination by any Governmental Body, and no matters are pending with respect to any BioKey Plan under any IRS program.

 

(c) Each
BioKey Plan intended to be qualified under section 401(a) of the Code, and the trust forming a part thereof, has received a favorable
determination letter from the IRS as to its qualification under the Code and to the effect that each such trust is exempt from
taxation under section 501(a) of the Code, or has an opinion letter from the IRS to the same effect, and each such determination
or opinion letter remains in effect and has not been revoked. Except as disclosed on Section 4.10(a) of the BioKey Schedule of
Exceptions, BioKey and its Subsidiaries have never maintained, sponsored or had any liability with respect to any other plan subject
to the requirements of section 401(a) of the Code. To the Knowledge of BioKey, nothing has occurred since the date of such determination
letter that could cause the loss of such qualification or tax-exempt status or the imposition of any liability, lien, penalty
or tax under ERISA or the Code. Each BioKey Plan has been timely amended to comply with applicable Law.

 

    - 29 -

     

    

 

(d) BioKey
and its Subsidiaries do not sponsor, maintain or contribute to, and have never sponsored, maintained or contributed to, or had
any liability with respect to, any employee benefit plan subject to section 302 of ERISA, section 412 of the Code or Title IV
of ERISA. None of the BioKey Plans is a multiemployer plan (as defined in section 3(37) of ERISA). BioKey and its Subsidiaries
do not contribute to, and have never contributed to or had any other liability with respect to, a multiemployer plan or with respect
to any plan that has two or more contributing sponsors at least two of whom are not under common Control. There is not
now, and to the Knowledge of BioKey there are no existing circumstances that would reasonably be expected to give rise to, any
requirement for the posting of security with respect to BioKey Plan or the imposition of any pledge, lien, security interest or
encumbrance on assets of BioKey or any of its Subsidiaries under ERISA or the Code, or similar Laws of foreign jurisdictions.

 

(e) The
execution, delivery and performance by BioKey of this Agreement and the consummation of the transactions contemplated hereby will
not (either alone or upon occurrence of any additional or subsequent events) (i) constitute an event under any BioKey Plan or
any trust or loan related to any of those plans or agreements that will or may result in a prohibition of the transactions contemplated
by this Agreement or any payment, acceleration, forgiveness of indebtedness, vesting, distribution, increase in benefits or obligation
to fund benefits with respect to any BioKey Employee, or (ii) result in the triggering or imposition of any restrictions or limitations
on the right of BioKey to amend or terminate any BioKey Plan. No BioKey Plan, program, agreement or other arrangement, either
individually or collectively, provides for any payment or benefits becoming due to any director or employee of BioKey that will
be considered an “excess parachute payment” under section 280G of the Code. BioKey and its Subsidiaries have not declared
any bonus compensation in contemplation of the transactions contemplated by this Agreement. No payments or benefits under any
BioKey Plan or other agreement of BioKey or any of its Subsidiaries are, or are expected to be, subject to the disallowance of
a deduction under section 162(m) of the Code. BioKey and its Subsidiaries do not have any obligation to indemnify, hold harmless
or gross-up any individual with respect to any excise tax, penalty tax or interest under section 280G or 409A of the Code. Each
BioKey Plan that is a “nonqualified deferred compensation plan” (as defined in section 409A(d)(1) of the Code) is
in documentary compliance with the requirements of section 409A of the Code. Each nonqualified deferred compensation plan has
been operated since January 1, 2005 in good faith compliance with section 409A of the Code. No option (other than an option the
terms of which comply with the requirements of section 409A of the Code) has an exercise price that has been or may be less than
the fair market value of the underlying stock as of the date such option was granted or has any feature for the deferral of compensation
that could render the grant subject to section 409A of the Code.

 

    - 30 -

     

    

 

(f) With
respect to any BioKey Plan that is a group health plan (within the meaning of section 4980B(g)(2) of the Code), such BioKey Plan
complies, and in each and every case has complied, with all requirements of section 4980B of the Code, ERISA, Title XXII of the
Public Health Service Act, the applicable provisions of the Social Security Act, the Health Insurance Portability and Accountability
Act of 1996, and other applicable Laws, except for instances of noncompliance that would not have, individually or in the aggregate,
a BioKey Material Adverse Effect. No BioKey Plan provides health or other benefits after an employee’s or former employee’s
retirement or other termination of employment except as required under section 4980B of the Code.

 

(g) BioKey
and each of its Subsidiaries have paid all amounts that BioKey and each of its Subsidiaries are required to pay as contributions
to the BioKey Plans as of the last day of the most recent fiscal year of each of the BioKey Plans; all benefits accrued under
any funded or unfunded BioKey Plan have been paid, accrued or otherwise adequately reserved in accordance with GAAP; and all monies
withheld from employee paychecks with respect to the BioKey Plans have been transferred to the appropriate BioKey Plan in a timely
manner as required by applicable Law.

 

(h) BioKey
and its Subsidiaries have made no plan or commitment to create any additional BioKey Plan or to modify or change any existing
BioKey Plan.

 

(i) BioKey
does not maintain any benefit or compensation arrangement outside the jurisdiction of the United States, or one that covers any
employee residing or working outside the United States.

 

Section
4.11Labor and Employment Matters. BioKey and its Subsidiaries do not have any labor contracts or collective bargaining
agreements with any persons employed by BioKey or any of its Subsidiaries or any persons otherwise performing services primarily
for BioKey and its Subsidiaries. To the Knowledge of BioKey, there are no unfair labor practice complaints pending against BioKey
or any of its Subsidiaries before the NLRB or any other labor relations tribunal or authority. There are no strikes, work stoppages,
slowdowns, lockouts, arbitrations or grievances, or other labor disputes pending or, to the Knowledge of BioKey, threatened against
or involving BioKey or any of its Subsidiaries. No labor organization or group of employees of BioKey or any of its Subsidiaries
has made a pending demand for recognition or certification. BioKey and its Subsidiaries have not experienced any labor strike,
dispute or stoppage or other labor difficulty involving its employees, and there are no representation or certification proceedings
or petitions seeking a representation proceeding presently pending or threatened to be brought or filed, with the NLRB or any
other labor relations tribunal or authority. BioKey and its Subsidiaries are in compliance with all applicable Laws respecting
employment and employment practices, classification of employees, terms and conditions of employment, wages and hours, occupational
safety and health, immigration and immigration practices, including, but not limited to, any such Laws respecting employment discrimination,
termination of employment, workers’ compensation, family and medical leave, the Immigration Reform and Control Act, except
for instances of noncompliance that would not have, individually or in the aggregate, a BioKey Material Adverse Effect.

 

    - 31 -

     

    

 

Section
4.12Insurance. All material insurance policies of BioKey and its Subsidiaries are listed in Section 4.12 of the BioKey
Schedule of Exceptions. Except as would not, or would not reasonably be expected to, individually or in the aggregate, have a
BioKey Material Adverse Effect: (a) all insurance policies of BioKey and its Subsidiaries are in full force and effect and provide
insurance in such amounts and against such risks as is sufficient to comply with applicable Law; (b) BioKey and its Subsidiaries
are not in breach or default, and BioKey and its Subsidiaries have not taken any action or failed to take any action which, with
notice or the lapse of time, would constitute such a breach or default, or permit termination or modification of, any of such
insurance policies; and (c) to the Knowledge of BioKey, no notice in writing of cancellation or termination has been received
with respect to any such policy except customary notices of cancellation in advance of scheduled expiration.

 

Section
4.13Properties. BioKey and its Subsidiaries own no real property. Section 4.13 of the BioKey Schedule of Exceptions
contains a complete and correct list of all real property leased by BioKey and its Subsidiaries (the “BioKey Leased Property”).
BioKey and its Subsidiaries have good and valid leasehold interests in all BioKey Leased Property. With respect to all BioKey
Leased Property, there is not, under any of such leases, any existing default by BioKey or any of its Subsidiaries or, to the
Knowledge of BioKey, the counterparties thereto, or event which, with notice or lapse of time or both, would become a material
default by BioKey or any of its Subsidiaries or, to the Knowledge of BioKey, the counterparties thereto. The BioKey Leased Property
is maintained in a state of repair and condition that is consistent with the normal conduct of BioKey’s business.

 

Section
4.14Tax Matters. (a) Subject to such exceptions that would not have a BioKey Material Adverse Effect:

 

(b) Each
of BioKey and its Subsidiaries has timely filed all Tax Returns required to be filed by it or has timely filed appropriate extensions
and each such Tax Return was complete and correct in all material respects at the time of filing. Each of BioKey and its Subsidiaries
has timely paid or caused to be timely paid all Taxes shown on such Tax Returns to be due with respect to the taxable periods
covered by such Tax Returns and all other Taxes as are due (including Taxes for which no Tax Returns are required to be filed),
and the BioKey Interim Financial Statements reflect an adequate reserve (in addition to any reserve for deferred Taxes established
to reflect timing differences between book and Tax income) for all Taxes payable by BioKey and its Subsidiaries for all taxable
periods and portions thereof through the date of such financial statements.

 

(c) To
the Knowledge of BioKey, no Tax Return of BioKey or any of its Subsidiaries is under audit or examination by any taxing authority.
Neither BioKey nor any of its Subsidiaries has received written or, to the Knowledge of BioKey, verbal notice of such an audit
or examination. There is no deficiency, refund litigation, proposed adjustment or matter in controversy with respect to any Taxes
due and owing by BioKey or any of its Subsidiaries. Each deficiency resulting from any completed audit or examination of BioKey
relating to Taxes by any taxing authority has been timely paid. Neither BioKey nor any of its Subsidiaries has received written
notice from a taxing authority in any jurisdiction in which BioKey or any Subsidiary has not filed a Tax Return for any period
that BioKey or such Subsidiary is required to file a Tax Return in such jurisdiction.

 

    - 32 -

     

    

 

(d) There
is no currently effective written agreement or other written document extending or waiving, or having the effect of extending
or waiving, the period of assessment (or reassessment) or collection of any Taxes of BioKey or any of its Subsidiaries, and no
such request for an extension or waiver is currently pending. No power of attorney (other than powers of attorney authorizing
employees of BioKey to act on behalf of BioKey) with respect to any Taxes has been executed or filed with any taxing authority.
Neither BioKey nor any of its Subsidiaries is party to or bound by any written Tax sharing agreement, Tax indemnity obligation
or similar arrangement with respect to Taxes (including any advance pricing agreement, closing agreement or other similar agreement
related to Taxes) (other than any such agreement, obligation or arrangement between or among BioKey and its Subsidiaries).

 

(e) Neither
BioKey nor any of its Subsidiaries (i) has been a member of an affiliated group of corporations with the meaning of Section 1504
of the Code or any group that has filed a combined, consolidated or unitary Tax Return (other than a group of which BioKey or
any of its Subsidiaries is or was the common parent) or (ii) has any liability for Taxes of another Person (other than BioKey
or its Subsidiaries) under Treasury Regulation sections 1.1502-6, 1.1502-78 (or similar provisions of state, local or foreign
Law), as a transferee or successor, by contract or otherwise.

 

(f)  No
Liens for Taxes exist with respect to any assets or properties of BioKey or any of its Subsidiaries, except for statutory Liens
for Taxes not yet due and Liens either not in excess of $50,000, in the aggregate, or set forth on Section 4.14(f) of the BioKey
Schedule of Exceptions.

 

(g) BioKey
and its Subsidiaries have complied in all respects with all applicable Laws relating to the payment and withholding of Taxes (including
withholding of Taxes pursuant to Sections 1441, 1442, 3121 and 3402 of the Code and similar provisions under any other domestic
or foreign Tax Laws) and have, within the time and the manner prescribed by Law, withheld from and paid over to the proper Governmental
Bodies all amounts required to be so withheld and paid over under applicable Laws.

 

(h) BioKey
and each of its Subsidiaries has disclosed on their United States federal income Tax Returns all positions taken therein that
could give rise to a substantial understatement of United States federal income tax within the meaning of Section 6662 of the
Code, and neither BioKey nor any of its Subsidiaries has ever participated in any listed transaction, as defined in Treasury Regulation
Section 1.6011-4(b)(2), required to be reported in a disclosure statement pursuant to Treasury Regulation Section 1.6011-4.

 

(i) During
the two (2) year period ending on the date hereof, neither BioKey nor any of its Subsidiaries was a “distributing corporation”
or a “controlled corporation” in a transaction intended to be governed by Section 355 of the Code.

 

    - 33 -

     

    

 

Section
4.15Information Supplied. None of the information supplied or to be supplied by BioKey expressly for inclusion or incorporation
by reference in (i) the S-4 Prospectus, will, at the time such document is filed with the SEC, at any time it is amended or supplemented
or at the time it is first published, sent or given to BioKey Stockholders, contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading, or (ii) if required to be delivered to BioKey’s stockholders
pursuant to applicable Law, the Proxy Statement will, at the date it is first mailed to BioKey Stockholders and at the time of
the BioKey Stockholders Meeting or at the date of any amendment thereof or supplement thereto, contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they are made, not misleading. The Proxy Statement, at the date such Proxy
Statement is first mailed to BioKey Stockholders and at the time of the BioKey Stockholders Meeting, will comply as to form in
all material respects with the requirements of the Exchange Act and the rules and regulations promulgated thereunder. Notwithstanding
the foregoing, BioKey makes no representation or warranty with respect to any information supplied by Parent or Merger Sub 2 or
any of their respective representatives which is contained or incorporated by reference in the Prospectus. Any audited financial
statements of BioKey included in the S-4 will have been prepared in accordance with GAAP and Regulation S-X for audited financial
statements in all material respects applied on a consistent basis throughout the periods involved (except as may be indicated
in the notes thereto) and fairly present in all material respects the consolidated financial position of BioKey at the respective
dates thereof and the consolidated statements of operations, cash flows and changes in stockholders’ equity for the periods
indicated therein. Any unaudited financial statements of BioKey included in the S-4 will have been prepared in accordance with
GAAP and Regulation S-X for interim financial statements in all material respects applied on a consistent basis throughout the
periods involved (except as may be indicated in the notes thereto) and fairly present in all material respects the consolidated
financial position of BioKey as of the respective dates thereof and the consolidated statements of operations and cash flows for
the periods indicated therein (subject to normal period-end adjustments).

 

Section
4.16Reserved. 

 

Section
4.17Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by and on behalf of BioKey or
any of its Subsidiaries or for which BioKey or any of its Subsidiaries may be financially liable.

 

Section
4.18Takeover Statutes. BioKey has no “rights plan,” “rights agreement,” or “poison pill”
in effect. Assuming the accuracy of the representations and warranties of Parent the Merger Subs, and BioLite, to the Knowledge
of BioKey as of the date hereof, no “fair price”, “moratorium”, “control share acquisition”,
“business combination” or other similar antitakeover statute or regulation enacted under U.S. state or federal Laws
applicable to BioKey, including those under the CGCL, will be applicable to the BioKey Merger or the other transactions contemplated
hereby. No takeover, business combination, control share acquisition, fair price, moratorium or similar statutes apply or purport
to apply to this Agreement, the BioKey Merger or any of the other transactions contemplated by this Agreement.

 

    - 34 -

     

    

 

Section
4.19Intellectual Property. Except as set forth in Section 4.19 of the BioKey Schedule of Exceptions, to the Knowledge
of BioKey, BioKey or one of its Subsidiaries (as specifically identified on Schedule 4.19(a)) is the sole and exclusive (as to
any third party) owner or assignee of the entire right, title and interest in and to the Intellectual Property set forth on Schedule
4.19(a) and all other Intellectual Property material to and used in its business, and is licensed perpetually and without royalty
or other payment obligations to third parties to the Intellectual Property set forth on Schedule 4.19(b), except as noted on Schedule
4.19(b). BioKey or such Subsidiary owns or has the rights to use, free and clear of any Liens, but subject to any existing licenses
or other grants of rights to third parties (to the extent set forth in Section 4.19(a) or Section 4.19(b) of the BioKey Schedule
of Exceptions), all material Intellectual Property as is necessary and sufficient (i) for its businesses as currently conducted
and (ii) for the services provided by BioKey and its Subsidiaries (collectively, the “BioKey Intellectual Property Rights”).
Except as would not reasonably be expected to, individually or in the aggregate, have a BioKey Material Adverse Effect, (a) there
is no Proceeding pending, or to the Knowledge of BioKey threatened, (i) alleging infringement, misappropriation, violation or
dilution by BioKey or any of its Subsidiaries of any Intellectual Property of a third party or challenging the validity, enforceability,
ownership or use of any of the Intellectual Property set forth in Section 4.19(a) or Section 4.19(b) of the BioKey Schedule of
Exceptions or the BioKey Intellectual Property Rights therein and (ii) by BioKey or any of its Subsidiaries alleging infringement
or misappropriation of any Intellectual Property against a third party; (b) the provision of products or services by BioKey and
its Subsidiaries do not infringe the valid Intellectual Property rights of any third party, and, to the Knowledge of BioKey, the
BioKey Intellectual Property Rights are not being infringed by any third party; (c) no BioKey Intellectual Property Right will
terminate or cease to be a valid right of BioKey or any of its Subsidiaries by reason of the execution and delivery of this Agreement
by BioKey, the performance of BioKey of its obligations hereunder, or the consummation by BioKey of the BioKey Merger; and (d)
except as set forth in Section 4.19 of the BioKey Schedule of Exceptions, BioKey and its Subsidiaries have not granted any license,
sublicenses or any other rights in, to or under the Intellectual Property.

 

Section
4.20Contracts. (a) Except for this Agreement and except for Contracts set forth in Section 4.20 of the BioKey Schedule
of Exceptions, as of the date of this Agreement, BioKey or any of its Subsidiaries thereof is not a party to or bound by any Contract:
(i) that would be required to be filed by BioLite as a “material contract” pursuant to Item 601(b)(10) of Regulation
S-K under the Securities Act; (ii) contains covenants binding upon BioKey or any of its Subsidiaries that restrict the ability
of BioKey or any of its Subsidiaries (or which, following the consummation of the BioKey Merger, would materially restrict the
ability of the BioKey Surviving Corporation or any BioKey Affiliate) to compete in any business or geographic area; or (iii) involving
the payment or receipt of royalties or other amounts of more than $10,000 related to any product of BioKey or any BioKey Affiliate
, or (iv) that would prevent, materially delay or materially impede BioKey’s ability to consummate the BioKey Merger or
the other transactions contemplated by this Agreement. Each such Contract described in clauses (i) through (iii) as well as each
Contract listed in Section 4.20(a) of the BioKey Schedule of Exceptions is referred to herein as a “BioKey Material Contract“.

 

(b) Each
of the BioKey Material Contracts is valid and binding on BioKey or the applicable Subsidiary of BioKey, as the case may be, and,
to the Knowledge of BioKey, each other party thereto and is in full force and effect, except for such failures to be valid and
binding or to be in full force and effect as would not, or would not reasonably be expected to, individually or in the aggregate,
have a BioKey Material Adverse Effect. There is no default under any BioKey Material Contract by BioKey or any of its Subsidiaries
and no event has occurred that with the lapse of time or the giving of notice or both would constitute a default thereunder by
BioKey or any of its Subsidiaries, in each case except as would not, or would not reasonably be expected to, individually or in
the aggregate, have a BioKey Material Adverse Effect.

 

    - 35 -

     

    

 

Section
4.21Affiliate Transactions. Except as otherwise disclosed in Section 4.21 of the BioKey Schedule of Exceptions, no
executive officer or director of BioKey or any Subsidiary thereof or any Person owning 4.99% or more of the shares of BioKey Capital
Stock or any other “affiliate” as defined in Rule 12b-2 under the Exchange Act (each a “BioKey Affiliate“)
is a party to any Contract with or binding upon BioKey or any Subsidiary thereof or any of its properties or assets or has any
material interest in any material property owned by BioKey or has engaged in any material transaction with any of the foregoing
within the last twelve (12) months preceding the date of this Agreement, in each case, that is of a type that would be required
to be disclosed under Item 404 of Regulation S-K under the Securities Act.

 

Section
4.22Potential Products; FDA; EMEA (a) BioKey possesses all certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct its business as currently conducted, including without limitation
all such certificates, authorizations and permits required by the FDA or any other federal, state or foreign agencies or bodies
engaged in the regulation of pharmaceuticals or biohazardous materials, except where the failure to so possess such certificates,
authorizations and permits, individually or in the aggregate, would not reasonably be expected to result in a BioKey Material
Adverse Effect. BioKey has not received any written notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling
or finding, would reasonably be expected to have a BioKey Material Adverse Effect.

 

(b)
BioKey has not received any written notices or statements from the FDA, the EMEA or any other governmental agency that (i) any
Potential Product of BioKey may or will be rejected or determined to be non-approvable; (ii) a delay in time for review and/or
approval of a marketing authorization application or marketing approval application in any jurisdiction for any Potential Product
is or may be required, requested or being implemented; (iii) one or more clinical studies for any Potential Product shall or may
be requested or required in addition to the clinical studies submitted to the FDA prior to the date hereof as a precondition to
or condition of issuance or maintenance of a marketing approval for any Potential Product; (iv) any license, approval, permit
or authorization to conduct any clinical trial of or market any product or Potential Product of BioKey has been, will be or may
be suspended, revoked, modified or limited, except in the cases of clauses (i), (ii), (iii) and (iv) where such rejections, determinations,
delays, requests, suspensions, revocations, modifications or limitations would not reasonably be expected to have, individually
or in the aggregate, a BioKey Material Adverse Effect.

 

(c)
To BioKey’s knowledge, the preclinical and clinical testing, application for marketing approval of, manufacture, distribution,
promotion and sale of the products and Potential Products of BioKey is in compliance, in all material respects, with all laws,
rules and regulations applicable to such activities, including without limitation applicable good laboratory practices, good clinical
practices and good manufacturing practices, except for such non-compliance as would not reasonably be expected to have, individually
or in the aggregate, have a BioKey Material Adverse Effect. BioKey is not aware of any studies, tests or trial the results of
which reasonably call into question the results of the tests and trials conducted by or on behalf of BioKey. BioKey has not received
written notice of adverse finding, warning letter or clinical hold notice from the FDA or any non-U.S. counterpart of any of the
foregoing, or any untitled letter or other correspondence or notice from the FDA or any other governmental authority or agency
or any institutional or ethical review board alleging or asserting noncompliance with any law, rule or regulation applicable in
any jurisdiction, except notices, letters, and correspondences and non-U.S. counterparts thereof alleging or asserting such noncompliance
as would not reasonably be expected to have, individually or in the aggregate, have a BioKey Material Adverse Effect. BioKey has
not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any
recall, field correction, market withdrawal or replacement, safety alert, warning, “dear doctor” letter, investigator
notice, or other notice or action relating to an alleged or potential lack of safety or efficacy of any product or Potential Product
of BioKey, any alleged product defect of any product or Potential Product of BioKey, or any violation of any material applicable
law, rule, regulation or any clinical trial or marketing license, approval, permit or authorization for any product or potential
product of BioKey, and BioKey is not aware of any facts or information that would cause it to initiate any such notice or action
and has no knowledge or reason to believe that the FDA, the EMEA or any other governmental agency or authority or any institutional
or ethical review board or other non-governmental authority intends to impose, require, request or suggest such notice or action.

 

    - 36 -

     

    

 

ARTICLE
5

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBS

 

Parent
and each Merger Sub hereby, jointly and severally, represent and warrant to BioLite and BioKey that, except as identified in the
SEC Reports (other than statements in the Risk Factors Sections that do not relate to historical facts and are forward looking
in nature) or as set forth on the Schedule of Exceptions delivered by Parent and Merger Subs to BioLite and BioKey prior to the
execution of this Agreement and thereafter prior to Closing (the “Parent Schedule of Exceptions”), it being
understood that a disclosure in any section of the Parent Schedule of Exceptions shall be deemed to have been set forth in all
other applicable sections of the Parent Schedule of Exceptions where it is readily apparent on the face of the disclosure that
such disclosure is applicable to such other sections, notwithstanding the omission of any cross reference to such other section;
and it being further understood that the Parent Schedule of Exceptions will be updated from time to time for events that occur
between execution of this Agreement and Closing and a final copy of the Parent Schedule of Exceptions will be delivered to BioLite
and BioKey prior to the Closing:

 

Section
5.1Organization and Qualification. Each of Parent, its Subsidiaries and each Merger Sub is a corporation duly organized,
validly existing and in good standing or active status under the Laws of the jurisdiction in which it is incorporated and has
all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as it is now
being conducted, except where any failure to be so organized, existing or in good standing or active status or to have such power
or authority would not, or would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse
Effect. Each of Parent, its Subsidiaries and each Merger Sub is duly qualified or licensed to do business, and is in good standing,
in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its activities makes
such qualification or licensing necessary, except for any failure to be so qualified or licensed or in good standing which would
not, or would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect. “Parent
Material Adverse Effect” means any change, effect, event or occurrence that has a material adverse effect on the assets,
business, financial condition or results of operations of Parent and its Subsidiaries taken as a whole or that would reasonably
be expected to prevent or materially delay Parent from performing its obligations under this agreement in any material respect
or materially delay consummating the transactions contemplated hereby;

 

    - 37 -

     

    

 

Section
5.2Articles of Incorporation and Bylaws. Parent has heretofore furnished or otherwise made available to Parent and
Parent a complete and correct copy of Articles of Incorporation and Bylaws of Parent and each of its Subsidiaries as in effect
on the date hereof and all minutes of their Board of Directors since January 1, 2015, other than those with respect to consideration
and approval of the Mergers and related transactions. The Articles of Incorporation and Bylaws of Parent and its Subsidiaries
are in full force and effect and no other organizational documents are applicable to or binding upon Parent or Merger Subs. Neither
Parent nor its Subsidiaries is in violation of any provisions of its Articles of Incorporation or Bylaws in any material respect.

 

Section
5.3Capitalization. (a) The authorized capital stock of Parent consists of three hundred sixty million (360,000,000)
shares of common stock, par value $0.001 per share.

 

(b) As
of the date of this Agreement: (i) two hundred thirteen million seven hundred forty-six thousand six hundred and forty-seven (213,746,647)
shares of Parent Common Stock were issued and outstanding, all of which were validly issued, fully paid and non-assessable and
were issued free of preemptive rights, and (ii) an aggregate of approximately nine million nine hundred thirty-one thousand nine
hundred sixty-six (9,931,966) shares of Parent Common Stock were reserved for issuance upon or otherwise deliverable in connection
with the grant of equity-based awards or the exercise of outstanding options to purchase Parent Common Stock issued pursuant to
the Parent’s 2016 Equity Incentive Plan (the “Parent Stock Plan”). Section 5.3 of the Parent Schedule of Exceptions
sets forth, as of the date of this Agreement, each equity-based award, phantom right, and option outstanding under the Parent
Stock Plan or otherwise, the number of shares of Parent Common Stock issuable thereunder and the expiration date and exercise
or conversion price relating thereto. Unless disclosed on Section 5.3 of the Parent Schedule of Exceptions, no other equity-based
award, phantom right or option is outstanding under a Parent Stock Plan or otherwise.

 

(c) As
of the date of this Agreement, except as set forth in clauses (a) and (b) of this Section 5.3, and except as set forth on Section
5.3 of the Parent Schedule of Exceptions: (i) there are not outstanding or authorized any (A) shares of capital stock or other
voting securities of Parent, (B) securities of Parent convertible into or exercisable or exchangeable for shares of capital stock
or voting securities of Parent or (C) options or other rights to acquire from Parent, or any obligation of Parent to issue, any
capital stock, voting securities or securities convertible into or exercisable or exchangeable for capital stock or voting securities
of Parent (collectively, “Parent Securities”); (ii) there are no outstanding obligations of Parent to repurchase,
redeem or otherwise acquire any Parent Securities; and (iii) there are no other options, calls, warrants or other rights, agreements,
arrangements or commitments of any character relating to the issued or unissued capital stock or other voting securities of Parent
to which Parent is a party.

 

    - 38 -

     

    

 

(d) Neither
Parent nor any of its Subsidiaries has outstanding bonds, debentures, notes or other obligations, the holders of which have the
right to vote (or that are convertible into or exercisable for securities having the right to vote) with the stockholders of Parent
on any matter.

 

(e) Section
5.3(e) of the Parent Schedule of Exceptions sets forth (x) each of Parent’s Subsidiaries and the ownership interest of Parent
in each such Subsidiary, as well as the ownership interest of any other Person or Persons in each such Subsidiary (including any
options or other rights to acquire an equity interest) and (y) Parent’s or its Subsidiaries’ capital stock, equity
interest or other direct or indirect ownership interest in any other Person other than securities in a publicly traded company
held for investment by Parent or any of its Subsidiaries and consisting of less than 1% of the outstanding capital stock of such
company. Parent has good title to all of its ownership interests in each of its Subsidiaries, free and clear of all Liens.

 

(f) Except
as set forth in Section 5.3(f) of the Parent Schedule of Exceptions, Parent and its Subsidiaries have good title to all of their
respective assets and properties, free and clear of all Liens.

 

(g) Except
as set forth in Section 5.3(g) of the Parent Schedule of Exceptions, there are no voting trusts, proxies or other agreements,
arrangements, commitments or understandings of any character to which Parent or its Subsidiaries or, to the Knowledge of Parent,
is a party or by which Parent is bound with respect to the issuance, holding, acquisition, voting or disposition of any shares
of capital stock or other security or equity interest of Parent or its Subsidiaries.

 

Section
5.4Authority. (a) Each of Parent and each Merger Sub has all necessary corporate power and authority to execute and
deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. Parent as
sole stockholder of each Merger Sub has approved this Agreement. The execution, delivery and performance of this Agreement by
each of Parent and each Merger Sub and the consummation by each of Parent and each Merger Sub of the transactions contemplated
hereby have been duly and validly authorized by all necessary action of Parent and each Merger Sub, and no other corporate proceedings
on the part of Parent or either Merger Sub are necessary to authorize this Agreement, to perform their respective obligations
hereunder, or to consummate the transactions contemplated hereby (other than the filing with the Secretary of State of the State
of Nevada of the BioLite Articles of Merger as required by the NRS and the filing with the Secretary of State of the State of
California of the BioKey Certificate of Merger as required by the CGCL). Neither the approval or adoption of this Agreement, the
Mergers or the other transactions contemplated hereby requires any approval of the stockholders of Parent. This Agreement has
been duly and validly executed and delivered by Parent and each Merger Sub and, assuming the due authorization, execution and
delivery hereof by BioLite and BioKey, constitutes a legal, valid and binding obligation of each of Parent and each Merger Sub
enforceable against each of Parent and each Merger Sub in accordance with its terms, subject to the effects of bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or affecting creditors’ rights generally,
general equitable principles (whether considered in a proceeding in equity or at law) and any implied covenant of good faith and
fair dealing.

 

    - 39 -

     

    

 

Section
5.5No Conflict; Required Filings and Consents. Except as set forth on Schedule 5.5(a) of the Parent Schedule of Exceptions:
(a) the execution, delivery and performance of this Agreement by Parent and Merger Subs do not and will not (i) conflict with
or violate the respective Articles of Incorporation or Bylaws of Parent or any Subsidiary, (ii) assuming that all consents, approvals
and authorizations contemplated by clauses (i) through (iii) of subsection (b) below have been obtained, and all filings described
in such clauses have been made, conflict with or violate any Law applicable to Parent or any Subsidiary or by which any of their
respective properties are bound or (iii) (A) result in any breach or violation of or constitute a default (or an event which with
notice or lapse of time or both would become a default), (B) result in the loss of a benefit under, or give rise to any right
of termination, cancellation, amendment or acceleration of, or (C) result in the creation of any Lien on any of the properties
or assets of Parent or any of its Subsidiaries under, any Contracts to which Parent or any Subsidiary is a party or by which Parent
or any of its Subsidiaries or any of their respective properties are bound, except, in the case of clauses (ii) and (iii), for
any such conflict, violation, breach, default, acceleration, loss, right or other occurrence which would not, or would not reasonably
be expected to, individually or in the aggregate, have or reasonably be expected to have a Parent Material Adverse Effect.

 

(b) The
execution, delivery and performance of this Agreement by each of Parent and each Merger Sub and the consummation of the transactions
contemplated hereby by each of Parent and each Merger Sub do not and will not require any consent, approval, authorization or
permit of, action by, filing with or notification to, any Governmental Body, except for (i) the filing with the SEC and declaration
of effectiveness of the registration statement on form S-4 in which the BioLite Exchange Fund and BioKey Exchange Fund are registered
and any filings or approvals under applicable state securities laws with respect to the issuance of Parent Common Stock in connection
with the Mergers, (ii) the filing with the Secretary of State of the State of Nevada of the BioLite Articles of Merger as required
by the NRS and the filing with the Secretary of State of the State of California of the BioKey Certificate of Merger as required
by the CGCL, and (iii) any such consent, approval, authorization, permit, action, filing or notification the failure of which
to make or obtain would not individually or in the aggregate, have or reasonably be expected to have, a Parent Material Adverse
Effect (collectively, the “Parent Required Consents”).

 

    - 40 -

     

    

 

Section
5.6Compliance.

 

(a) To
the Knowledge of Parent, Parent and its Subsidiaries are not in violation of any Law applicable to Parent or any of its Subsidiaries
or by which any of their properties are bound, and has not been notified in writing by any Governmental Body of any violation,
or any investigation with respect to any such Law, except for any such violation which would not, or would not reasonably be expected
to, individually or in the aggregate, have a Parent Material Adverse Effect.

 

(b) Parent
and its Subsidiaries, and their respective predecessors, have complied and are in compliance in all material respects with all
applicable Laws and orders and no Parent Proceeding has been filed or commenced, or to the Knowledge of Parent, threatened alleging
any failure so to comply, including, any claims arising under the Anti-Kickback Statute, False Claims Act, or any other federal
or state Law, whether or not corrected. Parent and its Subsidiaries have not received any notice or communication from any Governmental
Body alleging any non-compliance of the foregoing.

 

(c) Neither
Parent, nor any of its Subsidiaries, nor, to Parent’s Knowledge, any of their officers, managers, members, directors, agents,
employees or any other Persons acting on their behalf has (i) made any illegal payment to any officer or employee of any Governmental
Body, or any customer or supplier of Parent or its Subsidiaries, or (ii) accepted or received any unlawful contributions, payments,
expenditures or gifts; and no Proceeding has been filed or commenced alleging any such illegal payments.

 

Section
5.7SEC Filings; Financial Statements (a) Parent has filed or otherwise transmitted all forms, reports, statements,
certifications and other documents (including all exhibits, amendments and supplements thereto) required to be filed or otherwise
transmitted by it with the SEC) since September 30, 2016 and prior to the date hereof (such documents filed since September 30,
2016 and prior to the date hereof, the “SEC Reports”). As of their respective dates, each of the SEC Reports
complied as to form in all material respects with the applicable requirements of the Securities Act and the rules and regulations
promulgated thereunder and the Exchange Act and the rules and regulations promulgated thereunder, each as in effect on the date
so filed. Except to the extent amended or superseded by a subsequent filing with the SEC made prior to the date hereof, as of
their respective dates (and if so amended or superseded, then on the date of such subsequent filing), none of the SEC Reports
contained any untrue statement of a material fact or omitted to state a material fact required to be stated or incorporated by
reference therein or necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading.

 

(b) The
audited consolidated financial statements of Parent (including any related notes thereto) included in Parent’s Annual Report
on Form 10-K for the fiscal year ended September 30, 2017 filed with the SEC have been prepared in accordance with GAAP in all
material respects applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto)
and fairly present in all material respects the consolidated financial position of Parent at the respective dates thereof and
the consolidated statements of operations, cash flows and changes in stockholders’ equity for the periods indicated therein.
The unaudited consolidated financial statements of Parent (including any related notes thereto) for all interim periods included
in Parent’s quarterly reports on Form 10-Q filed with the SEC since September 30, 2016 have been prepared in accordance
with GAAP in all material respects applied on a consistent basis throughout the periods involved (except as may be indicated in
the notes thereto or may be permitted by the SEC under the Exchange Act) and fairly present in all material respects the consolidated
financial position of Parent as of the respective dates thereof and the consolidated statements of operations and cash flows for
the periods indicated therein (subject to normal period-end adjustments).

 

    - 41 -

     

    

 

(c) Parent’s
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are reasonably designed
to ensure that material information relating to Parent is made known to the chief executive officer and the chief financial officer
of Parent by others within the Parent.

 

(d) Since
September 30, 2016, Parent has not disclosed to Parent’s independent registered accounting firm and the audit committee
of Parent’s Board of Directors (i) any significant deficiencies and material weaknesses in the design or operation of its
internal control over financial reporting or (ii) any fraud, whether or not material, that involves management or other employees
who have a significant role in Parent’s internal control over financial reporting.

 

(e) Since
September 30, 2016, Parent has not identified any material weaknesses in the design or operation of its internal control over
financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). To the Knowledge of Parent, there is
no reason to believe that its chief executive officer and chief financial officer will not be able to give the certifications
required pursuant to the rules and regulations adopted pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 when next due.
Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act) that provides reasonable assurance that (i) transactions are executed in accordance with management’s general
or specific authorizations; (ii) access to assets is permitted only in accordance with management’s general or specific
authorization; and (iii) the recorded accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences.

 

(f) Parent
does not have any liabilities of any nature, except liabilities that (i) are accrued or reserved against in the most recent financial
statements included in the Parent SEC Reports filed prior to the date hereof or are reflected in the notes thereto, (ii) were
incurred in the ordinary course of business since the date of such financial statements, (iii) are incurred in connection with
the transactions contemplated by this Agreement, (iv) have been discharged or paid in full prior to the date of this Agreement
in the ordinary course of business, or (v) would not, or would not reasonably be expected to, individually or in the aggregate,
have a Parent Material Adverse Effect. Section 5.7(f) of the Parent Schedule of Exceptions sets forth a list of all outstanding
debt for money borrowed, the applicable lender, interest rate and the applicable payment dates.

 

(g) Each
of the “principal executive officer” of Parent (as defined in SOX) and the “principal financial officer”
of Parent (as defined in Sarbanes-Oxley Act of 2002 ) has made all certifications required by Sections 302 and 906 of Sarbanes-Oxley
Act of 2002 and any related rules and regulations promulgated by the SEC with respect to the SEC Reports and the statements contained
in any such certifications were true and accurate as of the date such certifications were made and have not been modified or withdrawn.

 

    - 42 -

     

    

 

Section
5.8Absence of Certain Changes or Events. Except as set forth on Section 5.8 of the Parent Schedule of Exceptions, since
September 30, 2017 until the date of this Agreement, and except as contemplated by this Agreement, Parent has conducted its business
in the ordinary course consistent with past practice and there has not been any change, event or occurrence which has had or would
reasonably be expected to have a Parent Material Adverse Effect.

 

Section
5.9Absence of Litigation. Except as set forth on Section 5.9 of the Parent Schedule of Exceptions, there are no suits,
claims, actions, proceedings, arbitrations, mediations or, to the Knowledge of Parent, governmental investigations (“Parent
Proceedings”) pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries, other than
any Parent Proceeding that would not, or would not reasonably be expected to, individually or in the aggregate, have a Parent
Material Adverse Effect. Neither Parent or any of its Subsidiaries nor any of their properties is or are subject to any order,
writ, judgment, injunction, decree or award except for those that would not, or would not reasonably be expected to, individually
or in the aggregate, have a Parent Material Adverse Effect.

 

Section
5.10Labor and Employment Matters. Parent and its Subsidiaries do not have any labor contracts or collective bargaining
agreements with any persons employed by Parent or any of its Subsidiaries or any persons otherwise performing services primarily
for the Company and its Subsidiaries. To the Knowledge of Parent, there are no unfair labor practice complaints pending against
Parent or any of its Subsidiaries before the NLRB or any other labor relations tribunal or authority. There are no strikes, work
stoppages, slowdowns, lockouts, arbitrations or grievances, or other labor disputes pending or, to the Knowledge of Parent, threatened
against or involving Parent or any of its Subsidiaries. No labor organization or group of employees of Parent or any of its Subsidiaries
has made a pending demand for recognition or certification. Parent and its Subsidiaries have not experienced any labor strike,
dispute or stoppage or other labor difficulty involving its employees, and there are no representation or certification proceedings
or petitions seeking a representation proceeding presently pending or threatened to be brought or filed, with the NLRB or any
other labor relations tribunal or authority. Parent and its Subsidiaries are in compliance with all applicable Laws respecting
employment and employment practices, classification of employees, terms and conditions of employment, wages and hours, occupational
safety and health, immigration and immigration practices, including, but not limited to, any such Laws respecting employment discrimination,
termination of employment, workers’ compensation, family and medical leave, the Immigration Reform and Control Act, except
for instances of noncompliance that would not have, individually or in the aggregate, a Parent Material Adverse Effect.

 

    - 43 -

     

    

 

Section
5.11Insurance. All material insurance policies of Parent and its Subsidiaries are listed in Section 5.11 of the Parent
Schedule of Exceptions. Except as would not, or would not reasonably be expected to, individually or in the aggregate, have a
Parent Material Adverse Effect: (a) all insurance policies of Parent and its Subsidiaries are in full force and effect and provide
insurance in such amounts and against such risks as is sufficient to comply with applicable Law; (b) Parent and its Subsidiaries
are not in breach or default, and Parent and its Subsidiaries have not taken any action or failed to take any action which, with
notice or the lapse of time, would constitute such a breach or default, or permit termination or modification of, any of such
insurance policies; and (c) to the Knowledge of Parent, no notice in writing of cancellation or termination has been received
with respect to any such policy except customary notices of cancellation in advance of scheduled expiration.

 

Section
5.12Properties. Parent and its Subsidiaries own no real property. Section 5.12 of the Parent Schedule of Exceptions
contains a complete and correct list of all real property leased by Parent and its Subsidiaries (the “Parent Leased Property”).
Parent and its Subsidiaries have good and valid leasehold interests in all Parent Leased Property. With respect to all Parent
Leased Property, there is not, under any of such leases, any existing default by Parent or any of its Subsidiaries or, to the
Knowledge of Parent, the counterparties thereto, or event which, with notice or lapse of time or both, would become a material
default by Parent or any of its Subsidiaries or, to the Knowledge of Parent, the counterparties thereto. The Parent Leased Property
is maintained in a state of repair and condition that is consistent with the normal conduct of Parent’s business.

 

Section
5.13Information Supplied. None of the information supplied or to be supplied by Parent or Merger Subs expressly for
inclusion or incorporation by reference in (i) the S-4, , will, at the time such document is filed with the SEC, at any time it
is amended or supplemented or at the time it is first published, sent or given to the BioLite Stockholders or BioKey Stockholders,
and in the case of the S-4, at the time it becomes effective under the Securities Act, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading, or (ii) the Proxy Statement will, at the date it is
first mailed to the BioLite Stockholders or BioKey Stockholders and at the time of the BioLite Stockholders Meeting or BioKey
Stockholders Meeting or at the date of any amendment thereof or supplement thereto, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they are made, not misleading. The Proxy Statement, at the date such Proxy Statement
is first mailed to BioLite Stockholders or BioKey Stockholders and at the time of the BioLite Stockholders Meeting and BioKey
Stockholders Meeting will comply as to form in all material respects with the requirements of the Securities Act and the rules
and regulations promulgated thereunder. Notwithstanding the foregoing, Parent and Merger Subs make no representation or warranty
with respect to any information supplied by BioLite or BioKey or any of their respective representatives which is contained or
incorporated by reference in the Proxy Statement.

 

Section
5.14Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by and on behalf of Parent or
any of its Subsidiaries or for which Parent or any of its Subsidiaries may be financially liable.

 

    - 44 -

     

    

 

Section
5.15Takeover Statutes. Parent has no “rights plan,” “rights agreement,” or “poison pill”
in effect. Assuming the accuracy of the representations and warranties of BioLite and BioKey, to the Knowledge of Parent as of
the date hereof, no “fair price”, “moratorium”, “control share acquisition”, “business
combination” or other similar antitakeover statute or regulation enacted under U.S. state or federal Laws applicable to
Parent, including those under the NRS, will be applicable to the Mergers or the other transactions contemplated hereby. No takeover,
business combination, control share acquisition, fair price, moratorium or similar statutes apply or purport to apply to this
Agreement, the Mergers or any of the other transactions contemplated by this Agreement.

 

Section
5.16Intellectual Property. Except as set forth in Section 5.16 of the Parent Schedule of Exceptions, to the Knowledge
of Parent, Parent or one of its Subsidiaries (as specifically identified on Schedule 5.16(a)) is the sole and exclusive (as to
any third party) owner or assignee of the entire right, title and interest in and to the Intellectual Property set forth on Schedule
5.16(a) and all other Intellectual Property material to and used in its business, and is licensed perpetually and without royalty
or other payment obligations to third parties to the Intellectual Property set forth on Schedule 5.16(b), except as noted on Schedule
5.16(b). Parent or such Subsidiary owns or has the rights to use, free and clear of any Liens, but subject to any existing licenses
or other grants of rights to third parties (to the extent set forth in Section 5.16(a) or Section 5.16(b) of the Parent Schedule
of Exceptions), all material Intellectual Property as is necessary and sufficient (i) for its businesses as currently conducted
and (ii) for the services provided by Parent and its Subsidiaries (collectively, the “Parent Intellectual Property Rights”).
Except as would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect, (a) there
is no Proceeding pending, or to the Knowledge of Parent threatened, (i) alleging infringement, misappropriation, violation or
dilution by Parent or any of its Subsidiaries of any Intellectual Property of a third party or challenging the validity, enforceability,
ownership or use of any of the Intellectual Property set forth in Section 5.16(a) or Section 5.16(b) of the Parent Schedule of
Exceptions or the Parent Intellectual Property Rights therein and (ii) by Parent or any of its Subsidiaries alleging infringement
or misappropriation of any Intellectual Property against a third party; (b) the provision of products or services by Parent and
its Subsidiaries do not infringe the valid Intellectual Property rights of any third party, and, to the Knowledge of Parent, the
Parent Intellectual Property Rights are not being infringed by any third party; (c) no Parent Intellectual Property Right will
terminate or cease to be a valid right of Parent or any of its Subsidiaries by reason of the execution and delivery of this Agreement
by Parent, the performance of Parent of its obligations hereunder, or the consummation by Parent of the Parent Merger; and (d)
except as set forth in Section 5.16 of the Parent Schedule of Exceptions, Parent and its Subsidiaries have not granted any license,
sublicenses or any other rights in, to or under the Intellectual Property.

 

Section
5.17Contracts. (a) Except for this Agreement and except for Contracts filed as exhibits to the SEC Reports, as of the
date of this Agreement, none of Parent or any of its Subsidiaries is not a party to or bound by any Contract: (i) that would be
required to be filed by BioLite as a “material contract” pursuant to Item 601(b)(10) of Regulation S-K under the Securities
Act; (ii) contains covenants binding upon Parent or any of its Subsidiaries that restrict the ability of Parent or any of its
Subsidiaries (or which, following the consummation of the Mergers, would materially restrict the ability of Parent or any Parent
Affiliate) to compete in any business or geographic area; or (iii) involving the payment or receipt of royalties or other amounts
of more than $10,000 related to any product of Parent or any Parent Affiliate , or (iv) that would prevent, materially delay or
materially impede Parent’s ability to consummate the Mergers or the other transactions contemplated by this Agreement. Each
such Contract described in clauses (i) through (iii) as well as each Contract listed in Section 5.17(a) of the Parent Schedule
of Exceptions is referred to herein as a “Parent Material Contract”.

 

    - 45 -

     

    

 

(b) Each
of the Parent Material Contracts is valid and binding on Parent or the applicable Subsidiary of Parent, as the case may be, and,
to the Knowledge of Parent, each other party thereto and is in full force and effect, except for such failures to be valid and
binding or to be in full force and effect as would not, or would not reasonably be expected to, individually or in the aggregate,
have a Parent Material Adverse Effect. There is no default under any Parent Material Contract by Parent or any of its Subsidiaries
and no event has occurred that with the lapse of time or the giving of notice or both would constitute a default thereunder by
Parent or any of its Subsidiaries, in each case except as would not, or would not reasonably be expected to, individually or in
the aggregate, have a Parent Material Adverse Effect.

 

Section
5.18Affiliate Transactions. Except as otherwise disclosed in Section 5.18 of the Parent Schedule of Exceptions, no
executive officer or director of Parent or any Subsidiary thereof or any Person owning 4.99% or more of the shares of Parent Common
Stock or any other “affiliate” as defined in Rule 12b-2 under the Exchange Act (each a “Parent Affiliate”)
is a party to any Contract with or binding upon Parent or any Subsidiary thereof or any of its properties or assets or has any
material interest in any material property owned by Parent or has engaged in any material transaction with any of the foregoing
within the last twelve (12) months preceding the date of this Agreement, in each case, that is of a type that would be required
to be disclosed under Item 404 of Regulation S-K under the Securities Act.

 

Section
5.19Operations of Merger Subs. As of the date of this Agreement, the authorized capital stock of each Merger Sub consists
of 1,000 shares of common stock, par value $0.01 per share, all of which are validly issued, fully paid and non-assessable. Each
Merger Sub is a direct, wholly-owned subsidiary of Parent that has been formed solely for the purpose of engaging in the transactions
contemplated hereby and prior to the Effective Time will have engaged in no other business activities and will have incurred no
liabilities or obligations other than as contemplated herein.

 

Section
5.20Ownership of Shares. Except as set forth on Section 5.20 of the Parent Schedule of Exceptions, neither Parent nor
either Merger Sub nor any of the Parent Affiliates owns (directly or indirectly, beneficially or of record) any shares of BioLite
Capital Stock or BioKey Capital Stock or holds any rights to acquire any shares of BioLite Capital Stock or BioKey Capital Stock
except pursuant to this Agreement.

 

Section
5.21Availability of Shares. Parent has sufficient shares of Common Stock authorized and available to be issued to consummate
the Mergers on the terms set forth herein.

 

    - 46 -

     

    

 

Section
5.22Potential Products; FDA; EMEA (a) Parent possesses all certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct its business as currently conducted, including without limitation
all such certificates, authorizations and permits required by the FDA or any other federal, state or foreign agencies or bodies
engaged in the regulation of pharmaceuticals or biohazardous materials, except where the failure to so possess such certificates,
authorizations and permits, individually or in the aggregate, would not reasonably be expected to result in a Parent Material
Adverse Effect. Parent has not received any written notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling
or finding, would reasonably be expected to have a Parent Material Adverse Effect.

 

(b)
Parent has not received any written notices or statements from the FDA, the EMEA or any other governmental agency that (i) any
Potential Product of Parent may or will be rejected or determined to be non-approvable; (ii) a delay in time for review and/or
approval of a marketing authorization application or marketing approval application in any jurisdiction for any Potential Product
is or may be required, requested or being implemented; (iii) one or more clinical studies for any Potential Product shall or may
be requested or required in addition to the clinical studies submitted to the FDA prior to the date hereof as a precondition to
or condition of issuance or maintenance of a marketing approval for any Potential Product; (iv) any license, approval, permit
or authorization to conduct any clinical trial of or market any product or Potential Product of Parent has been, will be or may
be suspended, revoked, modified or limited, except in the cases of clauses (i), (ii), (iii) and (iv) where such rejections, determinations,
delays, requests, suspensions, revocations, modifications or limitations would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect.

 

(c)
To Parent’s knowledge, the preclinical and clinical testing, application for marketing approval of, manufacture, distribution,
promotion and sale of the products and Potential Products of Parent is in compliance, in all material respects, with all laws,
rules and regulations applicable to such activities, including without limitation applicable good laboratory practices, good clinical
practices and good manufacturing practices, except for such non-compliance as would not reasonably be expected to have, individually
or in the aggregate, have a Parent Material Adverse Effect. Parent is not aware of any studies, tests or trial the results of
which reasonably call into question the results of the tests and trials conducted by or on behalf of Parent. Parent has not received
written notice of adverse finding, warning letter or clinical hold notice from the FDA or any non-U.S. counterpart of any of the
foregoing, or any untitled letter or other correspondence or notice from the FDA or any other governmental authority or agency
or any institutional or ethical review board alleging or asserting noncompliance with any law, rule or regulation applicable in
any jurisdiction, except notices, letters, and correspondences and non-U.S. counterparts thereof alleging or asserting such noncompliance
as would not reasonably be expected to have, individually or in the aggregate, have a Parent Material Adverse Effect. Parent has
not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any
recall, field correction, market withdrawal or replacement, safety alert, warning, “dear doctor” letter, investigator
notice, or other notice or action relating to an alleged or potential lack of safety or efficacy of any product or Potential Product
of Parent, any alleged product defect of any product or Potential Product of Parent, or any violation of any material applicable
law, rule, regulation or any clinical trial or marketing license, approval, permit or authorization for any product or potential
product of Parent, and Parent is not aware of any facts or information that would cause it to initiate any such notice or action
and has no knowledge or reason to believe that the FDA, the EMEA or any other governmental agency or authority or any institutional
or ethical review board or other non-governmental authority intends to impose, require, request or suggest such notice or action.

 

    - 47 -

     

    

 

ARTICLE
6

CONDUCT OF BUSINESS PENDING THE MERGER

 

Section
6.1Conduct of Business of BioLite Pending the Merger. BioLite covenants and agrees that, during the period from the
date hereof until the Effective Time, except as contemplated by this Agreement, as set forth in the BioLite Schedule of Exceptions
or as required by Law, or unless Parent and BioKey shall otherwise consent in writing (such consent not to be unreasonably conditioned,
withheld or delayed), the business of BioLite and its Subsidiaries shall be conducted in its ordinary course of business and,
to the extent consistent with and not in violation of any other provisions of this Section 6.1, BioLite shall use commercially
reasonable efforts to preserve substantially intact its and its Subsidiaries’ business organization, and to preserve its
and its Subsidiaries’ present relationships with customers, suppliers, employees, licensees, licensors, partners and other
Persons with which it or any of its Subsidiaries has significant business relations. Without limiting the generality of the foregoing,
between the date of this Agreement and the Effective Time, except as otherwise contemplated by this Agreement, as set forth in
the BioLite Schedule of Exceptions or as required by Law, BioLite and its Subsidiaries shall not, without the prior written consent
of Parent and BioKey (which consent shall not be unreasonably conditioned, withheld or delayed):

 

(a) amend
or otherwise change its Articles of Incorporation or Bylaws;

 

(b) except
as set forth in Section 6.1(b) of the BioLite Schedule of Exceptions, issue, deliver, sell, pledge, dispose of or encumber any
shares of capital stock, voting securities, or other equity interests, or any options, warrants, restricted stock or other rights
of any kind to acquire or receive any shares of capital stock, voting securities, or other equity interests (including stock appreciation
rights, phantom stock or similar instruments) (except for the issuance of shares of BioLite Common Stock upon the exercise of
options or in connection with other stock-based awards in each case outstanding as of the date hereof);

 

(c) declare,
set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any
of its capital stock;

 

(d) except
as set forth in Section 6.1(d) of the BioLite Schedule of Exceptions, adjust, recapitalize, reclassify, combine, split, subdivide,
redeem, purchase or otherwise acquire any shares of capital stock (other than in connection with the cancellation of options in
connection with Section 1.6 of this Agreement, the forfeiture or exercise of equity-based awards or options in accordance with
existing agreements or terms (or awards or options granted after the date hereof in compliance with Section 6.1(b));

 

(e) acquire
(whether by merger, consolidation or acquisition of stock or assets or otherwise) any Person, business or division (whether by
acquisition of assets or otherwise), enter into any new line of business;

 

    - 48 -

     

    

 

(f) sell
or otherwise dispose of (whether by merger, consolidation, acquisition of stock or assets, exclusive license or otherwise) any
Person, business or division thereof or any equity or assets, other than sales or dispositions of inventory in the ordinary course
of business consistent with past practice;

 

(g) except
as set forth in Section 6.1(g) of the BioLite Schedule of Exceptions, (A) enter into, renew, terminate or materially amend (i)
any contract or arrangement with revenues or payments in excess of $75,000 per annum, other than in the ordinary course of business
consistent with past practice or otherwise imposing any material restrictions on BioLite or any of its Subsidiaries or (ii) any
joint venture, partnership or other similar arrangement or (B) engage in any transaction or series of transactions with any BioLite
Affiliate that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act;

 

(h) authorize
any new capital expenditures in amounts more than $50,000 in the aggregate other than in the ordinary course of business consistent
with past practice;

 

(i) except
as set forth in Section 6.1(i) of the BioLite Schedule of Exceptions, incur or modify in any material respect the terms of any
indebtedness for borrowed money, or assume, guarantee or endorse, or otherwise as an accommodation become responsible for, the
obligations of any Person, or make any loans or advances to any other Person in an amount exceeding $50,000 in the aggregate;

 

(j) except
as set forth in Section 6.1(j) of the BioLite Schedule of Exceptions, (i) increase the compensation or benefits of any of its
directors, officers or employees (including the payment of bonuses and the granting of stock options, stock appreciation rights
or other equity or equity-like incentives) or pay any bonuses except that in the case of employees, BioLite or its Subsidiaries
may increase, without the prior written consent of the Parent and BioKey, compensation or benefits of BioLite or Subsidiary employees
by not more than $75,000 in the aggregate for all employees; (ii) grant or pay any severance or termination pay not provided for
under any plan, policy, guideline or agreement in effect on or prior to the date hereof; (iii) enter into, amend or modify the
terms of any employment, consulting, change of control, indemnification, termination or severance agreement or arrangement
with any of its present or former (A) directors, (B) officers or (C) employees or establish, adopt, enter into or materially amend
or terminate any BioLite Plan or collective bargaining agreement except that BioLite or any Subsidiary may enter into, without
the prior written consent of the Parent or BioKey, any employment agreement or independent contractor agreement without change
of control or severance provisions with any new field office employee or registered representative in the ordinary course of business
consistent with prior practice, and (iv) accelerate the vesting or time of payment of any compensation or benefits of any director,
officer, employee or consultant or fund or make any contribution to any BioLite Plan or trust not required to be funded;

 

(k) make
any material change in any financial or regulatory accounting principles, except as may be appropriate to conform to changes in
statutory or regulatory accounting rules or GAAP or regulatory requirements with respect thereto;

 

(l) materially
change any Tax accounting period, adopt or change any material Tax accounting method, file any material amended Tax Return, or
settle a material Tax claim or assessment, in each case, relating to BioLite or a Subsidiary of BioLite, unless required by GAAP
or applicable Law;

 

    - 49 -

     

    

 

(m) agree
to or otherwise settle, compromise or otherwise resolve in whole or in part any litigation, actions, suits, actual, potential
or threatened claims, investigations or proceedings, whether pending on the date hereof or hereafter made or brought, which settlement
or compromise would, in any single case, result in (i) damages, fines or other penalties payable to or by BioLite or any of its
Subsidiaries in excess of $50,000 net of insurance and net of collection from other parties or (ii) non-monetary relief, including
debarment, corporate integrity agreements, any other undertaking of any kind, deferred prosecution agreements, consent decrees,
plea agreements or mandatory or permissive exclusion;

 

(n) abandon,
sell, license (except in the ordinary course of business consistent with past practice), assign or grant any security interest
in or to any material item of BioLite Intellectual Property Rights or any other material assets; or

 

(o) agree
to take any of the actions described in Section 6.1(a) through Section 5.1(n).

 

Section
6.2Conduct of Business of BioKey Pending the Merger. BioKey covenants and agrees that, during the period from the date
hereof until the Effective Time, except as contemplated by this Agreement, as set forth in the BioKey Schedule of Exceptions or
as required by Law, or unless Parent and BioLite shall otherwise consent in writing (such consent not to be unreasonably conditioned,
withheld or delayed), the business of BioKey and its Subsidiaries shall be conducted in its ordinary course of business and, to
the extent consistent with and not in violation of any other provisions of this Section 6.2, BioKey shall use commercially reasonable
efforts to preserve substantially intact its and its Subsidiaries’ business organization, and to preserve its and its Subsidiaries’
present relationships with customers, suppliers, employees, licensees, licensors, partners and other Persons with which it or
any of its Subsidiaries has significant business relations. Without limiting the generality of the foregoing, between the date
of this Agreement and the Effective Time, except as otherwise contemplated by this Agreement, as set forth in the BioKey Schedule
of Exceptions or as required by Law, BioKey and its Subsidiaries shall not, without the prior written consent of Parent and BioLite
(which consent shall not be unreasonably conditioned, withheld or delayed):

 

(a) amend
or otherwise change its Articles of Incorporation or Bylaws;

 

(b) except
as set forth in Section 6.2(b) of the BioKey Schedule of Exceptions, issue, deliver, sell, pledge, dispose of or encumber any
shares of capital stock, voting securities, or other equity interests, or any options, warrants, restricted stock or other rights
of any kind to acquire or receive any shares of capital stock, voting securities, or other equity interests (including stock appreciation
rights, phantom stock or similar instruments) (except for the issuance of shares of BioKey Common Stock upon the exercise of options
or in connection with other stock-based awards in each case outstanding as of the date hereof);

 

(c) declare,
set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any
of its capital stock;

 

    - 50 -

     

    

 

(d) except
as set forth in Section 6.2(d) of the BioKey Schedule of Exceptions, adjust, recapitalize, reclassify, combine, split, subdivide,
redeem, purchase or otherwise acquire any shares of capital stock (other than in connection with the cancellation of options in
connection with Section 1.6 of this Agreement, the forfeiture or exercise of equity-based awards or options in accordance with
existing agreements or terms (or awards or options granted after the date hereof in compliance with Section 6.2(b));

 

(e) acquire
(whether by merger, consolidation or acquisition of stock or assets or otherwise) any Person, business or division (whether by
acquisition of assets or otherwise), enter into any new line of business;

 

(f) sell
or otherwise dispose of (whether by merger, consolidation, acquisition of stock or assets, exclusive license or otherwise) any
Person, business or division thereof or any equity or assets, other than sales or dispositions of inventory in the ordinary course
of business consistent with past practice;

 

(g) except
as set forth in Section 6.2(g) of the BioKey Schedule of Exceptions, (A) enter into, renew, terminate or materially amend (i)
any contract or arrangement with revenues or payments in excess of $75,000 per annum, other than in the ordinary course of business
consistent with past practice or otherwise imposing any material restrictions on BioKey or any of its Subsidiaries or (ii) any
joint venture, partnership or other similar arrangement or (B) engage in any transaction or series of transactions with any BioKey
Affiliate that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act;

 

(h) authorize
any new capital expenditures in amounts more than $50,000 in the aggregate other than in the ordinary course of business consistent
with past practice;

 

(i) except
as set forth in Section 6.2(i) of the BioKey Schedule of Exceptions, incur or modify in any material respect the terms of any
indebtedness for borrowed money, or assume, guarantee or endorse, or otherwise as an accommodation become responsible for, the
obligations of any Person, or make any loans or advances to any other Person in an amount exceeding $50,000 in the aggregate;

 

(j) except
as set forth in Section 6.2(j) of the BioKey Schedule of Exceptions, (i) increase the compensation or benefits of any of its directors,
officers or employees (including the payment of bonuses and the granting of stock options, stock appreciation rights or other
equity or equity-like incentives) or pay any bonuses except that in the case of employees, BioKey or its Subsidiaries may increase,
without the prior written consent of the Parent and BioLite, compensation or benefits of BioKey or Subsidiary employees by not
more than $75,000 in the aggregate for all employees; (ii) grant or pay any severance or termination pay not provided for under
any plan, policy, guideline or agreement in effect on or prior to the date hereof; (iii) enter into, amend or modify the terms
of any employment, consulting, change of control, indemnification, termination or severance agreement or arrangement with
any of its present or former (A) directors, (B) officers or (C) employees or establish, adopt, enter into or materially amend
or terminate any BioKey Plan or collective bargaining agreement except that BioKey or any Subsidiary may enter into, without the
prior written consent of the Parent or BioLite, any employment agreement or independent contractor agreement without change of
control or severance provisions with any new field office employee or registered representative in the ordinary course of business
consistent with prior practice, and (iv) accelerate the vesting or time of payment of any compensation or benefits of any director,
officer, employee or consultant or fund or make any contribution to any BioKey Plan or trust not required to be funded;

 

    - 51 -

     

    

 

(k) make
any material change in any financial or regulatory accounting principles, except as may be appropriate to conform to changes in
statutory or regulatory accounting rules or GAAP or regulatory requirements with respect thereto;

 

(l)  materially
change any Tax accounting period, adopt or change any material Tax accounting method, file any material amended Tax Return, or
settle a material Tax claim or assessment, in each case, relating to BioKey or a Subsidiary of BioKey, unless required by GAAP
or applicable Law;

 

(m) agree
to or otherwise settle, compromise or otherwise resolve in whole or in part any litigation, actions, suits, actual, potential
or threatened claims, investigations or proceedings, whether pending on the date hereof or hereafter made or brought, which settlement
or compromise would, in any single case, result in (i) damages, fines or other penalties payable to or by BioKey or any of its
Subsidiaries in excess of $50,000 net of insurance and net of collection from other parties or (ii) non-monetary relief, including
debarment, corporate integrity agreements, any other undertaking of any kind, deferred prosecution agreements, consent decrees,
plea agreements or mandatory or permissive exclusion;

 

(n) abandon,
sell, license (except in the ordinary course of business consistent with past practice), assign or grant any security interest
in or to any material item of BioKey Intellectual Property Rights or any other material assets; or

 

(o) agree
to take any of the actions described in Section 6.2(a) through Section 6.2(o).

 

ARTICLE
7

ADDITIONAL AGREEMENTS

 

Section
7.1BioLite Stockholders Meeting; BioKey Stockholders Meeting 

 

(a) BioLite
shall as soon as practicable following the execution of this Agreement, acting through its Board of Directors, (a) take all action
necessary to duly call, give notice of and convene a meeting of its stockholders for the purpose of obtaining the BioLite Requisite
Vote (the “BioLite Stockholders Meeting”).

 

(b) BioKey shall as soon as practicable following the execution of this Agreement, acting through its Board of Directors, (a) take
all action necessary to duly call, give notice of, and convene a meeting of its stockholders for the purpose of obtaining the
BioKey Requisite Vote (the “BioKey Stockholders Meeting”).

 

    - 52 -

     

    

 

(c) Parent
shall cause all shares of BioLite Common Stock, BioKey Common Stock and BioKey Preferred Stock owned by Parent, Merger Subs or
any other subsidiary of Parent to be voted in favor of the approval of this Agreement.

 

Section
7.2Regulatory Matters. (a) BioLite, BioKey, and Parent shall cooperate in preparing and promptly cause to be filed
with the SEC the Prospectus and the S-4. Parent, BioLite and BioKey shall, as promptly as practicable after receipt thereof, provide
the other parties with copies of any written comments and advise the other party of any oral comments with respect to the Prospectus
or the S-4 received from the SEC. Each party shall cooperate and provide the other parties with a reasonable opportunity to review
and comment on any amendment or supplement to the Prospectus on form the S-4 prior to filing such with the SEC. Each of Parent,
BioLite, and BioKey shall use reasonable best efforts to have the S-4 declared effective under the Securities Act as promptly
as practicable after such filing and to keep the S-4 effective as long as is necessary to consummate the Mergers and the other
transactions contemplated by this Agreement. At the expense of BioLite, BioLite shall mail or deliver the Proxy Statement to BioLite’s
stockholders as promptly as practicable after the S-4 is declared effective. At the expense of BioKey, BioKey shall mail or deliver
the Proxy Statement to BioKey’s stockholders as promptly as practicable after the S-4 is declared effective.

 

(b) Subject
to the other provisions of this Agreement, Parent, BioLite and BioKey shall cooperate with each other and use reasonable best
efforts to promptly prepare and file all necessary documentation, to effect all applications, notices, petitions and filings,
and to obtain as promptly as practicable any consents, approvals and authorizations of all third parties and Governmental Bodies
which are necessary or advisable to consummate the transactions contemplated by this Agreement (including the Mergers) and to
comply with the terms and conditions of all such consents, approvals and authorizations of all such third parties and Governmental
Bodies.

 

(c) Parent,
BioLite and BioKey shall, upon request, furnish each other with all information concerning themselves, their subsidiaries, directors,
officers and stockholders and such other matters as may be reasonably necessary or advisable in connection with the preparation
of the Prospectus on form S-4 or any other statement, filing, notice or application made by or on behalf of Parent, BioLite, BioKey
or any of their respective Subsidiaries to any Governmental Body in connection with the Mergers and the other transactions contemplated
by this Agreement. Parent, BioLite and BioKey shall make any necessary filings with respect to the Mergers under the Securities
Act and the Exchange Act and the rules and regulations thereunder.

 

    - 53 -

     

    

 

Section
7.3Access to Information; Confidentiality. (a) From the date hereof to the Effective Time or the earlier termination
of this Agreement, upon reasonable prior written notice, BioLite shall, and shall use commercially reasonable efforts to cause
its officers, directors and employees to, afford the officers, employees, auditors and other authorized representatives of Parent
and BioKey reasonable access, consistent with applicable Law, at all reasonable times to its officers, employees, properties,
offices, plants and other facilities and to all books and records of BioLite and its Subsidiaries, and shall furnish Parent and
BioKey with all financial, operating and other data and information as Parent and BioKey, through their respective officers, employees
or authorized representatives, may from time to time reasonably request in writing. Notwithstanding the foregoing, any such investigation
or consultation shall be conducted in such a manner as not to interfere unreasonably with the business or operations of BioLite
and its Subsidiaries. BioLite shall not be required to provide access to or to disclose information where such access or disclosure
would contravene any Law. Each of Parent, the Merger Subs and BioKey will hold and treat and will cause their respective officers,
employees, auditors and other authorized representatives to hold and treat in confidence all documents and information concerning
BioLite and its Subsidiaries furnished to Parent, Merger Subs or BioKey in connection with the transactions contemplated by this
Agreement.

 

(b) From
the date hereof to the Effective Time or the earlier termination of this Agreement, upon reasonable prior written notice, BioKey
shall, and shall use commercially reasonable efforts to cause its officers, directors and employees to, afford the officers, employees,
auditors and other authorized representatives of Parent and BioLite reasonable access, consistent with applicable Law, at all
reasonable times to its officers, employees, properties, offices, plants and other facilities and to all books and records of
BioKey and its Subsidiaries, and shall furnish Parent and BioLite with all financial, operating and other data and information
as Parent and BioLite, through their respective officers, employees or authorized representatives, may from time to time reasonably
request in writing. Notwithstanding the foregoing, any such investigation or consultation shall be conducted in such a manner
as not to interfere unreasonably with the business or operations of BioKey and its Subsidiaries. BioKey shall not be required
to provide access to or to disclose information where such access or disclosure would contravene any Law. Each of Parent, the
Merger Subs and BioLite will hold and treat and will cause their respective officers, employees, auditors and other authorized
representatives to hold and treat in confidence all documents and information concerning BioKey and its Subsidiaries furnished
to Parent, Merger Subs or BioLite in connection with the transactions contemplated by this Agreement.

 

(c) From
the date hereof to the Effective Time or the earlier termination of this Agreement, upon reasonable prior written notice, the
Parent shall, and shall use commercially reasonable efforts to cause its officers, directors and employees to, afford the officers,
employees, auditors and other authorized representatives of BioLite and BioKey reasonable access, consistent with applicable Law,
at all reasonable times to its officers, employees, properties, offices, plants and other facilities and to all books and records
of the Parent and its Subsidiaries, and shall furnish BioLite and BioKey with all financial, operating and other data and information
as BioLite and BioKey, through their respective officers, employees or authorized representatives, may from time to time reasonably
request in writing. Notwithstanding the foregoing, any such investigation or consultation shall be conducted in such a manner
as not to interfere unreasonably with the business or operations of the Parent and its Subsidiaries. The Parent shall not be required
to provide access to or to disclose information where such access or disclosure would contravene any Law. BioLite and BioKey will
hold and treat and will cause their respective officers, employees, auditors and other authorized representatives to hold and
treat in confidence all documents and information concerning the Parent and Merger Subs and their respective Subsidiaries furnished
to BioLite and BioKey in connection with the transactions contemplated by this Agreement.

 

    - 54 -

     

    

 

Section
7.4BioLite Acquisition Proposals. (a) BioLite agrees that (i) it and its officers and directors shall not, and (ii)
it shall use commercially reasonable efforts to ensure that its representatives shall not, in each case (A) directly or indirectly,
initiate, solicit or knowingly encourage any inquiries or the making of any proposal or offer with respect to the acquisition,
including by way of a tender offer, exchange offer, merger, consolidation or other business combination, of (x) an equity interest
representing a 10% or greater economic or voting interest in BioLite, or (y) the assets, securities or other ownership interests
of or in BioLite representing 10% or more of the consolidated assets of BioLite, other than the transactions contemplated by this
Agreement (any such proposal or offer being hereinafter referred to as an “BioLite Acquisition Proposal”),
or (B) directly or indirectly, engage in any negotiations concerning, or provide access to its properties, books and records or
any confidential information or data to, any Person relating to, a BioLite Acquisition Proposal; provided, however,
that BioLite and its representatives may, in response to a written BioLite Acquisition Proposal that the Board of Directors of
BioLite determines, in good faith, after consultation with its financial advisors, constitutes, a BioLite Superior Proposal, and
which BioLite Acquisition Proposal did not result from a material breach of this Section 7.4(a), (x) provide access or furnish
information with respect to BioLite to the Person making such BioLite Acquisition Proposal (and its representatives) pursuant
to a customary confidentiality agreement and (y) engage in discussions or negotiations with the Person making such BioLite Acquisition
Proposal (and its representatives) regarding such BioLite Acquisition Proposal; provided further, however, that,
subject to the right of BioLite to withhold information where such disclosure would contravene any Law, BioLite shall promptly
provide to Parent any non-public information that is provided to the Person making such BioLite Acquisition Proposal or its representatives
that was not previously provided to Parent or Merger Sub 1. BioLite shall, and shall cause its agents and representatives to,
promptly cease and cause to be terminated any existing activities, discussions or negotiations with any Persons conducted heretofore
with respect to any BioLite Acquisition Proposal. BioLite shall also promptly (within two (2) Business Days) notify Parent of
the receipt of any BioLite Acquisition Proposal after the date hereof, which notice shall include the identity of the Person making
such BioLite Acquisition Proposal and the material terms and conditions thereof, and shall keep Parent apprised of any related
material developments, discussions and negotiations related thereto.

 

For
purposes of this Agreement, the term “BioLite Superior Proposal” means any offer made by a third party that
the Board of Directors of BioLite reasonably determines to be bona fide for a transaction that (a) if consummated, would result
in such third party (or in the case of a direct merger between such third party and BioLite, the stockholders of such third party)
acquiring, directly or indirectly, more than 50% of the voting power of the BioLite Common Stock (or, in the case of a direct
merger, the common stock of the resulting company) or all or substantially all the consolidated assets of BioLite and its subsidiaries
for consideration consisting of consideration payable to holders of shares of BioLite Common Stock that the Board of Directors
of BioLite determines in good faith, after consultation with its financial advisors, to be more favorable from a financial point
of view to holders of BioLite Common Stock than the BioLite Merger, and is reasonably likely to be consummated in accordance with
its terms, taking into account all financial, regulatory, legal and other aspects of such offer and transaction (including the
likelihood of completion) and any changes to the terms of this Agreement proposed by Parent in response to such BioLite Superior
Proposal or otherwise.

 

    - 55 -

     

    

 

(b) The
Board of Directors of BioLite shall not (i) withdraw or modify in a manner adverse to Parent or Merger Subs, or propose publicly
to withdraw or modify in a manner adverse to Parent or Merger Subs, the BioLite Merger Recommendation or resolve or agree to take
any such action (any such action or any such resolution or agreement to take such action being referred to herein as a “BioLite
Adverse Recommendation Change” ), unless the Board of Directors of BioLite determines in good faith, after consultation
with its legal advisors, that the failure to take such action would result in a breach of or be reasonably likely to result in
a breach of its fiduciary duties, (ii) recommend, adopt or approve any BioLite Acquisition Proposal or propose publicly to recommend,
adopt or approve any competing BioLite Acquisition Proposal or resolve or agree to take any such action or (iii) cause or permit
BioLite to enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition agreement, merger
agreement, option agreement, joint venture agreement, partnership agreement or other agreement (each, a “BioLite Acquisition
Agreement“) constituting or related to, or which is intended to lead to any BioLite Acquisition Proposal (other than
a confidentiality agreement) or resolve or agree to take any such action. Notwithstanding anything in this Section 7.4(b) to the
contrary, the Board of Directors of BioLite may, in response to a BioLite Superior Proposal, cause BioLite to terminate this Agreement
pursuant to Section 9.1(g) in order to concurrently enter into a BioLite Acquisition Agreement; provided, however,
that BioLite shall not terminate this Agreement pursuant to Section 9.1(g), and any purported termination pursuant to Section
9.1(g) shall be void and of no force or effect, unless BioLite shall have complied with all the provisions of this Section 7.4,
including the notification provisions in this Section 7.4, and with all applicable requirements of Section 9.3(b) in connection
with such BioLite Superior Proposal; and provided further, however, that BioLite shall not exercise its right to
terminate this Agreement pursuant to Section 9.1(g) until after the second Business Day following Parent’s receipt of written
notice (a “Notice of BioLite Superior Proposal”) from BioLite advising Parent that the Board of Directors of
BioLite has received a BioLite Superior Proposal, identifying the Person making such BioLite Superior Proposal and the material
terms and conditions of the BioLite Superior Proposal and stating that the BioLite Board intends to exercise its right to terminate
this Agreement pursuant to Section 9.1(g) (it being understood and agreed that, prior to any such termination taking effect, (i)
any amendment to the price or any other material term of a BioLite Superior Proposal shall require a new Notice of BioLite Superior
Proposal (but shall not trigger any new waiting period) and (ii) the Board of Directors of BioLite shall discuss with Parent and
take into account any changes to the terms of this Agreement proposed by Parent in response to such BioLite Superior Proposal
or otherwise).

 

(c) Nothing
contained in this Section 7.4 or elsewhere in this Agreement shall prohibit BioLite from (i) taking and disclosing to its stockholders
a position contemplated by Rule 14d-9 and 14e-2(a) promulgated under the Exchange Act or (ii) making any disclosure to BioLite’s
stockholders if, in the good faith judgment of the Board of Directors of BioLite, after receipt of advice from its outside counsel,
failure so to disclose would result in a breach of or be reasonably like to result in a breach of its fiduciary duties or applicable
Law.

 

    - 56 -

     

    

 

Section
7.5BioKey Acquisition Proposals. (a) BioKey agrees that (i) it and its officers and directors shall not, and (ii) it
shall use commercially reasonable efforts to ensure that its representatives shall not, in each case (A) directly or indirectly,
initiate, solicit or knowingly encourage any inquiries or the making of any proposal or offer with respect to the acquisition,
including by way of a tender offer, exchange offer, merger, consolidation or other business combination, of (x) an equity interest
representing a 10% or greater economic or voting interest in BioKey, or (y) the assets, securities or other ownership interests
of or in BioKey representing 10% or more of the consolidated assets of BioKey, other than the transactions contemplated by this
Agreement (any such proposal or offer being hereinafter referred to as an “BioKey Acquisition Proposal”), or
(B) directly or indirectly, engage in any negotiations concerning, or provide access to its properties, books and records or any
confidential information or data to, any Person relating to, a BioKey Acquisition Proposal; provided, however, that
BioKey and its representatives may, in response to a written BioKey Acquisition Proposal that the Board of Directors of BioKey
determines, in good faith, after consultation with its financial advisors, constitutes, a BioKey Superior Proposal, and which
BioKey Acquisition Proposal did not result from a material breach of this Section 7.5(a), (x) provide access or furnish information
with respect to BioKey to the Person making such BioKey Acquisition Proposal (and its representatives) pursuant to a customary
confidentiality agreement and (y) engage in discussions or negotiations with the Person making such BioKey Acquisition Proposal
(and its representatives) regarding such BioKey Acquisition Proposal; provided further, however, that, subject to
the right of BioKey to withhold information where such disclosure would contravene any Law, BioKey shall promptly provide to Parent
any non-public information that is provided to the Person making such BioKey Acquisition Proposal or its representatives that
was not previously provided to Parent or Merger Sub 2. BioKey shall, and shall cause its agents and representatives to, promptly
cease and cause to be terminated any existing activities, discussions or negotiations with any Persons conducted heretofore with
respect to any BioKey Acquisition Proposal. BioKey shall also promptly (within two (2) Business Days) notify Parent of the receipt
of any BioKey Acquisition Proposal after the date hereof, which notice shall include the identity of the Person making such BioKey
Acquisition Proposal and the material terms and conditions thereof, and shall keep Parent apprised of any related material developments,
discussions and negotiations related thereto.

 

For
purposes of this Agreement, the term “BioKey Superior Proposal” means any offer made by a third party that
the Board of Directors of BioKey reasonably determines to be bona fide for a transaction that (a) if consummated, would result
in such third party (or in the case of a direct merger between such third party and BioKey, the stockholders of such third party)
acquiring, directly or indirectly, more than 50% of the voting power of the BioKey Capital Stock (or, in the case of a direct
merger, the common stock of the resulting company) or all or substantially all the consolidated assets of BioKey and its subsidiaries
for consideration consisting of consideration payable to holders of shares of BioKey Capital Stock that the Board of Directors
of BioKey determines in good faith, after consultation with its financial advisors, to be more favorable from a financial point
of view to holders of BioKey Capital Stock than the BioKey Merger, and is reasonably likely to be consummated in accordance with
its terms, taking into account all financial, regulatory, legal and other aspects of such offer and transaction (including the
likelihood of completion) and any changes to the terms of this Agreement proposed by Parent in response to such BioKey Superior
Proposal or otherwise.

 

    - 57 -

     

    

 

(b) The
Board of Directors of BioKey shall not (i) withdraw or modify in a manner adverse to Parent or Merger Subs, or propose publicly
to withdraw or modify in a manner adverse to Parent or Merger Subs, the BioKey Merger Recommendation or resolve or agree to take
any such action (any such action or any such resolution or agreement to take such action being referred to herein as a “BioKey
Adverse Recommendation Change” ), unless the Board of Directors of BioKey determines in good faith, after consultation
with its legal advisors, that the failure to take such action would result in a breach of or be reasonably likely to result in
a breach of its fiduciary duties, (ii) recommend, adopt or approve any BioKey Acquisition Proposal or propose publicly to recommend,
adopt or approve any competing BioKey Acquisition Proposal or resolve or agree to take any such action or (iii) cause or permit
BioKey to enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition agreement, merger
agreement, option agreement, joint venture agreement, partnership agreement or other agreement (each, a “BioKey Acquisition
Agreement”) constituting or related to, or which is intended to lead to any BioKey Acquisition Proposal (other than
a confidentiality agreement) or resolve or agree to take any such action. Notwithstanding anything in this Section 7.5(b) to the
contrary, the Board of Directors of BioKey may, in response to a BioKey Superior Proposal, cause BioKey to terminate this Agreement
pursuant to Section 9.1(h) in order to concurrently enter into a BioKey Acquisition Agreement; provided, however,
that BioKey shall not terminate this Agreement pursuant to Section 9.1(h), and any purported termination pursuant to Section 9.1(h)
shall be void and of no force or effect, unless BioKey shall have complied with all the provisions of this Section 7.5, including
the notification provisions in this Section 7.5, and with all applicable requirements of Section 9.3(b) in connection with such
BioKey Superior Proposal; and provided further, however, that BioKey shall not exercise its right to terminate this
Agreement pursuant to Section 9.1(h) until after the second Business Day following Parent’s receipt of written notice (a
“Notice of BioKey Superior Proposal”) from BioKey advising Parent that the Board of Directors of BioKey has
received a BioKey Superior Proposal, identifying the Person making such BioKey Superior Proposal and the material terms and conditions
of the BioKey Superior Proposal and stating that the BioKey Board intends to exercise its right to terminate this Agreement pursuant
to Section 9.1(h) (it being understood and agreed that, prior to any such termination taking effect, (i) any amendment to the
price or any other material term of a BioKey Superior Proposal shall require a new Notice of BioKey Superior Proposal (but shall
not trigger any new waiting period) and (ii) the Board of Directors of BioKey shall discuss with Parent and take into account
any changes to the terms of this Agreement proposed by Parent in response to such BioKey Superior Proposal or otherwise).

 

(c) Nothing
contained in this Section 7.5 or elsewhere in this Agreement shall prohibit BioKey from (i) taking and disclosing to its stockholders
a position contemplated by Rule 14d-9 and 14e-2(a) promulgated under the Exchange Act or (ii) making any disclosure to BioLite’s
stockholders if, in the good faith judgment of the Board of Directors of BioKey, after receipt of advice from its outside counsel,
failure so to disclose would result in a breach of or be reasonably like to result in a breach of its fiduciary duties or applicable
Law.

 

    - 58 -

     

    

 

Section
7.6Directors’ and Officers’ Indemnification and Insurance. (a) Without limiting any additional rights that
any Person may have under any agreement, document, law or Plan, from and after the Effective Time, each Surviving Corporation
shall indemnify and hold harmless each present (as of the Effective Time) and former officer, director or employee of such Surviving
Corporation and its Subsidiaries (the “Indemnified Parties“), against all claims, losses, liabilities, damages,
judgments, inquiries, fines and reasonable fees, costs and expenses, including attorneys’ fees and disbursements (collectively,
“Costs”), incurred in connection with any suit, claim, action, proceeding, arbitration, mediation or governmental
investigation, whether civil, criminal, administrative or investigative (an “Action”), arising out of or pertaining
to the fact that the Indemnified Party is or was an officer, director, fiduciary or agent of BioLite or BioKey, as applicable
or any of their respective Subsidiaries or another entity if such service to the other entity was at the request or for the benefit
of BioLite or BioKey, as applicable or any of their respective Subsidiaries, whether asserted or claimed prior to, at or after
the Effective Time, to the extent provided under applicable Law and BioLite or BioKey’s or a Subsidiary’s Articles
of Incorporation or Bylaws, as applicable, as at the date hereof. In the event of any such Action, each indemnified Person shall
be entitled to advancement of expenses incurred in the defense of any Action from the applicable Surviving Corporation to the
fullest extent that BioLite or BioKey or their respective Subsidiaries, as applicable, would be permitted under applicable Law
and BioLite’s, BioKey’s, or their respective Subsidiaries’ Articles of Incorporation or Bylaw, as applicable,
as at the date hereof; provided, that such Person shall execute and deliver an undertaking that such Person shall return such
amounts to BioLite or BioKey, as applicable, if it is determined that such Person was not entitled to such funds.

 

(b) Parent,
BioLite, and BioKey agree that all rights to indemnification and exculpation from liabilities for acts or omissions occurring
at or prior to the Effective Time (and rights for advancement of expenses) now existing in favor of the current or former directors
or officers of BioLite, BioKey or their respective Subsidiaries as provided in their Articles of Incorporation or Bylaws (or comparable
organizational documents) and any indemnification or other agreements of BioLite, BioKey or their respective Subsidiaries, as
applicable, as in effect on the date of this Agreement shall be assumed by the applicable Surviving Corporation and its Subsidiaries
in the applicable Merger, without further action, at the Effective Time and shall survive the applicable Merger and shall continue
in full force and effect in accordance with their terms. Further, the Articles of Incorporation and Bylaws of the Surviving Corporations
and their Subsidiaries shall contain provisions no less favorable with respect to indemnification, advancement of expenses and
exculpation of former or present directors and officers than are presently set forth in BioLite’s, BioKey’s and their
respective Subsidiaries’ Articles of Incorporation and Bylaws, as applicable, which provisions shall not be amended, repealed
or otherwise modified for a period of six (6) years from the Effective Time in any manner that would adversely affect the rights
thereunder of any such individuals, except as amendments may be required by the NRS or CGCL, as applicable, during such period.

 

(c) For
a period of not less than five (5) years after the Effective Time, Parent shall cause to be in effect either (i) BioLite’s
and BioKey’s and their respective Subsidiaries’ directors’ and officers’ liability insurance covering
each Person currently covered by BioLite’s and BioKey’s and their respective Subsidiaries’ directors’
and officers’ liability insurance for acts or omissions occurring prior to the Effective Time by way of purchasing a “tail”
or (ii) the Parent may substitute thereof policies of another insurance company, reasonably acceptable to the Board of Directors
of BioLite and BioKey, as applicable, the material terms of which, including coverage and amount, are no less favorable in any
material respect to such Persons than the most favorable of the Parent’s, BioLite’s and BioKey’s policies in
effect immediately prior to the date hereof, as applicable; and provided, further, that in no event shall Parent, BioLite or BioKEy
or their respective Subsidiaries be required to pay aggregate premiums for insurance under this Section 7.6(c) in excess of 125%
of the amount of the aggregate premiums paid by the Parent, BioLite, BioKey, or their respective Subsidiaries, as applicable,
for policy year 2016-2017 for such purpose, or notwithstanding such amount, not less than a reasonable amount in view of industry
practices. The Board of Directors of BioLite and BioKey shall each have the right to modify, in their discretion the ratio of
“Side A” Coverage to “Side B” Coverage without regard to the existing percentage allocation in their respective
existing coverage.

 

    - 59 -

     

    

 

(d) This
covenant is intended to be for the benefit of, and shall be enforceable by, each of the Indemnified Parties and their respective
heirs and legal representatives. The indemnification provided for herein shall not be deemed exclusive of any other rights to
which an Indemnified Party is entitled, whether pursuant to Law, contract or otherwise.

 

(e) In
the event that either Surviving Corporation or its successors or assigns (i) consolidates with or merges into any other Person
and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers or conveys
all or a majority of its properties and assets to any Person, then, and in each such case to the extent necessary, proper provision
shall be made so that the successors and assigns of such Surviving Corporation shall succeed to the obligations set forth in this
Section 7.6.

 

(f) Parent
shall pay all reasonable expenses, including reasonable attorneys’ fees, that may be incurred by any Indemnified Party in
enforcing the indemnity and other obligations provided in this Section 7.6.

 

Section
7.7Further Action; Efforts. (a) Subject to the terms and conditions of this Agreement, each party will use commercially
reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or
advisable under applicable laws and regulations to consummate the Mergers and the other transactions contemplated by this Agreement
as promptly as practicable and no party hereto shall take or cause to be taken any action which would reasonably be expected to
prevent, impede or delay the consummation of the Mergers.

 

(b) In
furtherance and not in limitation of the covenants of the parties contained in Section 7.7(a), if any objections are asserted
with respect to the transactions contemplated hereby under any Law or if any suit is instituted (or threatened to be instituted)
by any U.S. or foreign Governmental Body or any private party challenging any of the transactions contemplated hereby or which
would otherwise prevent, materially impede or materially delay the consummation of the transactions contemplated hereby, each
of Parent, each Merger Sub, BioLite, and BioKey shall use commercially reasonable efforts to resolve any such objections or suits
so as to permit consummation of the transactions contemplated by this Agreement.

 

(c) In
the event that any administrative or judicial investigation, suit, action or other proceeding is instituted (or threatened to
be instituted) by a Governmental Body or private party challenging the Mergers or any other transaction contemplated by this Agreement,
or any other agreement contemplated hereby, or that otherwise would reasonably be expected to prevent, impede or delay the Mergers,
or any such transaction or the satisfaction of any condition set forth in ARTICLE 8, each of Parent, each Merger Sub, BioLite
and BioKey shall cooperate in good faith with each other and use its respective commercially reasonable efforts to contest and
resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction or other
order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of
the transactions contemplated by this Agreement.

 

    - 60 -

     

    

 

Section
7.8Public Announcements. Each of BioLite, BioKey, Parent and each Merger Sub agrees that no public release or announcement
(including public filings with the SEC) concerning the transactions contemplated hereby shall be issued by any party without the
prior written consent of BioLite, BioKey and the Parent (which consent shall not be unreasonably conditioned, withheld or delayed),
except as such release or announcement may be required by Law or the rules or regulations of any applicable Governmental Body
to which the relevant party is subject or submits, wherever situated, in which case the party required to make the release or
announcement shall use commercially reasonable efforts to allow each other party reasonable time to comment on such release or
announcement in advance of such issuance, it being understood that the final form and content of any such release or announcement,
to the extent so required, shall be at the final discretion of the disclosing party; provided, that Parent may include
disclosures relating to the transactions contemplated hereby in its periodic filings with the SEC without seeking consent from,
or consulting with, any other party, so long as such disclosures are not inconsistent with the information contained in previous
press releases, public disclosures or public statements made jointly by Parent, BioLite and BioKey (or made individually by BioLite,
BioKey, or Parent, if previously consented to by the other party); provided, finally, that (i) BioLite shall not
be required to provide Parent or BioKey any such opportunity to review or comment in connection with the receipt and existence
of a BioLite Acquisition Proposal and matters related thereto or a BioLite Adverse Recommendation Change or other communications
contemplated by Section 7.4(b), and (ii) BioKey shall not be required to provide Parent or BioLite any such opportunity to review
or comment in connection with the receipt and existence of a BioKey Acquisition Proposal and matters related thereto or a BioKey
Adverse Recommendation Change or other communications contemplated by Section 7.5(b).

 

Section
7.9Notification. From and after the date of this Agreement until the earlier of the Effective Time or the termination
of this Agreement pursuant to and in accordance with Section 9.1, BioKey, BioLite, and Parent shall promptly notify each other
orally and in writing of the occurrence, or non-occurrence, of any event that, individually or in the aggregate, would make the
timely satisfaction of any of the conditions set forth in Section 8.1, Section 8.3 and Section 8.4 impossible or unlikely.

 

Section
7.10Transfer Taxes. Except as otherwise provided in Section 2.2(c), all stock transfer, real estate transfer, documentary,
stamp, recording and other similar Taxes (including interest, penalties and additions to any such Taxes) (“Transfer Taxes”)
incurred in connection with the Mergers shall be paid jointly and severally by BioLite and BioKey, and BioLite and BioKey shall
cooperate with the Merger Subs and Parent in preparing, executing and filing any Tax Returns with respect to such Transfer Taxes.

 

Section
7.11Anti-Takeover Statute. If any “fair price”, “moratorium”, “control share acquisition”,
“business combination” or other similar antitakeover statute or regulation enacted under U.S. state or federal Laws,
including those under the NRS or CGCL, is or may become applicable to this Agreement (including the Mergers and the other transactions
contemplated hereby), each of Parent, BioLite, BioKey and each Merger Sub and their respective Board of Directors shall grant
all such approvals and take all such actions as are necessary so that such transactions may be consummated as promptly as practicable
hereafter on the terms contemplated hereby and otherwise act to eliminate or minimize the effects of such statute or regulation
on such transactions.

 

    - 61 -

     

    

 

Section
7.12Conduct of Parent, BioLite, BioKey and Merger Subs Pending the Merger. Each of Parent, BioLite, BioKey and each
Merger Sub covenants and agrees that, between the date of this Agreement and the Effective Time, except as otherwise contemplated
by this Agreement, as set forth in the Parent Schedule of Exceptions, BioLite Schedule of Exceptions, BioKey Schedule of Exceptions
or as required by Law, Parent and each Merger Sub shall not, without the prior written consent of all the other parties (which
consent shall not be unreasonably withheld or delayed):

 

(a) declare,
set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any
of its capital stock;

 

(b) adjust,
recapitalize, reclassify, combine, split, or subdivide any shares of capital stock of Parent;

 

(c) acquire
(whether by merger, consolidation or acquisition of stock or assets or otherwise) any Person, business or division (whether by
acquisition of assets or otherwise), enter into any new line of business in an amount exceeding $1,500,000 in the aggregate;

 

(d) sell
or otherwise dispose of (whether by merger, consolidation, acquisition of stock or assets, exclusive license or otherwise) any
Person, business or division thereof or any equity or assets in an amount exceeding $1,500,000 in the aggregate, other than sales
or dispositions of inventory in the ordinary course of business consistent with past practice;

 

(e) incur
or modify in any material respect the terms of any indebtedness for borrowed money, or assume, guarantee or endorse, or otherwise
as an accommodation become responsible for, the obligations of any Person, or make any loans or advances to any other Person in
an amount exceeding $1,500,000 in the aggregate; or

 

(f)  agree
to take any of the actions described in Section 7.12(a) through Section 7.12(e).

 

Section
7.13 Fairness Opinion. Prior to Closing, Parent shall have engaged a qualified third party (the “Parent’s Financial
Advisor”) to serve as the financial advisor respecting the transactions contemplated and to provide an opinion (“Fairness
Opinion”) regarding the fairness of the transactions contemplated herein. Parent shall cause a copy of such Fairness Opinion
to be included in the registration statement on Form S-4 to be filed with the SEC. 

 

Section
7.14Certain Fees and Expenses. (a) At or prior to Closing, BioLite shall pay in full BioLite’s outside legal
counsel and BioLite’s accountants for any fees and expenses incurred in connection with the BioLite Merger and such shall
cause such persons to deliver to BioLite a statement that they have been paid in full. 

 

(b)
At or prior to Closing, BioKey shall pay in full BioKey’s outside legal counsel and BioKey’s accountants for any fees
and expenses incurred in connection with the BioKey Merger and such shall cause such persons to deliver to BioKey a statement
that they have been paid in full.

 

    - 62 -

     

    

 

 

ARTICLE 8

 

CONDITIONS OF MERGER

 

Section 8.1 Conditions to Obligation
of Each Party to Effect the Mergers. The respective obligations of each party to effect the Mergers shall be subject to the
satisfaction or waiver at or prior to the Effective Time of the following conditions:

 

(a) this Agreement shall have been approved
by the stockholders of BioLite by the BioLite Requisite Vote;

 

(b) solely with respect to the BioKey Merger,
this Agreement shall have been approved by the stockholders of BioKey by the BioKey Requisite Vote;

 

(c) no Law (whether temporary, preliminary
or permanent) shall have been enacted, entered, promulgated or enforced, nor any injunction shall have been issued and be in effect,
by any United States or state court or United States Governmental Body which prohibits, restrains or enjoins the consummation of
the Mergers; provided, however, that prior to invoking this condition each party agrees to comply with Section 7.7;

 

(d) the S-4 shall have become effective under
the Securities Act and shall not be the subject of any stop order or proceedings seeking a stop order shall have been issued and
no proceedings for that purpose shall have been initiated or threatened by the SEC. The S-4 shall not contain any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading;

 

(e) Each party receives and approves the other
parties’ updated Schedules of Exceptions on or before the Closing;

 

(f) Board of Directors of Parent will consist
of the eleven persons set forth on Schedule 1.5;

 

(g) Parent’s Financial Advisor will
have delivered to Parent the Fair ness Opinion and such Fairness Opinion will have been included in the S-4 that has been declared
effective by the SEC;

 

(h) BioLite will have provided to the Parent
and BioKey unaudited consolidated financial statements of BioLite (including any related notes thereto) for the three and nine
months ended September 30, 2017 (and any subsequent periods required for inclusion in the S-4) (the “BioLite Interim Financial
Statements”); and

 

(i) Solely with respect to the BioKey Merger,
BioKey will have provided to the Parent and BioLite (i) audited consolidated financial statements of BioKey (including any related
notes thereto) for the fiscal years ended June 30, 2017 and 2016 (and any subsequent periods required for inclusion in the S-4)
(the “BioKey Audited Financial Statements”) and (ii) unaudited consolidated financial statements of BioKey (including
any related notes thereto) for the nine months ended September 30, 2017 (and any subsequent periods required for including in the
S-4) (the “BioKey Interim Financial Statements”).

 

    - 63 -

     

    

 

For the avoidance of doubt, and not withstanding any provision
to the contrary in this Agreement, in the event that, at such time as all other conditions to the closing of the BioLite Merger
have been met and BioKey’s stockholders have not approved this Agreement, BioLite, Merger Sub 1 and the Parent shall have
the right, upon mutual consent, but no obligation, to effect the BioLite Merger (which, for clarification, will not require any
further stockholder approval).

 

Section 8.2 Conditions to Obligations
of Parent and Merger Subs. The respective obligations of Parent and Merger Subs to effect the Mergers shall be subject to the
satisfaction or waiver at or prior to the Effective Time of the following conditions:

 

(a) the representations and warranties of
BioLite and (solely with respect to the BioKey Merger) BioKey set forth in this Agreement shall be true and correct (without giving
effect to any limitation on any representation or warranty indicated by the words “BioLite Material Adverse Effect”,
“BioKey Material Adverse Effect”, “in all material respects”, “in any material respect”, “material”
or “materially”) as of the Effective Time as though made on and as of the Effective Time (except to the extent expressly
made as of an earlier date, in which case as of such earlier date), after giving effect to any updates made to the BioLite Schedule
of Exceptions and BioKey Schedule of Exceptions made on or after the date hereof and prior to Closing, in each case except where
the failure of any such representations and warranties to be so true and correct would not, or would not reasonably be expected
to, individually or in the aggregate, have a BioLite Material Adverse Effect or BioKey Material Adverse Effect;

 

(b) BioLite and (solely with respect to the
BioKey Merger) BioKey shall each have complied in all material respects with their respective obligations pursuant to Article 6
and Article 7;

 

(c) BioLite shall have obtained and delivered
to Parent any consent, approval, authorization, permit, action, or notification set forth on Schedule 3.5(a) of the BioLite Schedule
of Exceptions which (i) shall be in form and substance reasonably satisfactory to Parent, (ii) shall not be subject to the satisfaction
of any condition that has not been satisfied or waived, and (iii) shall be in full force and effect;

 

(d) Solely with respect to the BioKey Merger,
BioKey shall have obtained and delivered to Parent any consent, approval, authorization, permit, action, or notification set forth
on Schedule 4.5(a) of the BioKey Schedule of Exceptions which (i) shall be in form and substance reasonably satisfactory to Parent,
(ii) shall not be subject to the satisfaction of any condition that has not been satisfied or waived, and (iii) shall be in full
force and effect;

 

(e) stockholders of BioLite constituting the
BioLite Requisite Vote shall have approved this Agreement;

 

(f) solely with respect to the BioKey Merger,
stockholders of BioKey constituting the BioKey Requisite Vote shall have approved this Agreement;

 

    - 64 -

     

    

 

(g) holders owning no more than five percent
(5%), in the aggregate, of the outstanding BioLite Common Stock shall have perfected and not withdrawn a demand for dissenters’
rights pursuant to the NRS and Section 2.3;

 

(h) solely with respect to the BioKey Merger,
holders owning no more than five percent (5%), in the aggregate, of the outstanding BioKey Capital Stock shall have perfected and
not withdrawn a demand for dissenters’ rights pursuant to the CGCL and Section 2.3;

 

(i) the Parent shall have received Certificates
executed on behalf of BioLite by the chief executive officer of BioLite certifying that the conditions set forth in Section 8.2(a)
and (b) have been satisfied;

 

(l) solely with respect to the BioKey Merger,
the Parent shall have received Certificates executed on behalf of BioKey by the chief executive officer of BioKey certifying that
the conditions set forth in Section 8.2(a) and (b) have been satisfied; and

 

(m) the Parent shall have received opinions
of counsel of BioLite and (solely with respect to the BioKey Merger) BioKey in a form reasonably acceptable to Parent.

 

Section 8.3 Conditions to Obligations
of BioLite. The obligation of BioLite to effect the Mergers shall be further subject to the satisfaction or waiver at or prior
to the Effective Time of the following conditions:

 

(a) the representations and warranties of
Parent, (solely with respect to the BioKey Merger) BioKey, Merger Sub 1, and (solely with respect to the BioKey Merger) Merger
Sub 2 set forth in this Agreement shall be true and correct (without giving effect to any limitation on any representation or warranty
indicated by the words “Parent Material Adverse Effect”, “BioKey Material Adverse Effect”, “in all
material respects”, “in any material respect”, “material” or “materially”) as of the
Effective Time as though made on and as of the Effective Time (except to the extent expressly made as of an earlier date, in which
case as of such earlier date), after giving effect to any updates made to the Parent Schedule of Exceptions or BioKey Schedule
of Exceptions made on or after the date hereof and prior to Closing, in each case except where the failure of any such representations
and warranties to be so true and correct would not, or would not reasonably be expected to, individually or in the aggregate, have
a Parent Material Adverse Effect or BioKey Material Adverse Effect;

 

(b) the Parent and (solely with respect to
the BioKey Merger) BioKey shall have complied in all material respects with their respective obligations pursuant to Section 2.2
and Article 6 and Article 7;

 

(c) BioLite shall have received certificates
executed on behalf of Parent by the chief executive officer or chief financial officer of Parent, certifying that the conditions
set forth in Sections 8.3(a) and (b) (relating to Parent and Merger Subs) have been satisfied;

 

(d) Solely with respect to the BioKey Merger,
BioLite shall have received certificates executed on behalf of BioKey by the chief executive officer of BioKey, certifying that
the conditions set forth in Sections 8.3(a) and (b) (relating to BioKey) have been satisfied; and

 

    - 65 -

     

    

 

(e) Merger Sub 1 shall have delivered the
BioLite Merger Consideration to the BioLite Exchange Agent.

 

Section 8.4 Conditions to Obligations
of BioKey. The obligation of BioKey to effect the Mergers shall be further subject to the satisfaction or waiver at or prior
to the Effective Time of the following conditions:

 

(a) the representations and warranties of
Parent, BioLite and Merger Subs set forth in this Agreement shall be true and correct (without giving effect to any limitation
on any representation or warranty indicated by the words “Parent Material Adverse Effect”, “BioLite Material
Adverse Effect”, “in all material respects”, “in any material respect”, “material” or
“materially”) as of the Effective Time as though made on and as of the Effective Time (except to the extent expressly
made as of an earlier date, in which case as of such earlier date), after giving effect to any updates made to the Parent Schedule
of Exceptions or BioLite Schedule of Exceptions made on or after the date hereof and prior to Closing, in each case except where
the failure of any such representations and warranties to be so true and correct would not, or would not reasonably be expected
to, individually or in the aggregate, have a Parent Material Adverse Effect or BioLite Material Adverse Effect;

 

(b) the Parent and BioLite shall have complied
in all material respects with their respective obligations pursuant to Section 2.2 and Article 6 and Article 7;

 

(c) BioKey shall have received certificates
executed on behalf of Parent by the chief executive officer or chief financial officer of Parent, certifying that the conditions
set forth in Sections 8.4(a) and (b) (relating to Parent and Merger Subs) have been satisfied;

 

(d) BioKey shall have received certificates
executed on behalf of BioLite by the chief executive officer of BioLite, certifying that the conditions set forth in Sections 8.3(a)
and (b) (relating to BioLite) have been satisfied; and

 

(e) Merger Sub 2 shall have delivered the
BioKey Merger Consideration to the BioKey Exchange Agent.

 

ARTICLE 9

TERMINATION, AMENDMENT AND WAIVER

 

Section 9.1 Termination. This Agreement
may be terminated and the Mergers contemplated hereby may be abandoned at any time prior to the Effective Time, notwithstanding
approval by the stockholders of BioLite and BioKey:

 

(a) by mutual written consent of Parent, each
Merger Sub, BioLite and BioKey;

 

    - 66 -

     

    

 

(b) by Parent, BioLite, or BioKey if any court
of competent jurisdiction or other Governmental Body located or having jurisdiction within the United States shall have issued
a final order, decree or ruling or taken any other final action restraining, enjoining or otherwise prohibiting the Mergers and
such order, decree, ruling or other action is or shall have become final and nonappealable;

 

(c) by Parent, BioLite, or BioKey prior to
the Effective Time, if the Effective Time shall not have occurred on or before July 31, 2018 (the “Termination Date“),
provided that, the Termination Date may be extended upon the written consent of the Parties (which, for the avoidance of doubt,
will not require any shareholder approval) provided further, however, that the right to terminate this Agreement
pursuant to this Section 9.1(c) shall not be available to the party seeking to terminate if any action of such party (or,
in the case of Parent, either Merger Sub) or the failure of such party (or, in the case of Parent, either Merger Sub) to perform
any of its obligations under this Agreement required to be performed at or prior to the Effective Time has been the cause of, or
resulted in, the failure of the Effective Time to occur on or before the Termination Date and such action or failure to perform
constitutes a breach of this Agreement;

 

(d) by BioLite if there shall have been a
breach of any representation, warranty, covenant or agreement on the part of Parent, BioKey or either Merger Sub contained in this
Agreement such that a condition set forth in Section 8.1 or 8.3 would not be satisfied and, in either such case, such breach
shall not have been cured prior to the earlier of (A) fifteen (15) days following notice of such breach to Parent or
BioKey, as applicable, and (B) the Termination Date; provided that BioLite shall not have the right to terminate this
Agreement pursuant to this Section 9.1(d) if BioLite is then in material breach of any of its covenants or agreements contained
in this Agreement;

 

(e) by BioKey if there shall have been a breach
of any representation, warranty, covenant or agreement on the part of Parent, BioLite or either Merger Sub contained in this Agreement
such that a condition set forth in Section 8.1 or 8.4 would not be satisfied and, in either such case, such breach shall not
have been cured prior to the earlier of (A) fifteen (15) days following notice of such breach to Parent or BioLite, as
applicable, and (B) the Termination Date; provided that BioKey shall not have the right to terminate this Agreement
pursuant to this Section 9.1(d) if BioKey is then in material breach of any of its covenants or agreements contained in this
Agreement;

 

(f) by Parent if there shall have been a breach
of any representation, warranty, covenant or agreement on the part of BioLite or BioKey contained in this Agreement such that a
condition set forth in Section 8.1 or 8.2 would not be satisfied and, in either such case, such breach shall not have been cured
prior to the earlier of (A) fifteen (15) days following notice of such breach to BioLite or BioKey, as applicable, and
(B) the Termination Date; provided that Parent shall not have the right to terminate this Agreement pursuant to this
Section 9.1(f) if Parent or either Merger Sub is then in material breach of any of its covenants or agreements contained in
this Agreement;

 

(g) by BioLite in accordance with the terms
and subject to the conditions of Section 7.4; or

 

    - 67 -

     

    

 

(h) by BioKey in accordance with the terms
and subject to the conditions of Section 7.5;

 

(i) by Parent in the event a BioLite Adverse
Recommendation Change or BioKey Adverse Recommendation Change has occurred.

 

Section 9.2 Effect of Termination.
In the event of the termination of this Agreement pursuant to Section 9.1, this Agreement shall forthwith become void and
there shall be no liability or obligation on the part of any party hereto, except with respect to Section 3.17, Section 4.17,
Section 5.14, Section 7.9, this Section 9.2, Section 9.3 and ARTICLE 10, which shall survive such termination; provided,
however, that nothing herein shall relieve or release any party from liabilities or damages arising out of fraud or its
material and intentional breach of any provision of this Agreement.

 

Section 9.3 Fees and Expenses. (a)
Except as otherwise specifically provided herein, each party shall bear its own fees and expenses in connection with this Agreement
and the transactions contemplated hereby. All expenses incurred in connection with printing and mailing of the Registration Statement
on form S-4 and in connection with notices or other filings with any Governmental Bodies under any Laws shall be paid by the Parent.

 

(b) The parties acknowledge that the agreements
contained in this Section 9.3 are an integral part of the Transactions, and that, without these agreements, the parties would not
enter into this Agreement; accordingly, if a party fails to promptly pay the amount due pursuant to this Section 9.3, and,
in order to obtain such payment, the other party commences a suit that results in a judgment against such party for the fee set
forth in this Section 9.3 or any portion of such fee, such party shall pay to the other party its costs and expenses (including
attorneys’ fees) in connection with such suit, together with interest on the amount of the fee at the prime rate of Citibank,
N.A. in effect on the date such payment was required to be made through the date of payment; provided, however, that
if such party fails to prevail in any such suit, such party shall promptly pay the other party costs and expenses (including attorney’s
fees) in connection therewith.

 

Section 9.4 Amendment. This Agreement
may be amended by the parties hereto by action taken by or on behalf of their respective Boards of Directors at any time prior
to the Effective Time, whether before or after approval of this Agreement by the stockholders of BioLite and BioKey; provided,
however, that, after approval of this Agreement by the stockholders of BioLite or BioKey, no amendment may be made which
by Law requires the further approval of the stockholders of BioLite or BioKey, as applicable, without such further approval. This
Agreement may not be amended except by an instrument in writing signed by the parties hereto.

 

Section 9.5 Waiver. At any time prior
to the Effective Time, any party hereto may (i) extend the time for the performance of any of the obligations or other acts of
the other parties hereto, (ii) waive any inaccuracies in the representations and warranties contained herein or in any document
delivered pursuant hereto, and (iii) subject to the requirements of applicable Law, waive compliance with any of the agreements
or conditions contained herein; provided, however, that, after adoption of this Agreement by the stockholders of
BioLite or BioKey, no extension or waiver may be made which by Law requires the further approval of the stockholders of BioLite
or BioKey, as applicable, without such further approval. Any such extension or waiver shall be valid if set forth in an instrument
in writing signed by the party or parties to be bound thereby. The failure of any party to assert any rights or remedies shall
not constitute a waiver of such rights or remedies.

 

    - 68 -

     

    

 

ARTICLE 10

GENERAL PROVISIONS

 

Section 10.1 Non-Survival of Representations,
Warranties, Covenants and Agreements. None of the representations, warranties, covenants and agreements in this Agreement or
in any instrument delivered pursuant to this Agreement, including any rights arising out of any breach of such representations,
warranties, covenants and agreements, shall survive the Effective Time, except for (i) those covenants and agreements contained
herein that by their terms apply or are to be performed in whole or in part after the Effective Time and (ii) this ARTICLE
10.

 

Section 10.2 Notices. All notices,
requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have
been duly given upon receipt) by delivery in Person, by facsimile, by e-mail, or by registered or certified mail (postage prepaid,
return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be
specified by like notice):

 

	 	(a)	if to Parent or either Merger Sub:

 

American Brivision (Holding) Corporation 

11 Sawyers Peak Drive 

Goshen, NY 10924 

Attention: Jerry Hung

Facsimile: 886-2-87515901

Email: jerryhung@ambrivis.com

 

with an additional copy (which shall not constitute
notice) to:

 

Sichenzia Ross Ference Kesner LLP 

1185 Avenue of the Americas, 37th
Floor 

New York, NY 10036 

Attention: Jay Kaplowitz, Esq. 

Facsimile: 212-930-9725

 

    - 69 -

     

    

  

	 	(b)	if to BioLite:

 

BioLite Holding Inc. 

248 Section 1 Neihu Rd., 3rd Floor 

Taipei, Taiwan, 11493 

Attention: Wei-Ping Kiang 

Facsimile: 886-2-77208317

E-mail: webster@bioliteinc.com

 

with an additional copy (which shall not constitute
notice) to:

 

Sichenzia Ross Ference Kesner LLP 

1185 Avenue of the Americas, 37th
Floor 

New York, NY 10036 

Attention: Jay Kaplowitz, Esq. 

Facsimile: 212-930-9725

  

	 	(c)	if to BioKey:

 

Sam Chow 

President & CEO 

BioKey, Inc. 

44370 Old Warm Springs Blvd., Fremont, CA 94538 

Phone: 510-668-0881 

Fax: 510-252-0188

 

with an additional copy (which shall not constitute
notice) to:

 

George Lee, Chairman 

BioKey, Inc. 

44370 Old Warm Springs Blvd., Fremont, CA 94538 

Phone: 510-668-0881 

Fax: 510-252-0188 

 

Venture Pacific Law, PC 

425 N Whisman Road, #800 

Mountain View, CA 94043

  

Section 10.3 Certain Definitions.
For purposes of this Agreement, the term:

 

(a) “Business Day“ means
any day on which the principal offices of the SEC in Washington, D.C. are open to accept filings or, in the case of determining
a date when any payment is due, any day on which banks are not required or authorized by law to close in New York, New York.

 

(b) “Code” means the United
States Internal Revenue Code of 1986, as amended.

 

(c) “Contract” means any
contract, lease, evidence of indebtedness, mortgage, indenture, security agreement or other agreement (whether written or oral).

 

(d) “Control“ (including
the terms “Controlled”, “Controlled by” and “under common Control with”)
means the possession, directly or indirectly or as trustee or executor, of the power to direct or cause the direction of the management
policies of a Person, whether through the ownership of stock, as trustee or executor, by contract or credit arrangement or otherwise.

 

    - 70 -

     

    

 

(e) “Exchange Act” means
the Securities and Exchange Act of 1934, as amended.

 

(f) “GAAP“ means the generally
accepted accounting principles in the United States, set forth in the Financial Accounting Standards Board (“FASB”)
Statements of Financial Accounting Standards and Interpretations, FASB Emerging Issues Task Force consensuses, Accounting Principles
Board (“APB”) Opinions, and rules and interpretative releases of the SEC, including SEC Staff Accounting Bulletins
and other such statements by such other entity as may be approved by a significant segment of the accounting profession in the
United States, in each case, as applicable as of the time for the relevant financial statements referred to herein.

 

(g) “Governmental Body”
means any (i) nation, principality, state, commonwealth, province, territory, county, municipality, district or other governmental
jurisdiction of any nature, (ii) federal, state, local, municipal, foreign or other government, (iii) governmental or
quasi-governmental or regulatory authority of any nature (including any stock exchange, governmental division, subdivision, department,
agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit,
body or entity and any court or other tribunal), or (iv) individual, entity or body exercising, or entitled to exercise, any
executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.

 

(h) “Knowledge” means,
(i) with respect to BioLite or BioKey, the actual knowledge of the executive officers of BioLite or BioKey, as applicable,
after due inquiry, and (ii) with respect to Parent, the actual knowledge of the executive officers of the Parent, after due
inquiry.

 

(i) “Person” means an individual,
corporation, partnership, limited liability company, association, trust, estate, unincorporated organization, other entity or group
(as defined in Section 13(d)(3) of the Exchange Act).

 

(j) “Securities Act” means
the Securities Act of 1933, as amended.

 

(k) “Subsidiary” of a Person
means any corporation, partnership, joint venture or other legal entity of which such Person (either alone or through or together
with any other Subsidiary), owns, directly or indirectly, 50% or more of the stock or other equity interests the holder of which
is generally entitled to vote for the election of the board of directors or other governing body of such corporation or other legal
entity.

 

(l) “Tax” or “Taxes”
means all taxes, however, denominated, including any interest, penalties or other additions to tax that may become payable in respect
thereof, imposed by any federal, territorial, state or local government or any agency or political subdivision of any such government,
which taxes shall include all income or profits taxes (including federal income taxes and state income taxes), payroll and employee
withholding taxes, unemployment insurance, social security taxes, sales and use taxes, ad valorem taxes, excise taxes, franchise
taxes, gross receipts taxes, business license taxes, occupation taxes, real and personal property taxes, stamp taxes, environmental
taxes, transfer taxes, workers’ compensation, and other obligations of the same or of a similar nature to any of the foregoing,
which are required to be paid, withheld or collected.

 

    - 71 -

     

    

 

(m) “Tax Returns” means
all reports, estimates, declarations of estimated Tax, information statements and returns relating to, or required to be filed
with an appropriate Governmental Authority in connection with, any Taxes, including information returns or reports with respect
to backup withholding and other payments to third parties.

 

Section 10.4 Severability. If any
term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy,
all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic
or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party.

 

Section 10.5 Entire Agreement; Assignment.
This Agreement (including the Exhibits hereto), the BioLite Schedule of Exceptions, the BioKey Schedule of Exceptions, and the
Parent Schedule of Exceptions, constitute the entire agreement among the parties with respect to the subject matter hereof and
supersede all prior agreements and undertakings, both written and oral, among the parties, or any of them, with respect to the
subject matter hereof. This Agreement shall not be assigned by operation of law or otherwise without the prior written consent
of each of the other parties, except that Parent may assign all or any of its rights and obligations hereunder to any direct or
indirect wholly-owned Subsidiary of Parent; provided, however, that no such assignment shall relieve the Parent of
its obligations hereunder.

 

Section 10.6 Parties in Interest.
This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and their respective successors and
permitted assigns, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any
rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement, other than (a) with respect to
the provisions of ARTICLE 2 which shall be enforceable following the Effective Time by the holders of BioLite Certificates and
BioKey Certificates, and (b) with respect to the provisions of Section 7.6 which shall inure to the benefit of the Persons
or entities benefiting therefrom.

 

Section 10.7 Governing Law. This
Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to the
conflicts of laws principles thereof, which would result in the applicability of the laws of another jurisdiction, except to the
extent required under Nevada corporation law or California corporate law, as applicable.

 

Section 10.8 Headings. The descriptive
headings contained in this Agreement are included for convenience of reference only and shall not affect in any way the meaning
or interpretation of this Agreement.

 

    - 72 -

     

    

 

Section 10.9 Counterparts. This Agreement
may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute
one and the same agreement.

 

Section 10.10 Jurisdiction. Each
of the Parties: (i) consents to submit itself to the personal jurisdiction of the state and federal courts in New York county in
the State of New York in the event any dispute arises out of this Agreement or any transaction contemplated hereby; (ii) agrees
that it will not attempt to deny or defeat personal jurisdiction by motion or other request for leave from any such court; (iii)
waives any right to trial by jury with respect to any action related to or arising out of this Agreement or any transaction contemplated
hereby; (iv) consents to service of process by delivery pursuant to Section 10.2 hereof; and (v) irrevocably and unconditionally
waives (and agrees not to plead or claim) any objection to the laying of venue of any action, suit or proceeding arising out of
this Agreement or the transactions contemplated hereby in any state or federal court sitting in New York county in the State of
New York.

 

Section 10.11 Interpretation. When
a reference is made in this Agreement to an Article, Section, Exhibit or Schedule, such reference shall be to an Article of, a
Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated. The headings contained in this Agreement are
for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words
“include”, “includes”, “including” or “such as” are used in this Agreement, they
shall be deemed to be followed by the words “without limitation”. The word “will” shall be construed to
have the same meaning and effect as the word “shall.” The words “hereof”, “herein” and “hereunder”
and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision
of this Agreement. The word “or” shall not be exclusive. The word “extent” in the phrase “to the
extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if”.
Whenever used in this Agreement, any noun or pronoun shall be deemed to include the plural as well as the singular and to cover
all genders. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation
against the party drafting or causing any instrument to be drafted. References to “this Agreement” shall include the
BioLite Schedule of Exceptions, BioKey Schedule of Exceptions, and Parent Schedule of Exceptions. All terms defined in this Agreement
shall have the defined meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise
defined therein. Any Contract, instrument or Law defined or referred to herein or in any Contract or instrument that is referred
to herein means such Contract, instrument or Law as from time to time amended, modified or supplemented, including (in the case
of Contracts or instruments) by waiver or consent and (in the case of Law) by succession of comparable successor Law and references
to all attachments thereto and instruments incorporated therein. References to a Person are also to its permitted successors and
assigns.

 

Section 10.12 Waiver of Jury Trial.
Each of the parties to this Agreement irrevocably waives any and all right to trial by jury in any legal proceeding arising out
of or relating to this Agreement or the transactions contemplated by this Agreement.

 

[Remainder of Page Left Blank Intentionally]

 

    - 73 -

     

    

 

Execution Version

 

IN WITNESS WHEREOF, Parent, Merger Subs, BioLite
and BioKey have caused this Agreement to be executed as of the date first written above by their respective officers thereunto
duly authorized.

 

	 	AMERICAN BRIVISION (HOLDING) CORPORATION
    
	 	 	 
	 	By:	/s/ Howard Doong
	 	Name: 	Dr. Howard Doong
	 	Title:	Chief Executive Officer
	 	 	 
	 	BIOLITE ACQUISITION CORP.
	 	 	 
	 	By:	/s/ Howard Doong
	 	Name: 	Dr. Howard Doong
	 	Title:	Chief Executive Officer
	 	 	 
	 	BIOKEY ACQUISITION CORP.
	 	 	 
	 	By:	/s/ Howard Doong
	 	Name: 	Dr. Howard Doong
	 	Title:	Chief Executive Officer
	 	 	 
	 	BIOLITE HOLDING, INC.
	 	 	 
	 	By:	/s/ TS Jiang
	 	Name: 	Dr. TS Jiang
	 	Title:	Chairman and CEO
	 	 	 
	 	BIOKEY, INC.
	 	 	 
	 	By:	/s/ George Lee
	 	Name: 	Dr. George Lee
	 	Title:	Chairman

 

     

     

    

 

SCHEDULE 1.5

 

POST-MERGER

 

	Entities	 	Directors	 	Executive Officers
	 	 	 	 	 
	The Parent	 	Eugene Jiang, Tsang Ming Jiang, Ming-Fong Wu, Norimi Sakamoto, Yen-Hsin Chou, Tsung-Shann Jiang, Chang-Jen Jiang, Shin-Yu Miao, Yoshinobu Odaira, Shih-Chen Tzeng, George Lee	 	CEO: Howard Doong 
  
CFO: Jerry Hung
	 	 	 	 	 
	BioLite Surviving Corporation	 	Tsung-Shann Jiang, Chang-Jen Jiang, Shin-Yu Miao, Yoshinobu Odaira, Shih-Chen Tzeng	 	CEO: Tsung-Shann Jiang 
  
CFO: Hsin-Shih (Cynthia) Chen 
  
CBO( chief business officer): Wei-Ping Kiang
	 	 	 	 	 
	BioKey Surviving Corporation	 	George Lee, Sam Chow, Richard Houng	 	CEO: Sam Chow 
  
Chairman: George Lee

 

    - 1 -

     

    

 

BIOLITE SCHEDULE OF EXCEPTIONS

 

Section 3.21

 

Related party transactions

 

For the year ended December 31, 2016, the related
party transactions are summarized as follows:

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Receivable from	 	 	 	 	 	 	 
	Related	 	Amounts	 	 	Amounts	 	 	Merchandise	 	 	Accounts	 	 	Collaboration	 	 	collaboration	 	 	Deferred	 	 	Rent	 
	Parties	 	due from	 	 	due to	 	 	sales to	 	 	receivable	 	 	Revenue (a)	 	 	Partners (a)	 	 	Revenues (a)	 	 	Expenses (b)	 
	LION	 	$	-	 	 	$	-	 	 	$	3,121	 	 	$	617	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	35,463	 
	BioFirst	 	 	258	 	 	 	-	 	 	 	9,536	 	 	 	648	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 
	BHK	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	1,150,743	 	 	 	-	 	 	 	2,287,017	 	 	 	-	 
	BriVision	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	6,738,774	 	 	 	6,431,675	 	 	 	3,310,741	 	 	 	-	 
	JIANGS	 	 	-	 	 	 	19,910	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 
	Total	 	$	258	 	 	$	19,910	 	 	$	12,657	 	 	$	1,265	 	 	$	7,889,517	 	 	$	6,431,675	 	 	$	5,597,758	 	 	$	35,463	 

 

    - 2 -

     

    

 

ABVC SCHEDULE OF EXCEPTIONS

 

Related Party Transactions are listed as following:

 

	Related	 	 	 	 	 	 	 	 	 	 	 	 	 	Paid-in Capital Revenue under common	 	 	Receivable from	 	 	Paid-in Capital	 	 	 	 
	Parties	 	Amounts	 	 	Profession	 	 	Accrued	 	 	Interest	 	 	 Control	 	 	 Collaboration	 	 	Stock based	 	 	Rent	 
	 	 	due from	 	 	Fee	 	 	Interest	 	 	Expense	 	 	 Contribution	 	 	 Partner	 	 	Compensation	 	 	Expenses (b)	 
	Rgene	 	$	-	 	 	$	-	 	 	$		 	 	$		 	 	$	3,000,000	 	 	$	2,550,000	 	 	$	-	 	 	 	 $	 
	BioFirst	 	 	3,950,000	 	 	 	-	 	 	 	8,460	 	 	 	74,960	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 
	Asia Gene	 	 	160,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	 	 	 	 	-	 	 	 	 	 	 	 	522,205	 
	Yuan Gene	 	 	3,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	-	 
	Lion Gene	 	 	-	 	 	 	 	 	 	 	-	 	 	 	-	 	 	 	70,000	 	 	 	-	 	 	 	 	 	 	 	-	 
	Euro-Asia	 	 	 	 	 	 	124,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	55,000	 	 	 	 	 
	Kim Ho	 	 	 	 	 	 	193,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	80,000	 	 	 	 	 
	Total	 	$	4,113,000	 	 	$	31,700	 	 	$	8,460	 	 	$	74,960	 	 	$	3,070,000	 	 	$	2,550,000	 	 	$	135,000	 	 	$	522,205	 

 

    - 3 -

     

    

 

BioKey Schedule of Exceptions

  

This BioKey Schedule
of Exceptions is made and given pursuant to Article 4 of the Agreement and Plan of Merger dated as of January 31, 2018 (the “Agreement”),
by and among American Brivision (Holding) Corporation, a Nevada corporation (“Parent”), BioLite Acquisition Corp.,
a Nevada corporation and a direct wholly-owned Subsidiary of Parent (“Merger Sub 1”), BioKey Acquisition Corp., a California
corporation and a direct wholly-owned Subsidiary of Parent (“Merger Sub 2”, and together with Merger Sub 1, the “Merger
Subs”)), BioLite Holding, Inc., a Nevada corporation (“BioLite”), and BioKey, Inc., a California corporation
(“BioKey”). Unless the context otherwise requires, all capitalized terms are used herein as defined in the Agreement.
The item numbers below correspond to the item numbers in Article 4 of the Agreement. Disclosures made under one heading apply to
and/or qualify only the correspondingly numbered representation of the BioKey in Article 4 of the Agreement except to the extent
that it is reasonably apparent from the text of the disclosure itself that such disclosure also applies to another representation.
The information contained herein is disclosed solely for the purposes of the Agreement, and no information contained herein shall
be deemed to be an admission by any party hereto to any third party of any matter whatsoever, including without limitation, any
violation of law or breach of any agreement. The information contained in this Schedule of Exceptions is confidential, proprietary
information of the BioKey, and the other parties to the Agreement shall be obligated to maintain and protect such confidential
information pursuant to the Agreement.

 

Section 4.3

 

A capitalization table listing all equity securities is attached
hereafter as Appendix A.

 

As of the date of this Agreement, pursuant to the BioKey Stock
Plan, three million nine hundred forty-eight thousand thirty-four (3,948,034) shares of BioKey Common Stock have been exercised
under the Plan, two hundred sixty-one thousand nine hundred forty (261,940) shares of BioKey Common Stock are exercisable, and
forty thousand twenty-six (40,026) shares of BioKey Common Stock remain available to grant, which shall be cancelled upon the consummation
of the BioKey Merger.

 

Section 4.10 (also referred to in the Agreement
as Section 4.10(a))

 

The BioKey Plan consists of the following: (1) a health plan
and (2) a 401k retirement plan.

 

Section 4.12

 

BioKey carries general commercial liability insurance.

 

Section 4.13

 

BioKey Leased Property consists of an office at 44370 Old Warm
Springs Blvd., Fremont, CA 94538.

 

Section 4.19a (also referred to in the Agreement
as Schedule 4.19(a))

 

A listing of Intellectual Property of BioKey, i.e., Biokey’s
patents, inventions, copyrights, software, trademarks, service marks, domain names, trade dress, trade secrets and all other intellectual
property and intellectual property rights of any kind or nature, is attached hereafter as Appendix B.

 

    - 4 -

     

    

 

APPENDIX A

 

Capitalization Table

 

    - 5 -

     

    

 

APPENDIX B

 

Listing of Intellectual Property

 

- 6 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]